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Summary 
Cytosolic recognition of viral replication intermediates by RIG-I, the founding member of the 
RIG-I-like receptor (RLR) family, initiates a signalling cascade which culminates in the 
activation of latent transcription factors IRF3 and IRF7, inducing the expression of type I and 
type III interferons (IFNs) and interferon-stimulated genes (ISGs). These work in concert to 
combat viral infection. Thus, regulation of RIG-I activity is crucial in mounting a balanced 
antiviral response strong enough to ward off infection, but strictly transient in order to avoid 
tissue damage. Initially, death-associated protein kinases (DAPKs) were described as 
initiators of cell death. Since then, they have been found to mediate a variety of cellular 
processes, such as cell growth and survival, cytoskeletal remodelling and inflammatory 
responses, but had not been linked to the regulation of innate antiviral signalling. 
We identified death-associated protein kinase 1 (DAPK1) as a negative feedback-regulator of 
RIG-I activity. The present study confirms that a minimal DAPK1 construct, DAPK1KCA, 
comprising only the kinase, calmodulin (CaM)-binding and Ankyrin repeats domains, inhibits 
RIG-I in a kinase-dependent manner. DAPK1KCA harbours residues targeted by growth factor 
signalling-related kinases. We could demonstrate, however, that inhibition of RIG-I signalling 
mediated by DAPK1 happened independently of its role in growth factor signalling. 
Nevertheless, DAPK1 expression was strongly influenced by cell growth and division. 
Since the kinase domains of the different DAPKs are homologous and share some substrate 
specificity, we investigated if, in addition to DAPK1, other DAPK family members would 
interfere with RIG-I signalling. Upon over-expression, all DAPK family members inhibited 
RIG-I signalling, except DRAK2 which, in our hands, was kinase-inactive. Reciprocally, 
siRNA-mediated knockdown of DAPK1 and DAPK3 resulted in increased antiviral signalling 
activity. Moreover, silencing of DAPK1 and DAPK3 reduced the replication of two different 
RNA viruses, emphasizing the physiological relevance of these kinases in the regulation of 
RIG-I signalling. 
Similar to what was observed for DAPK1, we found DAPK2 to inhibit RIG-I signalling in a 
kinase activity-dependent fashion. Moreover, the kinase domain of DAPK3 alone inhibited 
RIG-I signalling. While all DAPK family members phosphorylated RIG-I in vitro, interaction 
with RIG-I could only be shown for DAPK1 and DAPK2. Although we found DAPKs to 
physically interact with each other, we observed no interdependence of the kinases regarding 
their inhibitory function in RIG-I signalling. In order to further study DAPK functions in RIG-I 
signalling, we created single and combined knockout cell lines for DAPK1, DAPK2, and 
DAPK3. However, there was no change in the antiviral response in these cells, possibly due 
to up-regulation of other proteins compensating for loss of the DAPKs. 
We observed that inhibition of RIG-I signalling by DAPKs happened independently of their 
well-studied role in apoptotic as well as autophagic cell death induction. In fact, we did not 
detect any induction of autophagy upon DAPK expression. 
Ultimately, we discovered that regulation of antiviral signalling by DAPKs is not limited to an 
inhibition of RIG-I, but that they also inhibited MDA5-mediated signalling. Moreover, we found 
evidence that DAPKs additionally inhibit antiviral signalling at the level or downstream of 
IRF3-mediated gene transcription. 
In summary, the present study identifies a conserved role for DAPKs in the regulation of 
antiviral RLR signalling independent of known DAPK functions in cell death and survival. 
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Zusammenfassung 
Die Erkennung von viralen Replikationsintermediaten durch das zytosolische Rezeptorprotein 
RIG-I löst eine Signalkaskade aus, die in der Aktivierung der Transkriptionsfaktoren IRF3 und 
IRF7 mündet und damit die Expression von Typ I- und Typ III-Interferonen sowie von Interferon-
stimulierten Genen (ISGs) auslöst. RIG-I ist namensgebend für die Familie der RIG-I-like 
Rezeptoren (RLRs). Interferone und ISGs tragen grundlegend zur Bekämpfung von 
Virusinfektionen bei. Deshalb ist es besonders wichtig, dass RIG-I kontrolliert aktiviert wird, 
sodass die antivirale Antwort stark genug ist, um eine Infektion zu bekämpfen, aber nicht ausufert 
und damit Gewebeschäden verursacht. Death-associated protein kinases (DAPKs) wurden initial 
lediglich als Verursacher von Zelltod beschrieben. Inzwischen ist bekannt, dass sie verschiedene 
zelluläre Prozesse wie Wachstum, Überleben, Umbau des Zytoskeletts und 
Entzündungsreaktionen beeinflussen. Dennoch wurden die Kinasen bisher nicht im 
Zusammenhang mit der antiviralen angeborenen Immunantwort untersucht. 
Unsere Gruppe identifizierte death-associated protein kinase 1 (DAPK1) als Teil eines negativen 
Rückkopplungsmechanismus, welcher in einer Hemmung von RIG-I resultiert. Innerhalb der 
vorliegenden Dissertation wurde bestätigt, dass ein kleinstmögliches DAPK1-Konstrukt, 
DAPK1KCA, bestehend aus der Kinase-, der Calmodulin-Binde- und der Ankyrin-Repeats-
Domäne, RIG-I Kinase-abhängig inhibiert. DAPK1KCA enthält Aminosäurereste, die von Kinasen 
des Wachstumsfaktor-aktivierten Signalwegs phosphoryliert werden, welches die Aktivität von 
DAPK1 beeinflusst. Dennoch konnten wir zeigen, dass DAPK1 den RIG-I-Signalweg unabhängig 
von seiner Funktion im Wachstumsfaktor-aktivierten Signalweg beeinflusst. 
Da die Kinasedomänen der DAPKs eine ausgeprägte Homologie aufweisen und die Kinasen zum 
Teil ähnliche Proteinsubstrate phosphorylieren, wurde untersucht, ob, zusätzlich zu DAPK1, noch 
andere Mitglieder der DAPK Kinasefamilie den RIG-I-Signalweg hemmen. Tatsächlich wurde 
dieser durch Überexpression alle Mitglieder der Kinasefamilie inhibiert. Umgekehrt war die 
Aktivität des RIG-I-Signalwegs erhöht, wenn die Expression von DAPK1 und DAPK3 durch 
siRNA-Transfektion vermindert wurde. Dies resultierte außerdem in einer niedrigeren 
Replikationsrate zweier RNA-Viren wodurch die physiologische Relevanz der DAPKs in der 
Regulation des RIG-I-Signalwegs bestätigt werden konnte. 
Ähnlich wie im Falle von DAPK1 inhibierte DAPK2 den RIG-I-Signalweg abhängig von seiner 
Kinaseaktivität. Außerdem konnten wir beobachten, dass alleinige Überexpression der 
Kinasedomäne von DAPK3 ausreichte, um den RIG-I-Signalweg zu inhibieren. Obwohl alle 
DAPKs RIG-I in vitro phosphorylierten, konnten wir eine Interaktion mit demselbigen nur für 
DAPK1 und DAPK2 zeigen. Wir stellten zwar fest, dass die DAPKs einander binden, konnten 
aber bezüglich der Hemmung des RIG-I-Signalwegs keine gegenseitige Abhängigkeit der 
Kinasen untereinander feststellen. Um die Funktion der DAPKs in der antiviralen Immunantwort 
weiter untersuchen zu können, generierten wir Einzel- sowie  kombinierte Knockout-Zelllinien für 
DAPK1, DAPK2 und DAPK3, konnten in diesen aber keine Änderung in Bezug auf die antivirale 
Immunantwort beobachten. Der Grund hierfür könnte eine kompensatorische Heraufregulation 
eines anderen Proteins sein, welches im Falle des Verlusts der Kinasen ihre Funktion übernimmt. 
Unsere Ergebnisse zeigen, dass die DAPK-abhängige Inhibition des RIG-I-Signalwegs 
unabhängig von den bisher beschriebenen Funktionen der DAPKs als Zelltod-Initiatoren 
geschieht. Tatsächlich konnten wir nach Überexpression der DAPKs keine vermehrte Induktion 
von Autophagie feststellen. 
Schlussendlich zeigen unsere Beobachtungen, dass die DAPKs nicht die RIG-I- sondern auch die 
MDA5-abhängige Signalantwort hemmen. Zudem inhibierten die DAPKs die antivirale 
Signalantwort auf der Ebene der Aktivierung von IRF3 und/oder der IRF3-abhängigen 
Gentranskription. 
Zusammenfassend beschreibt die vorliegende Dissertation eine konservierte Funktion der DAPKs 
als Regulatoren der antiviralen RLR-abhängigen Immunantwort. Dies geschieht dabei 
unabhängig von der DAPK-abhängigen Regulation von Zelltod und –überleben. 
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1 Introduction 
Every higher organism has to fight infections on a daily basis. In order to prevent 
disease, the immune system (lat. “immunis”, “unspoilt” or “pure”) has evolved, a 
combination of different mechanisms and processes acting in concert to fight pathogens. 
In mammals the immune system consists of two major parts, the innate and the adaptive 
immune system. These two components are tightly interconnected, working together in 
preventing infection. 
This study deals with an important part of innate immunity, the RIG-I signalling pathway 
and how it is activated and modulated in response to viral infections. Further introduction 
is, therefore, mainly focused on composition and function of the innate immune system. 
1.1 The innate immune system 
As a first line of defence against invading pathogens, the innate immune system takes 
action which is usually very fast (activation takes place within seconds to minutes). There 
are several mechanisms which ward off infection. First in line are physical barriers, e.g. 
epithelial layers, which separate the outside from the inside of an organism. 
Furthermore, these barriers are often covered in mucus (e.g. epithelial layers of the 
respiratory or the digestive tract) or secrete fluids (e.g. tear ducts) which not only make it 
difficult for pathogens to attach, but also often contain antimicrobial substances (such as 
lysozyme in tear fluid) which help to kill or attenuate pathogens even before they might 
invade a cell. Pathogens which manage to defy cellular barriers are recognised upon 
entering cells or interstitial space. In the blood stream, the complement system acts as 
an important part of innate immunity in that it “complements” other anti-microbial 
mechanisms, marking infiltrating microbes for destruction by phagocytic cells which are 
also part of the innate immune system. A successful mechanism of recognising basic 
microbial structures as foreign is the recognition by so-called “pattern recognition 
receptors” (PRRs). PRRs recognise “pathogen-associated molecular patterns” (PAMPs), 
such as parts of bacterial or fungal cell walls or nucleic acids from genomes of incoming 
viruses. Activated PRRs trigger an innate immune response which ultimately results in 
the secretion of soluble factors. These induce an anti-microbial state not only in the 
infected, but also in neighbouring cells, thereby preventing spread of infections. 
Moreover, soluble factors will attract specialised cells of the innate immune system 
whose activation will, eventually, prime adaptive immunity. 
Although it requires up to several weeks to be fully efficient, only the adaptive immune 
system allows recognition of a multitude of microbial structures much more complicated 
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than regular PAMPs. These will be recognised not only as antigens by B-cell secreted 
antibodies, but also as peptides recognised by T-cell receptors. Also, initiation of an 
adaptive immune response results in formation of an immunologic memory as it gives 
rise to long-lived memory lymphocytes crucial for permanent immunity to certain 
pathogens. This is the working principle of vaccines. Without adequate priming by innate 
immunity, no effective adaptive immune response will be generated. The innate immune 
response as a first line of defence is, therefore, crucial for proper establishment of long-
term immunity. 
1.1.1 Specialised cells of the innate immune system 
All cells of the immune system originate from precursor cells in the bone marrow, 
pluripotent hematopoietic stem cells. Early in their differentiation, these cells give rise to 
two distinct lineages, the lymphoid and the myeloid lineage. An overview of all immune 
cell types and their origin is shown in figure 1. Most specialised cells of the innate 
immune system belong to the myeloid lineage and originate from a common myeloid 
progenitor cell. These progenitors not only give rise to blood-building cells like 
megakaryocytes or erythroblasts, but also granulocytes, mast cells, monocytes, and 
dendritic cells. Granulocytes are, based on staining properties of the granules to which 
they owe their name, divided into neutrophils, eosinophils, and basophils. These have 
distinct functions such as phagocytosis of invading pathogens and killing of parasites too 
large to endocytose. Mast cells are potent inducers of inflammatory responses which are 
thought to have originally developed to fight helminthic infections, but were found to be 
especially important in the context of allergic reactions. Monocytes cycle the blood and 
mature into macrophages. These phagocytic, tissue-resident cells not only take up 
microbes, but also engulf dead cells and cellular debris. Moreover, activated 
macrophages will recruit other specialised immune cells by cytokine secretion. Another 
tissue-resident type of phagocytic cells are dendritic cells (DCs). Phagocytosed microbial 
components are presented on the surface of DCs, making them the most prevalent form 
of antigen-presenting cells essential for the maturation of T lymphocytes. 
Interestingly, natural killer (NK) cells, another important cell type of the innate immune 
system, originate from the lymphoid lineage. These cells recognise abnormal cells such 
as tumour cells or virus-infected cells. Upon recognition, NK cells will release contents of 
their cytoplasmic granules (e.g. perforin and granzymes) leading to target cell lysis. 
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Figure 1 Overview of cell types of adaptive and innate immunity 
All immune cells originate from a common precursor in the bone marrow. Whereas B- and T-cells, the major 
effectors of adaptive immunity, stem from a common lymphoid progenitor, most cells of the innate immune 
system belong to the myeloid lineage. Natural killer (NK) cells are effectors of innate immunity, based on 
their invariant receptors, but develop along the lymphoid lineage. Adapted from [1]. 
1.1.2 Pattern recognition receptors 
As mentioned above, pattern recognition receptors (PRRs) recognise conserved 
molecular structures, so-called PAMPs. PAMPs are found in a variety of pathogens but 
do not occur in the host. Therefore, they can be identified as foreign and potentially 
harmful.  As pathogens present a diversity of structures, different classes of PRRs have 
evolved. They recognise microbial proteins, peptidoglycans, protein-lipid structures, and 
nucleic acids, respectively. A common feature of PRRs is the activation of a signalling 
cascade which, ultimately, establishes an anti-microbial state in the infected cell and 
results in the secretion of soluble factors such as interferons, cytokines and chemokines. 
On top of activating a paracrine immune response in surrounding cells, these factors 
also attract phagocytes and, eventually, cells which are necessary for the initiation of 
adaptive immunity. 
A class of PRRs which recognise carbohydrate residues on microbial surfaces are 
lectins, more specifically mannose-binding lectin (MBL) and calcium-dependent (C-type) 
lectins. MBL binds mannose and fucose residues only when they are presented in a 
defined spatial orientation, e.g. on bacterial surfaces, thereby marking pathogens for 
phagocytosis. C-type lectins expressed on antigen-presenting cells comprise a large 
group of different receptors. They recognise a variety of glycan structures which, again, 
stimulates phagocytosis of the pathogen. However, viruses may exploit binding to these 
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receptors, as in the case of HIV-1 which interacts with C-type lectin DC-SIGN, promoting 
infection and spread among T-cells [2]. 
Toll-like receptors (TLRs) are trans-membrane PRRs located either on cell surfaces or in 
endosomal compartments. In humans 10 different TLRs have been identified of which 
TLR1/TLR2, TLR2/TLR6 (both signal as heterodimers), TLR4 and -5 recognise bacterial 
PAMPs, such as flagellin for TLR5. TLR3, -7, -8, and -9 recognise foreign, often viral, 
nucleic acids, more specifically single stranded RNA (ssRNA), double stranded RNA 
(dsRNA), and unmethylated CpG DNA. 
In addition to these free or membrane bound receptors, there are a number of cytosolic 
PRRs. 
NOD-like receptors (NLRs) are cytosolic PRRs which bind bacterial proteoglycans. To 
date, 23 NLRs are known which are categorised based on their domain structure. 
Signalling initiated by NLRs results in the activation of pro-inflammatory genes (through 
inflammasome activation [3]) and cytokines. Inept activation of NLRs, however, may 
result in excessive inflammation causing tissue damage such as in inflammatory bowel 
disease [4]. 
In addition to cytosolic PRRs which sense bacterial or fungal surface components, there 
are also sensors recognising foreign nucleic acids, especially those stemming from viral 
genomes and replication intermediates [5]. 
As DNA is only located in the nucleus and in mitochondria of healthy mammalian cells, 
cytosolic DNA activates sensors such as Absent in melanoma 2 (AIM2), DNA-dependent 
activator of IRFs (DAI), and cyclic GMP-AMP synthase (cGAS). While AIM2, similar to 
NLRs, activates an inflammatory response [6], DAI and cGAS will, via the adaptor 
molecule Stimulator of interferon gene (STING), engage signalling cascades culminating 
in an activation of interferon signalling and expression of interferon-stimulated genes 
(ISGs) [7]–[9]. Interestingly, with interferon-g-inducible protein 16 (IFI16), a sensor of 
dsDNA was discovered which can be localised both in the cytosol and in the nucleus, 
where it acts as a sensor of viral DNA, such as in case of herpesviruses [10], [11]. It is, 
therefore, unlikely that differentiation between host and viral DNA is based solely on 
spatial separation. 
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1.1.3 RIG-I-like receptors 
The family of RIG-I-like receptors (RLRs) consists of three members: retinoic acid-
inducible gene I (RIG-I, also called DDX58), melanoma-differentiation associated protein 
5 (MDA5, also called IFIH1) and laboratory of genetics and physiology 2 (LGP2, also 
called DHX58). RLRs sense viral RNAs in the cytoplasm and are expressed in most cell 
types. 
 
Figure 2 Overview of the RIG-I-like receptor family domain structure 
All RLRs comprise a central DECH helicase domain consisting of two tandem helicase domains (Hel1 and 
Hel2) and an interspersed helicase insertion domain (Hel2i). Furthermore, they contain a pincer domain (P) 
and a C-terminal domain (CTD). Unlike RIG-I and MDA5, LGP2 does not contain the N-terminal tandem 
caspase activation and recruitment domains (CARD). The repressor domains (RD) in the CTD of RIG-I and 
LGP2 may interact. In an inactive state RIG-I RD interacts with its CARDs, masking them from other 
interaction partners. 
As they contain a central DECH helicase domain (figure 2), RLRs are grouped into the 
DExD/H helicase family (superfamily 2). All RLRs contain a pincer domain which not only 
connects helicase domain 2 to the C-terminal domain (CTD), but also stabilises the 
ATPase core of the helicase domain, thereby regulating enzymatic activity [12]. The CTD 
contributes to substrate specificity of RLRs. RIG-I and MDA5 contain two N-terminal 
tandem caspase activation and recruitment (CARD) domains necessary for signal 
transmission. RLR CARDs interact with and activate mitochondrial antiviral signalling 
(MAVS, also called IPS-1, Cardif or VISA). This interaction takes place after activation of 
RIG-I and MDA5 by recognition of their ligands, different species of dsRNA. It results in 
the expression of type I and III interferons (IFNs), some ISGs, and, to a smaller extent, 
pro-inflammatory cytokines and chemokines. Since LGP2 does not harbour CARD 
domains it cannot initiate downstream signalling and is, therefore, thought to modulate 
RIG-I and MDA5 function [13], [14]. 
RLRs are essential for the recognition of intracellular viral replication. Their activation is 
crucial for the establishment of an antiviral response in infected and surrounding cells. 
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1.1.3.1 Structure and substrate specificity of RIG-I 
RIG-I is the founding member of the RLR receptor family. It was initially described to be 
activated by the presence of dsRNA in the cytoplasm, triggering IFN expression by 
signalling through its tandem CARD domains [15]. Since then, intensive research on the 
mechanism of substrate recognition by RIG-I has revealed that it is particularly well 
activated by 5’-triphosphorylated dsRNAs [16]–[18], which were shown to be natural 
ligands of RIG-I in viral infection, for instance in influenza A virus (FluAV) infection [19]. 
RIG-I was also found to be essential for the recognition of RNA viruses belonging to the 
family of paramyxoviridae and flaviviridae such as Japanese encephalitis virus [20]. 
Although it was first proposed that RIG-I relies on a 5’-triphosphate for substrate 
recognition and mostly recognises short (< 25 bp) dsRNA, it was later shown that, 
depending on substrate length, RIG-I will also bind long (> 200 bp) dsRNA independently 
of the presence of the 5’-triphosphate moiety [21], [22]. Furthermore, 5’-diphosphorylated 
RNAs, which are generated in reovirus infection, were found to potently activate RIG-I 
[23], further challenging the view that RIG-I relies on a 5’-triphosphate for substrate 
binding. Upon substrate recognition, RIG-I will oligomerise along RNA strands, a process 
which has been shown to be ATP-dependent [24]. Recently, this ATP-dependency was 
shown to be a mechanism of discrimination between self and non-self RNA structures 
[25]. 
Substrate binding by RIG-I is mediated through its CTD which was shown to interact with 
dsRNA 5’-triphosphates [26]. Interestingly, the groove in which this binding happens is 
distinct in LGP2 and MDA5 which suggests it confers some degree of substrate 
specificity. Binding of RNA promotes a conformational change of RIG-I which exposes its 
CARD domains and enables interaction with downstream signalling adaptor MAVS. 
1.1.3.2 Structure and substrate specificity of MDA5 
The domain structure of MDA5 is similar to that of RIG-I with 23% amino acid sequence 
homology in the CARD and 35% sequence homology in the helicase domains, 
respectively (figure 2 and [27]). Originally, MDA5 was identified as a negative regulator 
of growth and differentiation in melanoma cells in which it is increasingly expressed in 
response to IFN and TNFa stimulation [28]. Although it is a well-characterised ISG, 
MDA5 is induced independently of cytokine signalling, but in an interferon-regulatory 
factor 3 (IRF3)-dependent manner in mature DCs infected with Sendai virus C (SeV-C) 
[29] and is essential for the recognition of defective interfering particles generated during 
paramyxovirus replication [30]. MDA5 was found to preferentially recognise long RNA 
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templates [21], which can be, as in the case of encephalomyocarditis virus (EMCV, a 
picornavirus), 5’-capped. In fact, MDA5 was shown to be essential for proper immune 
induction to picornavirus infection [31], [32] and in paramyxovirus infection [33]. Upon 
recognition of long dsRNAs, MDA5 oligomerises, forming filaments along an RNA 
template, a process which has been described to be regulated by MDA5 ATPase activity 
[34]–[36]. Similar to RIG-I, the CTD of MDA5 contains a positively charged region which 
preferentially recognises blunt-ended dsRNA, but, compared to RIG-I and LGP2, binds 
this RNA with lower affinity [37]. Formation of MDA5 filaments along RNA will expose 
MDA5 CARD domains and allow interaction with MAVS. 
Interestingly, not only (long) viral RNAs will activate type I IFN and ISG expression, but 
also small duplex self-RNAs generated by RNase L activity, a process which is initiated 
upon viral infection and depends on RIG-I and MDA5 activity [38]. 
1.1.3.3 The role of LGP2 
The most obvious difference between LGP2 and the other two RLRs, RIG-I and MDA5, 
is the absence of the tandem CARD domains (figure 2), which does not allow interaction 
with MAVS, thereby rendering LGP2 incapable of signal transmission. Nevertheless, the 
CTD of LGP2 recognises dsRNAs [39], [40] and binds them with the highest affinity of all 
RLRs [37]. Because of this, it was concluded that LGP2 must have a regulatory function 
in antiviral signalling, binding dsRNA and “competing” with RIG-I and MDA5. The 
mechanism by which LGP2 influences antiviral signalling, however, seems to be more 
complicated. Early reports suggested an inhibitory role of LGP2 in RIG-I-mediated 
signalling [41]. LGP2 was thought to interact with RIG-I by a shared repressor domain 
which would maintain RIG-I in an inactive state [42]. In line with this, a first study using 
LGP2 knockout mice found that mice lacking LGP2 were particularly resistant to infection 
with RIG-I-dependent viruses, but at the same time were extremely sensitive to MDA5-
dependent virus infection [43]. In contrast to this, a later study using different LGP2 
knockout mice found a positive regulatory effect of LGP2 on both RIG-I and MDA5 [44]. 
It is yet to be determined how exactly LGP2 regulates RIG-I-mediated signalling. 
It is accepted that LGP2 acts as a positive regulator of MDA5 in antiviral signalling. This 
view is supported by the fact that viral proteins which inhibit MDA5 often display the 
same behaviour towards LGP2 [45], [46]. Furthermore, LGP2 enhances MDA5 binding to 
RNA and regulates filament assembly [47]. 
Another mechanism of LGP2-mediated inhibition of antiviral signalling downstream of 
RLR activation was described. It was proposed that LGP2 competes with inhibitor of 
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nuclear factor kappa-B kinase e (IKKe) for a binding site on MAVS, thereby inhibiting IFN 
production [14]. 
1.1.4 Induction of type I and III IFNs by RLRs 
As described above, RIG-I and MDA5 undergo conformational changes upon substrate 
recognition which exposes their CARD domains. RLR CARDs will interact with MAVS, a 
signalling adaptor which is, other than its name suggests, not only localised to 
mitochondria, but is also found on peroxisomes and mitochondria-associated 
membranes of the ER (MAMs). Although different localisation of MAVS was initially 
thought to influence signalling kinetics with peroxisomal MAVS inducing a quick, initial 
IFN response and mitochondrial MAVS establishing stable, amplified IFN induction [48], 
later studies could not confirm this assumption. As a matter of fact, there are no major 
differences between IFN induction by mitochondrial or peroxisomal MAVS in hepatocytes 
[49]. Upon binding of RLR CARDs, MAVS CARD domains will oligomerise, leading to an 
accumulation of MAVS on the mitochondrial surface, a process which has been 
compared to the aggregation of prions, especially since filamentous MAVS will promote 
aggregation of non-activated MAVS [50]. MAVS aggregates form highly ordered, a-
helical structures [51] depending on lysine 63 (K63)-linked polyubiqutinylation. Only 
recently E3-ubiquitin ligase tripartite motif-containing protein 31 (TRIM31) was identified 
as the effector important for initiation and modulation of MAVS aggregation [52]. 
MAVS aggregates provide a platform for the recruitment of additional signalling factors. 
RLR signalling will induce two pathways which result in the initiation of an antiviral 
response. On the one hand, transcription factors IRF3 and IRF7 are phosphorylated and 
activated by effector kinases TANK-binding kinase 1 (TBK1) and IKKe. These kinases 
are activated by E3 ubiquitin ligase TNF receptor associated factor (TRAF) 3 which is 
engaged by clustering and self-ubiquitinylation within the MAVS signalosome [53], [54]. 
On the other hand, nuclear factor k B (NFkB) is activated by RLR signalling. This is 
achieved by TRAF6 activation which results in the recruitment of IKKa, IKKb and 
IKKg/NEMO [55]. Additionally, TRAF6 signals trough TGFb-activated kinase 1 (TAK1) 
and induces the mitogen-activated protein kinase (MAPK) pathway [56]. Upon 
phosphorylation of the inhibitor of NFkB a (IkBa) by the IKKa/b/NEMO complex, NFkB is 
released and translocates to the nucleus. 
Transcription factors IRF3, IRF7, and NFkB will activate type I and III IFNs, pro-
inflammatory cytokines and some ISGs. Other than their name suggests, ISGs are not 
only induced by IFN signalling, but are also expressed in response to IRF3 and IRF7 
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activation. An ISG which is strongly induced by activated IRF3 is Interferon-induced 
protein with tetratricopeptide repeats 1 (IFIT1), also called ISG56 [57]. Because of this, 
IFIT1 expression is often used as a direct readout for IRF3 activity. An overview of the 
RLR signalling pathway and its main effectors is given in figure 3. 
 
Figure 3 Overview of the RLR signalling pathway 
Activation of RIG-I and MDA5 by their respective ligands results in a conformational change exposing the 
CARD domains which interact with and activate MAVS. (Note that LGP2 was described to inhibit RIG-I but 
promote MDA5 activity [13], [41].) MAVS oligomerisation provides a signalling platform which recruits TRAF3 
and TRAF6 leading either to the activation of IRF3 by phosphorylation through TBK1 (or IKKe, not 
displayed), or NFkB activation by recruitment of IKKa and IKKb. Phosphorylation of IkBa (IkB) by these 
kinases marks the inhibitor for degradation. Highlighting the importance of MAVS as an central signalling 
adaptor, it is targeted by NS3-NS4A protease of hepatitis C virus (HCV) which cleaves and thereby 
inactivates MAVS.  Both IRFs and NFkB activation results in expression of type I and III IFNs, pro-
inflammatory cytokines and some ISGs. Activated IRFs are recognised by effectors of the ubiquitinylation 
pathway and labelled for degradation. Adapted from [58]. 
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1.1.5 Interferons and the interferon signalling pathway 
Interferons were named after their ability to interfere with viral replication when they are 
added to cells in culture prior to infection. They are a group of cytokines which are 
commonly induced in response to viral infection and which will, ideally, help to clear an 
infection by induction of an antiviral state. Based on their amino acid sequence, they are 
grouped into three classes: Type I, type II, and type III IFNs. While there are several type 
I and III IFNs, there is only one type II interferon, IFNg. Since IFNg is not directly secreted 
in response to viral infection, but rather by activated T and NK cells in the course of 
adaptive immunity, further introduction is going to focus on type I and III IFNs only. 
1.1.5.1 Type I interferons 
Type I IFNs were first described 60 years ago by Isaacs & Lindemann [59]. While there 
are at least seven different type I IFNs in mammals, only IFNa (which comprises a group 
of 13 genes in humans) and IFNb (monogenic in humans) are induced in response to 
viral infection. The role of the other type I IFNs, IFNw, e, t, d, and k, is less well-defined, 
but some were found to have distinct roles, such as IFNw and IFNt which act at the 
placental interface and are important for maternal recognition of pregnancy [60], [61]. 
All type I IFNs bind to a common receptor which is a heterodimeric complex consisting of 
the interferon alpha receptor (IFNAR) 1 and 2 proteins. IFNs induce classical Janus 
kinase/signal transducers and activators (Jak/STAT) signalling pathways (figure 4 and 
[62]). Binding of IFNs to IFNAR1 and 2 induces oligomerisation which brings both 
receptors into close proximity. This causes receptor-associated kinases Tyk2 (bound to 
IFNAR1) and JAK1 (bound to IFNAR2) to cross-phosphorylate not only the cytoplasmic 
tails of the IFNARs, but also STAT2 and STAT1. These are weakly associated with the 
IFNARs prior to stimulation but associate more strongly to phosphorylated receptors [63]. 
Phosphorylated STATs form a stable heterodimer which, together with IRF9, forms the 
interferon-stimulated gene factor 3 (ISGF3) complex capable of binding interferon-
stimulated response elements (ISRE) present in the promoter regions of most ISGs 
(figure 4 and [64]). 
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Figure 4 Classical Jak/STAT pathway induction by type I 
and type III IFNs 
Binding of type I IFNs induces dimerisation of IFNAR receptor 
proteins 1 and 2 which results in cross-phosphorylation of 
cytoplasmic receptor chains as well as subsequent interaction 
with and phosphorylation of STAT1 and STAT2. Phosphorylated 
STATs heterodimerise and translocate to the nucleus where 
they induce transcription of antiviral ISGs. While they bind a 
heterodimeric receptor consisting of IFNLR1 and IL10R2 
proteins, intracellular signalling induced by type III IFNs is very 
similar to that in response to type I IFNs. Adapted from [62]. 
 
 
 
 
 
Interestingly, it was found that ISGF3 complexes are formed directly at the level of 
IFNARs by recruitment of cytoplasmic CREB-binding protein (CBP) which acetylates 
IFNAR2, thereby inducing IRF9 association. Furthermore, IRF9, STAT1, and STAT2 
require acetylation by CBP for proper ISGF3 complex activation [65]. All components of 
the ISGF3 complex are IFN-inducible themselves which not only facilitates signal 
amplification, but may also reduce the requirement of STAT1 phosphorylation in the 
phase after initial pathway activation [66], [67]. 
As IFNAR1 and 2 are ubiquitously expressed, type I IFNs are the main inducers of 
antiviral responses in most cell types and tissues. Moreover, ubiquitous expression of 
IFNARs results in a systemic response to type I IFNs. An overshooting systemic immune 
reaction might be detrimental which is probably the reason why type I IFNs usually 
induce a strong but short expression of ISGs [68], [69]. 
1.1.5.2 Type III interferons 
Type III IFNs were discovered much later than type I IFNs with first reports published by 
two independent groups in 2002/2003 [70], [71]. So far, four different type III IFN genes 
have been identified, encoding for IFNl1/IL-29, IFNl2/IL-28A, IFNl3/IL-28B, and IFNl4. 
Similar to type I IFNs, l-IFNs signal through a heterodimeric receptor complex which is 
composed of the interferon lambda receptor 1 (IFNLR1, also called IL28RA) and the 
interleukin 10 receptor chain 2 (IL10R2). Interestingly, this receptor chain is shared with 
the receptor complexes binding IL-10, IL-22, and IL-26. The downstream signalling 
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cascade induced by type III IFNs is almost identical with that induced by type I IFNs in 
that it culminates in ISGF3 complex formation and nuclear translocation (figure 4). In 
contrast to type I IFN signalling in which JAK1 is an effector kinase, JAK2 was reported 
to be implicated in type III IFN signalling [72], although another group observed normal 
STAT activation in JAK2-deficient cells [73]. 
Type III IFN expression and effects are limited to mucosal surfaces due to the selective 
expression of IFNLR1 in cells of epithelial origin [74], [75]. Sure enough, epithelial cells in 
the respiratory and gastrointestinal tract frequently encounter different viruses. It was 
found that especially type III IFNs contribute to resistance against viruses which 
commonly infect these cells while they were less efficient against viruses with different 
tropism, e.g. hepatotropic viruses [76], [77]. Moreover, type III IFNs act with different 
kinetics than type I IFNs in that l-IFNs induce a delayed but prolonged ISG response 
[68], [78]. 
Both type I and type III IFNs are induced upon antiviral signalling initiated by RLRs and 
have similar effects when they bind their respective receptors on target cells. However, 
differential expression of IFN receptors allows fine-tuning of the IFN response, just as 
certain modulators of the IFN signalling pathway may have an effect on one, but not the 
other signalling pathway. For example, Ubl carboxyl-terminal hydrolase 18 (USP18) is 
involved in negative feedback regulation of IFN signalling and is induced in response to 
type I and type III IFN. Since it competes with JAK1 for its binding site on IFNAR2, 
however, it suppresses IFNa signalling much stronger than IFNl responses [79]. This is 
only one of many mechanisms which modify IFN signalling and result in an adequate 
response to virus infections of different cells and tissues. 
1.1.6 Interferon-stimulated genes and antiviral effectors 
As mentioned above, IFN signalling results in the expression of many different ISGs and 
antiviral effectors. While some ISGs merely interfere with a specific step in a viral life 
cycle, others display greater potency in that they enhance further IFN production 
resulting in an even stronger ISG response. Because of this, many viruses have 
developed effective countermeasures and are capable of inhibiting certain classes of 
ISGs, some even using specific genes to their advantage. Remarkably, ISGs modulate a 
multitude of cellular processes such as cytoskeletal remodelling, apoptosis induction, 
regulation of RNA translation and post-translational modifications. As examples, two 
“classical” and well-studied ISGs will be discussed in this section. Lastly, some viral 
stress-induced genes will be introduced. 
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1.1.6.1 Mx GTPases 
One important group of ISGs whose expression strongly depends on type I and type III 
IFNs are the Myxovirus resistance protein (Mx) family of GTPases [80]. There are two 
Mx proteins in humans, Mx1 and Mx2. While the antiviral activity of Mx1 has been 
thoroughly examined, it is not clear to which extent Mx2 restricts viral infection [81]. Mx 
proteins contain an N-terminal GTPase domain, a central interacting domain (CID) and a 
C-terminal leucine zipper domain. Their main targets seem to be viral nucleocapsids as 
shown for orthomyxoviruses [82]. Due to its localisation at the smooth ER [83], Mx1 
recognises viral components early in the viral life cycle. Moreover, it was shown to 
effectively block viral gene transcription in influenza virus replication by binding and 
inhibiting the viral polymerase [84]. As Mx proteins effectively counteract viral replication 
and spread, several viruses have developed mechanisms to evade or overcome this 
inhibition. West Nile virus (WNV), for one, produces cytoplasmic membrane structures 
which hide viral components from Mx1 recognition [85], and Hepatitis B virus (HBV) core 
protein was shown to suppress Mx1 expression by binding the Mx1 promoter region [86]. 
1.1.6.2 ISG15 
Another prominent ISG is ubiquitin homologue ISG15 which post-translationally 
conjugates to proteins [87]. This process is referred to as ISGylation. Similar to what is 
known for ubiquitinylation (compare section 1.3.1), ISGylation requires an E1-activating 
enzyme (E1-like ubiquitin-activating enzyme, UBE1L) as well as E2-conjugating 
enzymes (e.g. UBCH6 or UBCH8). Finally, an E3-ligase (e.g. HERC5 or TRIM25) 
mediates the transfer of ISG15 to its target protein [88]. Just as it is observed for 
ubiquitinylation, ISG15 may be removed from target proteins by deconjugating enzymes 
such as USP18 [89]. Unlike K48-linked (poly)ubiquitinylation, ISGylation does not mark 
proteins for degradation, but rather mirrors the activating effect of K63-linked 
ubiquitinylation. On the one hand, ISGylation can prevent the degradation of vital factors 
in antiviral signalling like IRF3 [90] and RIG-I [91]. On the other hand it is secreted from 
cells and may act as a cytokine [92]. Viral countermeasures against ISG15 include 
binding of viral factors to ISG15, like in the case of influenza B virus NS1 protein [93], 
and promotion of deISGylation by several other viruses such as SARS-associated 
coronavirus [94]. 
1.1.6.3 Viral stress-induced genes 
Ultimately, some antiviral factors are directly induced in response to the presence of viral 
components in the cytoplasm without the necessity for IFN induction, although IFN 
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signalling often leads to an additional up-regulation of those genes. These viral stress-
induced genes are activated upon sensing of viral genomes, glycoproteins and 
lipoproteins and effectively inhibit viral spread, often by shutting down cap-dependent 
translation. An important factor which senses dsRNA and inhibits cap-dependent 
translation by phosphorylation of eukaryotic translation initiation factor 2 a (eIF2a) is 
protein kinase R (PKR). PKR is usually ubiquitously expressed at low levels, but is up-
regulated upon viral infection [95]. 
Another type of viral stress-induced genes are 2’-5’ oligoadenylate synthases (OASs). 
Similar to PKR, these proteins are usually present at low levels in cells and are induced 
upon viral infection. OASs recognise dsRNA whose binding induces a conformational 
change, activating the enzyme. Activated OASs synthesize 2’-5’-linked oligoadenylates 
which facilitate homodimerisation of RNase L [96], activating its enzymatic function. 
Thereby, OASs induce degradation of viral RNAs. 
1.2 RNA viruses 
As mentioned in the previous sections, RLRs are the predominant cytosolic receptors for 
foreign RNAs, i.e. viral genomes. Hence, RLR signalling is strongly initiated after 
infection with viruses, especially those with RNA genomes since these will, at some 
point, give rise to replication intermediates recognised by RLRs. This section will 
introduce the different RNA viruses used to trigger RLR signalling in the present study. 
1.2.1 Sendai virus 
Sendai virus (SeV), also called murine parainfluenza virus type 1, is a negative sense, 
single-stranded RNA virus belonging to the family of paramyxoviridae. While the natural 
host of SeV has not been identified, the virus seems to infect mostly rodents, although it 
was also isolated from humans. SeV causes mostly upper respiratory tract disease and 
was found to replicate with similar efficiency as human parainfluenza virus type 1 in the 
respiratory tract of nonhuman primates [97]. SeV infection in humans is usually 
asymptomatic, whereas it can be fatal in mice [98]. Replication of SeV genomes results 
in the formation of double-stranded intermediates which are recognised by RIG-I [20] 
and induce a strong IFN response. Interestingly, in addition to viral particles containing 
full-length viral genomes, Sendai virus infection also produces so-called defective 
interfering (DI) particles containing smaller fragments of the viral genome which do not 
support replication and, therefore, do not enhance viral spread [99]. Moreover, probably 
because they are 5’-triphosphorylated, double-stranded, and relatively short, they are 
strong inducers of interferons [100], [101]. 
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1.2.2 Rift Valley Fever Virus 
Belonging to the family of bunyaviridae, Rift Valley Fever virus (RVFV) has a segmented, 
single-stranded RNA genome of negative (L and M segment) and ambisense orientation 
(S segment). If transmitted from mosquito vectors to humans, RVFV causes mostly 
fevers, which in about 1% of all cases develop into severe haemorrhagic fever and 
meningoencephalitis [102]. Although RVFV replication does not produce large amounts 
of dsRNA, the 5’-triphosphorylated dsRNA panhandle structure of its genome is 
recognised by RIG-I and strongly induces IFN [103], [104] which RVFV is highly sensitive 
to. Consequently, mice are protected from disease when they are pre-treated with 
interferon-inducing agents [105]. In order to avoid and counteract recognition by RIG-I, 
the S segment of the RVFV genome encodes non-structural protein NSs, a potent 
inhibitor of IFN signalling. This is reflected in RVFV clone 13 which is attenuated due to a 
large in-frame deletion within the NSs gene [106]. Among other effects, NSs was found 
to shut off cellular translation by sequestration of transcription factor II H (TFIIH) [107]. 
Moreover, NSs induces proteasomal degradation of PKR [108] which, if not degraded, is 
a strong inhibitor of RVFV replication. Deletion of NSs does not only result in attenuation 
of RVFV virus and increased IFN sensitivity, but also allows the introduction of reporter 
genes in its place. A luciferase-tagged RVFV has been used to study the effect of IFN 
pre-treatment on viral replication [109] and is employed in RVFV replication assays 
within this study. 
1.2.3 Influenza A virus 
Influenza A virus (FluAV) belongs to the family of orthomyxoviruses, together with 
influenza B, C, and D virus. It is the most common and also the most virulent of the 
different types of influenza. FluAV has a negative-sense ssRNA genome which is divided 
into 8 segments. The best-characterised viral proteins are hemagglutinin (H) and 
neuraminidase (N) which are used to classify FluAV serotypes (e.g. H5N1, “bird flu”). 
FluAV causes annual epidemics which are characterised by slight changes in 
antigenicity, usually requiring a new round of vaccination each year to sustain protection 
[110]. Infection with FluAV leads to febrile disease accompanied by headache, 
weakness, cough, muscle and joint pain, and can become severe, resulting in viral 
pneumonia, secondary bacterial pneumonia and heart failure. Similar to RVFV, 
complementary regions in the 5’ and 3’ regions of the FluAV genome form a panhandle 
structure which is recognised by RIG-I [111]. Additionally, U/A-rich stretches in the 
untranslated region of the FluAV genome activate RIG-I independently of a 5’-
triphosphate [112]. Induction of IFN is efficiently inhibited by FluAV NS1 protein, which 
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was shown to interact with a multitude of cellular proteins (e.g. RIG-I or TRIM25 [18], 
[113]) thereby repressing the RIG-I signalling pathway [114]. Influenza A/WSN/(19)33 of 
serotype H1N1 replicates in many different cell lines [115] and is used in this study to 
examine RIG-I signalling in response to FluAV infection. 
1.2.4 Hepatitis C virus 
A member of the family of flaviviridae, Hepatitis C Virus (HCV) is a member of the genus 
hepacivirus. HCV is a positive-strand ssRNA virus which is hepatotropic and causes 
chronic hepatitis in the majority of infected individuals. Perpetual liver inflammation often 
leads to the development of liver cirrhosis and hepatocellular carcinoma. Spontaneous 
clearance within acute HCV is very rare and is usually associated with rapid induction of 
IFN and ISGs early in infection and a delayed onset of the adaptive immune response 
[116]. Both RIG-I and MDA5 have been reported to be involved in the sensing of HCV 
replication intermediates [42], [117] and will induce IFN in response to HCV infection. As 
an evasion mechanism HCV NS3-4A protease cleaves MAVS off the mitochondrial 
membrane and inhibits IFN induction (figure 3 and [118]). By tagging the viral genome 
with a reporter gene HCV replication can be monitored [119]. The present study made 
use of a HCV JCR2A, a genotype 2 reporter virus harbouring a renilla luciferase gene. 
1.3 Post-transcriptional modifications modulating the RLR signalling 
pathway 
Several different post-translational modifications (PTMs) are necessary for effective 
induction of antiviral signalling, be it on the level of IRF induction by RLRs or the IFN 
signalling pathway resulting in the expression of ISGs. ISGylation is an important PTM 
directly induced by IFN signalling, which influences RIG-I stability [91], and has been 
described in the previous section. Furthermore, acetylation of IFNARs was mentioned as 
another PTM which modulates IFN signalling [65]. There is a plethora of different PTMs 
many of which are involved in regulating the RLR signalling pathway, but the most 
prominent and well-studied ones are ubiquitinylation and phosphorylation, which the 
following sections will describe in more detail. 
1.3.1 Ubiquitinylation 
Section 1.1.4 already highlighted that ubiquitinylation is necessary for proper signalling 
induction by RLRs, e.g. for the activation of effector kinase TBK1 by E3-ubiquitin ligase 
TRAF3. Generally, ubiquitinylation can have several effects on a protein target. The best 
understood are K48-linked ubiquitinylation which targets a protein for proteasomal 
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degradation [120], and K63-linked ubiquitinylation which, in contrast, often activates the 
target [121]. Ubiquitinylation is carried out by three different enzymes, the ubiquitin-
activating enzyme (E1), the ubiquitin-conjugating enzyme (E2), and an ubiquitin-ligase 
(E3) which transfers activated ubiquitin onto a target protein. There are over 600 E3-
ubiquitin ligases encoded in the human genome which allows precise regulation of 
signalling pathways. 
Already early in the initiation of antiviral signalling, on the level of receptor activation, the 
RLR signalling pathway is controlled by ubiquitinylation. K63-linked ubiquitinylation of the 
RIG-I CARD domains by TRIM25 and RING finger protein 135 (RNF135, also called 
Riplet) are necessary for tetramerisation and MAVS interaction [122], [123]. Only 
recently, a similar activating mechanism was found for MDA5 whose oligomerisation 
depends on TRIM65 K63-linked ubiquitinylation [124]. Interestingly, RIG-I is not only 
down-regulated by K48-linked ubiquitinylation by RNF125 [125], but its activity is also 
decreased by USP3 and ubiquitin C-terminal hydrolase [126], [127] which remove 
previously attached activating ubiquitin chains. Control of RLR activity is also carried out 
by enzymes like USP15. This deubiquitinylating enzyme has a dual role in RLR 
signalling. It removes inactivating K48-linked ubiquitin chains from TRIM25 on the one 
hand, but may also remove K63-linked ubiquitin chains from RIG-I [128], [129]. 
Ubiquitinylation further controls RLR signalling downstream of its RNA sensors. Central 
signalling adaptor MAVS itself is subject to activating ubiquitinylation by TRIM31 [52], but 
is, at the same time, also regulated through K48-linked ubiquitinylation by TRIM25, a 
mechanism which is thought to detach MAVS from its mitochondrial location, releasing 
the signalling complex to the cytosol [130]. Among many other negative regulators of 
MAVS activity, membrane-associated RING finger protein 5 (MARCH5), a mitochondrial 
membrane-bound E3 ligase, plays an important part in MAVS inactivation since it 
resolves MAVS aggregates at the mitochondria by marking them for proteasomal 
degradation [131]. 
E3-ubiquitin ligases TRAF3 and TRAF6 are mediators of RLR signalling directly 
downstream of MAVS. They are not only auto-ubiquitinylated but also activate their 
targets TBK1 and IKKs, engaging IRF3 and NFkB. At the same time, TRAF3 and TRAF6 
activity is tightly regulated by enhancing ubiquitinylation, e.g. by RNF166 which targets 
both TRAFs [132], and inhibiting/down-regulating ubiquitinylation, such as that conferred 
by cellular inhibitor of apoptosis 2 (cIAP2) which mostly targets TRAF3 [133]. 
Interestingly, cIAP2 itself is activated by TRAF6 and can also increase TRAF3 activity, 
suggesting that, depending on the context, cIAP2 can serve as an activator or as an 
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inhibitor of antiviral signalling [134]. There are also a number of cellular deubiquitinases 
targeting TRAF3 and TRAF6, which will suppress RLR signalling. 
Although TRAF-activated effector kinases TBK1 and IKKe are quite similar and often 
simultaneously induced upon viral infection, there are functional differences between the 
two. A mechanism which could confer a different means of regulation of IKKe and TBK1 
could be K63-ubiquinitylation by mindbomb 1 (MIB1) which only targets TBK1 [135]. 
Additionally, there are a few ubiquitinylation events which target TBK1 for proteasomal 
degradation. 
Lastly, activity of IRF3 and IRF7 is greatly influenced by ubiquitinylation. Only some of 
the multiform ubiquitinylation events which regulate the IRFs will be highlighted here. 
Nuclear activated IRF3 quickly binds peptidyl-prolyl cis/trans isomerase NIMA-interacting 
1 (Pin1) which promotes IRF3 degradation [136]. Among others, TRIM26 was found to 
K48-ubiquitinylate IRF3 [137]. Since down-regulation of IRF3 is undesirable in early 
stages of infection, there are several mechanisms which inhibit premature IRF3 
degradation. Again, there are factors which have a dual role in IRF3 degradation, 
capable of either stabilising or degrading IRF3. One of these is TRIM21, which may on 
the one hand interrupt IRF3-Pin1 interaction, but can on the other hand also target IRF3 
for proteasomal degradation [138], [139]. Importantly, TRIM21 also targets and down-
regulates IRF7, although this mechanism was, so far, only studied in TLR-mediated 
signalling [140]. IRF3 activity is, furthermore, stabilised by HECT and RRC1-ilke domain-
containing protein (HERC5) which ISGylates several residues on IRF3 so that it cannot 
bind to Pin1 [141]. This interplay between ISGylation and ubiquitinylation highlights that 
different PTMs are employed to fine-tune the RLR signalling pathway. 
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Figure 5 RIG-I signalling is regulated by 
ubiquitinylation events which are 
targeted by viral effectors 
K63-linked ubiquitinylation may activate effectors 
of the RIG-I signalling network and happens on 
every level of pathway activation. At the same 
time, this is counteracted by K48-linked 
ubiquitinylation which targets RLR signalling 
effectors for proteasomal degradation. Examples 
for viruses which target ubiquitinylation events 
are shown. IAV, Influenza A virus. HBV, 
Hepatitis B virus, SARS CoV, SARS-associated 
corona virus. HSV, Herpes simplex virus. HIV, 
human immunodeficiency virus. RoV, Rotavirus. 
KSHV, Kaposi’s sarcoma-associated 
herpesvirus. Adapted from [142]. 
 
 
 
 
 
 
In summary, ubiquitinylation is a major PTM which modulates the RLR signalling 
pathway and occurs on every level of pathway activation. It is used to target most 
effectors of the RLR signalling cascade and can have, based on the composition of 
ubiquitin chains, either negative or positive influence on effector activity. Consequently, 
many viruses encode proteins which counteract cellular ubiquitinylation events, an 
overview of which is given in figure 5. 
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1.3.2 Phosphorylation 
Protein phosphorylation is one of the most common PTMs influencing protein activity. 
Often, phosphorylation of a protein by a kinase is directly counter-regulated by a 
phosphatase, creating a dynamic and flexible equilibrium in phosphorylation events. 
As was mentioned in section 1.1.4, some of the main effector proteins in the RLR 
signalling pathway are kinases signalling downstream by their ability to phosphorylate 
the respective target, like TBK1 and IKKe, which are both capable of IRF3 and IRF7 
phosphorylation. Similarly, NFkB activation requires phosphorylation of IkBa by the 
activated IKKa/IKKb/NEMO complex. This section is not going to focus on those 
phosphorylation events which are employed to directly transfer the signal resulting in 
gene transcription, but rather highlight a few phosphorylation events which influence 
RLR signalling effector activities. With over 500 members [143], the human kinome 
provides a variety of candidates which are potentially capable of influencing RLR 
signalling, many of which might not have been studied in this context yet. 
RIG-I and MDA5 activity is regulated by several (de)phosphorylation events. Firstly, 
dephosphorylation of both RLRs is necessary for IFN production in response to various 
RNA viruses. Phospho-protein phosphatases 1 a and g (PP1a/g) were identified to 
remove inhibiting phosphate moieties from the CARD domains of both RLRs [144]. 
Furthermore, RIG-I activity is inhibited by protein kinase C a and b (PKCa/b), as well as 
casein kinase II (CK2) which phosphorylate residues in its CARD, as well as its RD 
domain, respectively [145], [146]. In this context, phosphorylation of RIG-I CARD 
domains was shown to inhibit TRIM25-RIG-I interaction. For MDA5, RIO kinase 3 
(RIOK3) was reported as a negative regulator, phosphorylating the C-terminus of MDA5 
and blocking oligomerisation [147]. 
Although there are a few signalling pathways which result in TBK1 activation, not all of 
them culminate in an activation of IRF3 and subsequent expression of IFNs. 
Remarkably, it was recently discovered that phosphorylation of MAVS by TBK1 was 
required for IRF3 recruitment. Moreover, this mechanism was found to be conserved 
among all IRF3-mediated IFN-inducing signalling pathways, including the cGAS/STING 
pathway of DNA recognition and TRIF-mediated signalling after TLR stimulation [148]. 
There are indications that tyrosine phosphorylation of MAVS is not only increased after 
viral infection, but is even required for proper signal transmission [149]. Finally, there are 
also phosphorylation events limiting MAVS activity. One of these is conferred by polo-like 
kinase 1 (PLK1) which inhibits MAVS-TRAF3 interaction [150]. 
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Downstream of MAVS, (de)phosphorylation controls not only TRAF3 and TRAF6 activity, 
but also TBK1 activity since it is recruited to active TRAF3. As a matter of fact, without 
CK1e-mediated phosphorylation TRAF3 is not efficiently ubiquitinylated and therefore 
incapable of TBK1 recruitment [151]. Phosphorylation of TRAF6 by serine/threonine 
kinase 26, on the contrary, inhibits TRAF6 auto-ubiquitinylation and oligomerisation 
which inhibits an inflammatory response [152]. 
TBK1 itself undergoes auto-phosphorylation at serine 172 (S172) [153], an event which 
is facilitated by interaction with GSK3b. Remarkably, this happens independently of 
GSK3b kinase activity [154]. TBK1 phosphorylation by proto-oncogene tyrosine-protein 
kinase Src, however, is required for efficient auto-phosphorylation. Interestingly, Src 
does not directly interact with TBK1, but is instead recruited to signalling complexes by 
adaptors like MAVS or STING [155]. Based on these findings, it is not surprising that 
removal of the S172 phosphate moiety by protein phosphatase 1 b (PPM1B) reduces 
TBK1 activity, resulting in decreased IFN production in response to virus infection [156]. 
Similar mechanisms probably regulate IKKe activity which was, similar to TBK1, found to 
auto-phosphorylate at S172 [157], but has not been investigated as extensively. 
Within the RLR signalling pathway, phosphorylation events for IRF3 and IRF7 were 
found to be mediated predominantly by TBK1 and IKKe. While these kinases 
phosphorylate several residues at the IRF3 and IRF7 C-terminus, thereby activating the 
transcription factors, protein phosphatase 2A (PP2A) counteracts this by IRF3 
dephosphorylation, dependent on its adaptor Receptor of activated protein C kinase 1 
(RACK1) [158]. 
As described in this section, protein (de)phosphorylation is one of the most important 
PTMs in RLR signalling and influences protein activity, stability and interaction on every 
level of signal transmission. Since its discovery, many kinases and phosphatases have 
been found to modulate the RLR signalling cascade. Hence, it is feasible that out of the 
hundreds of seemingly uninvolved kinases at least a few more are important regulators 
of antiviral signalling. 
This study focuses on a family of kinases which influences RIG-I signalling, the death-
associated protein kinases (DAPKs), which the next section is going to introduce. 
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1.4 Death-associated protein kinases 
The death-associated protein kinase (DAPK) family consists of five members, namely 
DAPK1, DAPK2, DAPK3, serine threonine kinase 17A (STK17A)/DAPK-related 
apoptosis inducing kinase1 (DRAK1), and STK17B/DRAK2. An overview of the kinases 
is shown in figure 6. Only DAPK1 and DAPK2 are calmodulin (CaM)-dependent kinases 
and possess a CaM auto-regulatory domain. Both DAPK1 and DAPK2 undergo an auto-
phosphorylation mechanism on serine 308/318 in their CaM domain (figure 6) which 
regulates their kinase activity. Both kinases attain full kinase activity when they are 
dephosphorylated [159], [160]. 
Based on the structure of their kinase domains DAPKs are related to myosin light chain 
kinases (MLCKs). Accordingly, they phosphorylate myosin light chain which results in 
membrane blebbing [159], [161]–[163]. All DAPKs are serine/threonine kinases and are, 
as their name suggests, involved in the induction of cell death. While DAPK1, DAPK2, 
and DAPK3 have been described to induce both type I (apoptotic) and type II 
(autophagic) cell death, DRAK1 and DRAK2 have, so far, only been linked to apoptotic 
cell death. DAPK1, DAPK2, and DAPK3 are, furthermore, considered tumour 
suppressors. 
 
Figure 6 Overview of the family of death-associated protein kinases 
The DAPK family comprises five kinases. DAPK1 is its founding member and the largest protein. In addition 
to its kinase and CaM domain, DAPK1 contains 8 Ankyrin repeats, a ROC-COR domain, and a death 
domain (DD). The kinase domains of DAPK2 and DAPK3 display 80% and 83% amino acid sequence 
homology to DAPK1. Like DAPK1, DAPK2 is a CaM-dependent kinase and contains a C-terminal domain 
with no homology to any known protein. DAPK3 contains several nuclear localisation signals (NLS) and a C-
terminal leucine zipper domain. The kinase domains of DRAK1 and DRAK2 share less amino acid sequence 
homology to DAPK1, but are highly homologous to each other. 
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This section is going to introduce the DAPKs and key findings about their role in cellular 
metabolism, while section 1.5 focuses on the cell death pathways DAPKs have been 
found to influence. 
1.4.1 DAPK1 
In addition to its kinase and CaM domain, DAPK1 contains 8 Ankyrin repeats, a ROC-
COR domain and a death domain (DD). It is the founding member of the DAPK family of 
protein kinases and was originally described as the main effector of IFNg-induced cell 
death in HeLa cells [164]. Interestingly, it was later discovered that IFNg-stimulation 
induced DAPK1 expression in an cyclic AMP-dependent transcription factor 6 
(ATF6)/ERK-dependent fashion and resulted in the induction of autophagy dependent on 
apoptosis signal-regulating kinase 1 [165], [166]. 
As mentioned above, DAPK1 was first identified as a mediator of apoptosis induction, 
e.g. in response to transforming growth factor b (TGFb) stimulation [167]. Furthermore, 
netrin receptor UNC5H2 induces apoptosis via DAPK1. UNC5H2 directly interacts with 
DAPK1 via its DD and recruits PP2A which dephosphorylates DAPK1 S308 and thereby 
increases its activity [168], [169]. DAPK1 does not only mediate type I (apoptotic) cell 
death, but also type II (autophagic) cell death. Autophagy induction by DAPK1 is 
achieved through either phosphorylation of Beclin1 or protein kinase D (PKD), which has 
similar outcomes. Phosphorylated Beclin1 is released from a complex with B cell 
lymphoma 2 (Bcl-2) or Bcl-XL, allowing interaction with and activation of lipid kinase 
autophagy-promoting vacuolar protein sorting 34 (VPS34). Activation of PKD results in 
direct phosphorylation of VPS34, which, once activated, produces phosphatidylinositol 3 
phosphate (PI3P) and thereby promotes autophagosome formation ([170]–[172]). 
In addition to its cell death promoting function, DAPK1 influences a variety of other 
processes and pathways in the cell. 
One of the main cellular functions of DAPK1 seems to be that of a tumour suppressor, 
which was first postulated based on the finding that its promoter region is frequently 
hyper-methylated in a variety of solid tumours [173]–[175] and in follicular lymphoma 
[176]. As a matter of fact, DAPK1 was not only found to activate p53 in a p19ARF-
dependent manner which suppresses oncogenic transformation [177], but was also 
found to control metastasis formation, most probably by inhibition of integrin-mediated 
cell polarity pathways [178], [179]. 
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Additionally, DAPK1 is important in brain metabolism. DAPK1 not only mediates 
neuronal cell death by direct phosphorylation of p53 in ischemic tissue, but also binds 
and phosphorylates NMDA receptor NM2B which results in exacerbated brain damage 
after stroke due to increased Ca2+ influx [180], [181]. Moreover, DAPK1 contributes to 
the development of Alzheimer’s disease. Direct phosphorylation of Pin1, which regulates 
tau protein stability, and tau itself by DAPK1 promote tau aggregation [182]–[184]. 
Interestingly, cell growth and survival, especially via ERK-mediated growth factor 
signalling, is positively and negatively regulated by DAPK1. Src, a kinase identified as a 
proto-oncogene, which signals downstream of the epithelial growth factor receptor 
(EGFR) phosphorylates residues located in the DAPK1 Ankyrin repeats resulting in 
DAPK1 inhibition. LAR phosphatase counteracts Src-mediated phosphorylation [185]. 
Unlike Src, its downstream effector ERK does not inhibit DAPK1, but promotes its 
apoptotic function, phosphorylating serine 735 within the DAPK1 DD. As ERK itself is a 
target of DAPK1, its phosphorylated form being retained in the nucleus, this describes a 
positive feedback mechanism, which, ultimately, results in cell death [186]. To make 
matters even more complex, DAPK1 targets the tuberous sclerosis 1 (TSC1)/TSC2 
complex which results in activation of the mammalian target of rapamycin (mTOR) 
complex [187]. This promotes cell growth and survival by activation of ribosomal S6 
kinase (RSK). RSK itself targets and inhibits DAPK1 which constitutes another feedback 
mechanism reinforcing cell survival [188]. Hence, depending on the activity and 
expression of different growth factor pathway members, DAPK1 can either promote or 
inhibit cell death. 
Recently, the importance of recognising the role of DAPK1 in cell survival was 
highlighted as it was discovered that, other than previously assumed, DAPK1 does not 
always act as a tumour suppressor. On the contrary, it can promote tumour growth in 
cancers harbouring p53 mutations, since its cell death-inducing function is based on an 
activation of p53. In combination with its ability to enhance cell growth by activation of 
the mTOR signalling pathway, loss of cell death inducing properties of DAPK1 actually 
makes it an oncogene. This was demonstrated not only in p53 mutant breast cancer, but 
also ovarian cancer and pancreatic cancer [189]. 
Because of the manifold role of DAPK1 in both cell death and survival, its activity is 
tightly controlled. On the one hand, DAPK1 S308 needs to be dephosphorylated in order 
to allow interaction with CaM for full kinase activity, as was mentioned above. On the 
other hand, several other kinases phosphorylate and thereby activate or deactivate 
DAPK1, such as previously mentioned Src, ERK, and S6K. Another level of 
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intramolecular regulation of activity is provided by the ROC-COR domain of DAPK1 
which has intrinsic GTPase activity [190]. Upon binding of GTP to DAPK1 ROC-COR 
S308 auto-phosphorylation is increased  and DAPK1 activity is reduced [191]. 
DAPK1 protein stability is controlled by chaperone Heat Shock Protein 90 (HSP90). 
Upon inhibition of HSP90, activated DAPK1 is ubiquitinylated by E3 ligases carboxyl 
terminus of HSC70-interacting protein (CHIP) or MIB1 and degraded [192]–[194]. MIB1 
has been described to regulate the innate immune response (section 1.3.1 and [135]), 
and could provide a link between DAPK1 and innate signalling. Another E3 ligase, kelch-
like protein 20 (KLHL20), interacts with the DAPK1 DD and marks DAPK1 for 
degradation. KLHL20 is inhibited by IFNa and IFNg treatment and DAPK1 levels are 
stabilised [195]. This is another finding that connects DAPK1 to immune signalling. 
As a matter of fact, DAPK1 has been examined in the context of immune and 
inflammatory responses. It was found to inhibit NFkB activation after T cell receptor 
stimulation by promoting IKK sequestration in membrane rafts [196] and was identified 
as a crucial activator of NLRP3 inflammasome assembly, as loss of DAPK1 impaired IL-
1b maturation [197]. Importantly, DAPK1 was initially described as an IRF3/IRF7-
interacting protein based on a yeast two hybrid screen. In the respective study, DAPK1 
promoted IFN signalling independently of its kinase activity [198]. In contrast to that, our 
group has very recently described DAPK1 to control RIG-I activity by inhibitory 
phosphorylation. We have established that DAPK1 is involved in a negative feedback 
loop which helps to control IFN induction after initial RIG-I activation [199]. Parts of the 
findings which contributed to that publication are presented in the results section of this 
study. 
1.4.2 DAPK3 
DAPK3 was first described three years after the discovery of DAPK1 as a 54 kDa large 
kinase similar to DAPK1 which mediates apoptosis induction and contains a leucine 
zipper domain [200]. Hence, it is also called zipper-interacting kinase (ZIPK). DAPK3 
leucine zipper domains were found to mediate heterodimerisation [200] and might also 
mediate DAPK3 homodimerisation [201]. DAPK3 contains two nuclear localisation 
signals (NLS, figure 6). Thus, DAPK3 can translocate to the nucleus depending on the 
phosphorylation status of specific residues located close to its NLS sequences [202]. 
Generally, DAPK3 is highly phosphorylated which directly influences its kinase activity. A 
residue which was found to be especially important for full DAPK3 kinase activity is 
threonine 265 (T265), whose phosphorylation is induced in response to IL-6 stimulation 
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[203], [204]. Interestingly, DAPK3 is phosphorylated and activated by DAPK1, which 
demonstrates that DAPKs interact and might depend on each other in order to attain full 
activity [201]. 
DAPK3 induces apoptosis by phosphorylation of MDM2 and p21WAF1 both of which are 
effectors of the p53 pathway [205]. Furthermore, DAPK3 interacts with pro-apoptotic 
PRKC apoptosis WT1 regulator protein (Par4) and induces mitochondrial cytochrome c 
release [206]. Just as DAPK1, DAPK3 is involved in autophagy induction. It 
phosphorylates myosin II, facilitating autophagosome formation [207], and Beclin1 [208]. 
Interestingly, DAPK3 does not target the same residues on Beclin1 as DAPK1, indicating 
a non-redundant role for DAPK3 in controlling autophagy induction. There are indications 
that DAPK3 is, additionally, involved in cell cycle control as it was not only shown to 
localise to centrosomes and the contractile ring during mitosis [209], but also interacts 
with cell division cycle 14A (cdc14A) phosphatase which is known to influence cell cycle 
progression [210]. 
Reminiscent of what has been reported for DAPK1, DAPK3 is thought to be a tumour 
suppressor as it often harbours loss of function mutations in different cancers [162], 
[211]. In prostate cancer DAPK3 is specifically inhibited. Thus, cancer cell survival is 
increased due to diminished autophagy induction [212], [213]. Remarkably, a recent 
study described DAPK3 to modify the ERK signalling pathway in non-small cell lung 
cancer, resulting in promotion of cell growth and division [214]. Hence, it is possible that, 
just like DAPK1, DAPK3 has a dual role in cell death and survival. 
To this day, DAPK3 has not been linked to classical immune-modulatory signalling 
pathways, but has been described in the context of inflammation, albeit with conflicting 
results. DAPK3 promotes vascular inflammation in the context of hypertension by 
promoting p38 and Akt activity [215], but also represses inflammatory genes by 
phosphorylation of ribosomal protein L13a, a central regulator of inflammation [216]. 
This study describes DAPK3 as a potential regulator of RIG-I-mediated antiviral 
signalling. 
1.4.3 DAPK2 
DAPK2 is a 43 kDa protein and, therefore, significantly smaller than DAPK1 and slightly 
smaller than DAPK3 (figure 6). Its most common isoform, DAPK2a, contains, in addition 
to its kinase and CaM-regulatory domain, a C-terminal domain which is not homologous 
to any known protein [217]. Interestingly, an alternatively spliced isoform termed 
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DAPK2b was discovered in which the extra-catalytic part of the kinase is replaced with a 
sequence similar to the extra-catalytic region of DAPK3, harbouring a leucine zipper 
domain. DAPK2b apparently retains all of its kinase-related functions towards known 
DAPK2 substrates, but appears to have some DAPK3-related properties as well, such as 
binding of transcription factor ATF4 [218]. In this study, analyses focused on the more 
common DAPK2a, referred to as DAPK2 in the rest of this thesis. 
As mentioned above, DAPK2 activity is increased by dephosphorylation at S318 which 
also enhances DAPK2 homodimerisation. Consequently, a S318D phospho-mimetic 
mutant is kinase inactive, whereas a S318A mutant displays increased kinase activity. 
The C-terminal domain of DAPK2 seems to be necessary for dimerisation and full 
DAPK2 activity [160], [217], [219]. 
Just like DAPK1 and DAPK3, DAPK2 acts as a tumour suppressor. Restoring DAPK2 
expression in tumours induces apoptosis in malignant cells [220]. Additionally, DAPK2 
expression is frequently reduced in hepatocellular carcinomas, but can be induced by 
thyroid hormone stimulation which suppresses carcinogenesis via autophagy induction 
[221]. 
Although DAPK2 can promote cell death, the extent to which it induces apoptosis is still 
not clear. It was reported that membrane blebbing and cell detachment after DAPK2 
over-expression happened independently of caspase activation [219]. In line with this, 
another group showed inhibition of DAPK2 in granulocytes did not interfere with 
apoptosis induction and could not detect an increase in apoptotic cell death after DAPK2 
over-expression [222]. DAPK2 inhibition in granulocytes, however, resulted in loss of 
migration due to improper polarisation. Furthermore, it was found that epithelial cancer 
cells were unaffected by DAPK2 over-expression as long as they were attached to the 
extracellular matrix (ECM), but induced apoptosis in response to DAPK2 expression 
when ECM attachment was lost [223]. Apoptosis induction by DAPK2 was further linked 
to cell polarity and cytoskeletal organisation by the finding that DAPK2 binds tubulin and 
promotes apoptosis after nocodazole treatment [224]. Importantly, DAPK2 activity is 
down-regulated by binding of anti-apoptotic 14-3-3 proteins, an interaction which is 
promoted by survival kinase Akt-mediated phosphorylation of DAPK2 [225], [226]. Thus, 
extra- and intracellular cues seem to determine if and to which extent DAPK2 promotes 
apoptosis. Interestingly, DAPK2 might behave similar to DAPK1 in that it might promote 
cell survival in some instances since tumor necrosis factor ligand superfamily member 10 
(TRAIL)-induced apoptosis is increased after DAPK2 knockdown [227]. 
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The role of DAPK2 in autophagy is less controversial. One of the first reports on DAPK2 
already reported that it localised to autophagic vesicles [219], and it was later discovered 
that DAPK2 negatively regulates mTOR signalling by phosphorylation of raptor [228]. 
Moreover, a recent screening approach found that DAPK2 interacted with ATG14, a 
member of the Beclin1-VPS34 autophagy-promoting complex [225]. DAPK1, DAPK3, 
and DAPK2 seem to differently regulate cell death induction. These non-redundant 
mechanisms might confer increased control of cell death pathways, which, ultimately, 
ensures proper regulation of cellular metabolism and survival. 
So far, DAPK2 has not been examined in the context of immune regulation. This study 
links DAPK2 activity to regulation of the RIG-I signalling pathway. 
1.4.4 DRAK1 and DRAK2 
DRAK1/STK17A and DRAK2/STK17B were identified by searching existing expressed 
sequence tag (EST) clone libraries for sequences homologous to DAPK1. Although their 
kinase domains display only ~50% amino acid homology to that of DAPK1, DRAKs 
behave similar to conventional DAPKs in that they are subject to auto-phosphorylation 
and phosphorylate MLC. They were also initially described to be inducers of apoptosis 
[163], although the exact mechanisms have not been investigated. 
Interestingly, there is no DRAK1 orthologue in the mouse genome, but mouse DRAK2 
was reported to behave similar to human DRAK1. Unlike DAPK1, which promotes 
apoptosis upstream of p53, DRAK1 seems to be a p53-induced protein which mediates 
cell death downstream of p53 activation [229]. However, DRAK1 can also have a dual 
function in that it promotes cell growth and survival, as was shown in glioblastoma where 
high DRAK1 expression correlates with poor prognosis [230]. Furthermore, high DRAK1 
expression in head and neck cancers results in suppression of TGFb signalling and, 
therefore, reduced expression of p21WAF, leading to increased cell survival and growth 
[231]. 
Whether DRAK2, which is highly expressed in human T cells, influences TGFb signalling 
is still debated. While one study described a negative feedback regulation of TGFb 
signalling by DRAK2 in T cells [232], another study could not reproduce these findings 
using cells from DRAK2-deficient mice [233]. It seems clear, however, that DRAK2 is 
involved in T cell receptor signalling, most probably as a negative regulator [234], [235]. 
Unlike DRAK1, DRAK2 has been described in the context of viral infection. It was 
reported to contribute to lethal encephalitis in WNV infection as DRAK2-/- mice had 
Page | 29 
 
 
Introduction 
significantly reduced viral titres and lower numbers of T cells in the brain compared to 
WT mice [236]. Whether this is due a role of DRAK2 in T cell migration or pro-
inflammatory responses which might influence the permeability of the blood brain barrier 
is not yet clear. In murine coronavirus infection DRAK2 deficiency results in increased T 
cell activation and memory [237]. 
It remains to be determined if and how DRAKs might influence innate immune signalling 
in response to viral infection. Some findings concerning RIG-I signalling regulation by 
DRAK1 are described in this study. 
1.5 Cell death 
To this day, several forms of programmed cell death have been identified, such as 
apoptosis, autophagy, necroptosis, and pyroptosis. As DAPKs have been described in 
the context of apoptosis and autophagy, this introduction is going to focus on these two 
best known and investigated types of cell death. 
1.5.1 Apoptosis 
The process of apoptosis has been studied extensively and is relatively well understood. 
It can be triggered either extrinsically, e.g. by growth factor withdrawal or ligand binding 
to death receptors, or intrinsically, e.g. by DNA damage. Extrinsic and intrinsic apoptotic 
pathways engage different effectors but both culminate in the activation of caspases, 
which are ubiquitously expressed as inactive zymogens. Initiator caspases, such as 
caspase 8 and 9, are usually activated by homodimerisation and subsequent proteolytic 
cleavage and will then activate effector caspases, such as caspase 3 or caspase 7 [238]. 
Activation of those culminates in proteolytic degradation of cellular components, resulting 
in membrane blebbing, cell shrinkage, chromatin condensation as well as nuclear 
fragmentation, all of which are typical signs of apoptosis. Apoptotic bodies produced 
during this process are taken up by phagocytic cells so that no intracellular molecules 
reach extracellular space where they could serve as inducers of inflammatory responses. 
A main inducer of the intrinsic apoptotic pathway is p53 which is usually activated in 
response to DNA damage and will activate Bcl-2 associated X protein (BAX) or Bcl-2 
homologous antagonist/killer (Bak) whose accumulation results in mitochondrial 
cytochrome C (cyt C) release and apoptosome formation (figure 7). 
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Figure 7 Overview of apoptotic 
pathways 
Binding of ligands of cell surface 
receptors CD95 or tumor necrosis 
factor superfamily member 1A (TNFR1) 
activates an apoptotic cascade 
resulting in the activation of procaspase 
8 whose activated form cleaves effector 
caspases 3 and 7. Intrinsic signals 
result in the inhibition of Bcl-2 (or Bcl-
XL) which releases Bax and Bak at the 
mitochondrial membranes. Pore 
formation by those two effectors 
releases cytochrome c (Cyt c) into the 
cytoplasm, contributing to apoptosome 
formation together with procaspase 9 
and Apoptotic protease-activating factor 
1 (APAF1). This again culminates in 
effector caspase activation which carry 
out the consecutive steps to apoptotic 
cell death. Inhibitors of apoptosis are 
highlighted in orange. Adapted from [239]. 
As described in the previous chapter, DAPKs promote apoptosis by different means, e.g. 
through interaction with p53 or promotion of cytochrome C release. 
Apoptosis induction is usually measured in the extent of caspase activity. Early after its 
discovery, it was found that activated caspase-3 cleaves poly(ADP-ribose) polymerase 
(PARP) [241], a protein usually involved in sensing DNA damage and eliciting repair 
[242]. The accumulation of cleaved PARP (c-PARP) is, therefore, a direct measure of 
caspase activity and apoptosis induction. 
1.5.2 Autophagy 
(Macro)autophagy is a process in which proteins and organelles are degraded by 
engulfing them in double membrane vesicles, the autophagosomes, which later fuse with 
lysosomes.  
Autophagy induction is inhibited by mTOR complex 1 (mTORc1) which restricts 
formation of the ULK1 complex necessary for isolation membrane formation, a step 
referred to as initiation. Consequently, inhibition of mTORc1, e.g. by small molecule 
inhibitors such as Torin-1 [243], will result in enhanced autophagy induction. After 
isolation membranes have been formed, nucleation leads to phagophore formation via a 
complex of activated Beclin1, VPS34, VPS15 and autophagy-related protein (ATG) 14L 
which locally induces phosphatidylinositol 3-phosphate (PI3P) production necessary for 
isolation membrane enlargement. Autophagy induction is, therefore, efficiently 
counteracted by inhibitors such as Spautin-1 which interfere with PI3P production [244]. 
In a final step, the isolation membranes are expanded by a complex consisting of ATG5, 
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ATG12, and ATG16, which facilitates the lipidation of microtubule-associated protein 1 
light chain 3 B (MAP1LC3B or LC3B) forming phosphatidylethanolamine-conjugated 
LC3B-II (LC3-PE). In its unlipidated state LC3B is referred to as LC3B-I. Cleavage of 
LC3B by ATG4 and subsequent lipidation (figure 8) change its running behaviour in 
polyacrylamide gels and can, therefore, be observed on Western Blot level by a shift of 
LC3B to a lower molecular weight [245]. As described above, by phosphorylation of 
mTORc1 member Raptor, Beclin1, or ATG4, DAPKs have been shown to promote 
autophagy induction. 
Ultimately, autophagosomes fuse with lysosomes, generating autolysosomes, in which 
their contents are degraded. Usually, autophagy precedes apoptosis and is detectable 
before phenotypic signs of apoptotic cell death are visible [246]. 
 
Figure 8 Overview of autophagosome formation and degradation of cellular components in the 
lysosome 
Autophagosome formation starting with initiation of isolation membranes by ULK1 complex, nucleation by 
recruitment of PI3P-producing Beclin1-VPS34 complex, and expansion by LC3(B)-PE is shown. Active 
mTORc1 inhibits autophagosome formation, just as Bcl-2 family members inhibit PI3P production. Adapted 
from [246]. 
 
  
Page | 32  Material 
2 Material 
2.1 General lab consumables 
Table 1 General lab consumables 
Name Supplier 
1,5 ml reaction tube Sarstedt AG & Co., Germany 
10 cm bacteria culture plate Falcon Corning GmbH, Germany 
12 well cell culture plate Corning GmbH, Germany 
15 ml Falcon Corning GmbH, Germany 
2 ml reaction tube Sarstedt AG & Co., Germany 
24 well cell culture plate Corning GmbH, Germany 
50 ml Falcon Corning GmbH, Germany 
6 well cell culture plate Greiner Bio-One GmbH, Germany 
96 well cell culture plate Corning GmbH, Germany 
96 well flat bottom plate Corning GmbH, Germany 
Cell scraper Sarstedt AG & Co., Germany 
CELLSTAR® Cell Culture Dishes  6cm Greiner Bio-One GmbH, Germany 
CELLSTAR® Cell Culture Dishes 10cm Greiner Bio-One GmbH, Germany 
CELLSTAR® Cell Culture Dishes 15cm Greiner Bio-One GmbH, Germany 
Cover slips Glaswarenfabrik Karl Hecht GmbH, Germany 
Cryo vials Greiner Bio-One GmbH, Germany 
Extra thick blotting paper Bio-Rad Laboratories GmbH, Germany 
Face mask Rösner-Mautby Meditrade Holding GmbH, Germany 
Filter 0,2 µm GE Healthcare, USA 
Filter 0,45 µm GE Healthcare, USA 
Glas slides SuperfrostTM Thermo Fisher Scientific Inc., USA 
Hard-Shell® 96-Well PCR Plates Bio-Rad Laboratories GmbH, Germany 
Neubauer counting chamber Neolab, Germany 
PVDF Western blot membrane Bio-Rad Laboratories GmbH, Germany 
Scalpel  B. Braun Melsungen AG, Germany 
Sealing sheets PCR plates Bio-Rad Laboratories GmbH, Germany 
Stericup® 0,22 µm Thermo Fisher Scientific Inc., USA 
Stericup® 0,45 µm Millipore, Germany 
Stripetten 2, 5, 10, 25 and 50 ml Corning GmbH, Germany 
Syringe 5, 10, 20 ml BD, Germany 
Tips 10, 100 and 1000, filtered STARLAB GmbH, Germany 
Tips 10, 200 and 1000 µl, refill pack Greiner Bio-One GmbH, Germany 
Tips 10, 200 and 1000, Stecksystem STARLAB GmbH, Germany 
Whatman filter paper GE Healthcare Life Sciences, UK 
XCEED Nitrile Gloves, S Barrier Safe Solutions International, Inc., USA 
2.2 Kits 
Table 2 Kits 
Name Supplier Application 
BD Cytofix/CytopermTM BD Biosciences, Germany FACS stain 
CalPhos™ Mammalian 
transfection kit BD Biosciences, Germany Lentiviral transduction 
High-Capacity cDNA Reverse 
Transcription Kit with RNase 
Inhibitor 
Thermo Fisher Scientific Inc., 
Germany 
Reverse transcription/cDNA 
preparation 
NucleoBond® PC 500 Macherey-Nagel GmBH & Co. KG, Germany Plasmid purification 
NucleoSpin® Gel and PCR Clean-
up 
Macherey-Nagel GmBH & Co. KG, 
Germany Gel and PCR purification 
NucleoSpin® Plasmid Macherey-Nagel GmBH & Co. KG, Germany Plasmid purification 
NucleoSpin® RNA Plus Macherey-Nagel GmBH & Co. KG, Germany RNA extraction 
Pierce™ BCA Protein Assay Kit Thermo Fisher Scientic Inc., 
Germany 
Determination of protein 
concentration 
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2.3 Chemicals and Reagents 
Table 3 Chemicals and reagents 
Name Supplier 
100 bp DNA ladder Thermo Fisher Scientific Inc., USA 
5x Q5® Reaction buffer New England Biolabs GmbH, Germany 
Aceton Sigma Aldrich, Germany 
Actinomycin D Sigma Aldrich, Germany 
Adenosine triphosphate Roche, Germany 
Agarose Sigma Aldrich, Germany 
Ammonium peroxydisulfate Carl Roth GmbH & Co. KG, Germany 
Anchored Oligo dT Primer Thermo Fisher Scientific Inc, USA 
Anti-HA, Agarose conjugate (beads) Sigma Aldrich, Germany 
Blasticidin S hydrochloride AppliChem, Germany 
BP clonase II Enzyme Mix Life Technologies, Germany 
BSA, IgG-free Sigma Aldrich, Germany 
BsmBI restriction enzyme New England Biolabs GmbH, Germany 
BsrGI restriction enzyme New England Biolabs GmbH, Germany 
BXT - biotin elution buffer IBA Life Sciences, Germany 
Calcium chloride dihydrate AppliChem, Germany 
Calf Intestinal Phosphatase New England Biolabs, Germany 
Calmodulin, bovine Th Geyer, Germany 
Calyculin A Sigma Aldrich, Germany 
Carbenicillin Thermo Fisher Scientific Inc., USA 
ClarityTM ECL Western Blotting Substrate Bio-Rad Laboratories GmbH, Germany 
Coelentarazine PJK, Germany 
Complete protease inhibitor cocktail Roche, Germany 
DEPC Carl Roth GmbH & Co. KG, Germany 
Dimethylsulfate VWR International, Germany 
Di-potassium phosphate Carl Roth GmbH & Co. KG, Germany 
D-Luciferin PJK, Germany 
DMEM, high glucose Life Technologies, Germany 
DMSO Carl Roth GmbH & Co. KG, Germany 
DNA Gel Loading Dye (6X) Thermo Fisher Scientific Inc, USA 
dNTPs Peqlab, Germany 
DTT Sigma Aldrich, Germany 
ECL Plus Western Blot Detection System PerkinElmer, Germany 
EDTA AppliChem, Germany 
Effectene transfection reagent Qiagen, Germany 
EGTA AppliChem, Germany 
Ethanol Sigma Aldrich, Germany 
Expand Reverse Transcriptase System Roche, Mannheim 
Fetal Calf serum (FCS) PAA Laboratories, USA 
FideliTaq USB, USA 
Gamma-32-ATP PerkinElmer, Germany 
Geneticin (G418) sulfate Santa Cruz Biotechnology, Inc, USA 
Gentamicin Life Technologies, Germany 
Gibson Assembly® Master Mix New England Biolabs GmbH, Germany 
Glycerol Sigma Aldrich, Germany 
HEPES Carl Roth GmbH & Co. KG, Germany 
Isopropanol Sigma Aldrich, Germany 
iTaqTM Universal SYBR® Green Supermix Bio-Rad Laboratories GmbH, Germany 
Kanamycin Serva, Germany 
Lambda DNA/Eco1301 (Styl) Marker AppliChem, Germany 
Lipofectamine 2000 Life Technologies, Germany 
Lipofectamine RNAiMax Life Technologies, Germany 
LR clonase II Enzyme Mix Life Technologies, Germany 
Magnesium chloride hexahydrate Merck Millipore, Germany 
Magnesium sulfate heptahydrate Merck Millipore, Germany 
MagStrep "type3" XT Beads IBA Life Sciences, Germany 
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MEM Non-essential amino acids Life Technologies, Germany 
Methanol Sigma Aldrich, Germany 
Midori Green Nippon Genetics Europe GmbH, Germany 
Milk powder, blotting grade Carl Roth GmbH & Co. KG, Germany 
NEBuffer Set 1.1, 2.1, 3.1 and Cutsmart New England Biolabs GmbH, Germany 
Nonidet P-40 AppliChem, Germany 
OptiMEM Life Technologies, Germany 
Paraformaldehyde, ultrapure Merck Millipore, Germany 
Penicillin/Streptomycin Life Technologies, Germany 
Pepton Sigma Aldrich, Germany 
Poly(I:C) Sigma Aldrich, Germany 
Poly(I:C), HMW InvivoGen, France 
Potassium dihydrogen phosphate AppliChem, Germany 
Precision Plus ProteinTM Dual Color Standard Bio-Rad Laboratories GmbH, Germany 
Purified recombinant RIG-I Joseph Marcotrigiano, NIH, Bethesda, USA 
Puromycin Sigma Aldrich, Germany 
Q5® High-Fidelity DNA Polymerase New England Biolabs GmbH, Germany 
Q-VD-OPh Biomol GmbH, Germany 
rNTPs Roche, Germany 
Rotiphorese® Gel 40 (29:1) Carl Roth GmbH & Co. KG, Germany 
Sodium chloride Sigma Aldrich, Germany 
Sodium fluoride Sigma Aldrich, Germany 
Spautin-1 Sigma Aldrich, Germany 
Spectinomycin Merck Millipore, Germany 
Staurosporine Biomol GmbH, Germany 
Sulfuric acid Carl Roth GmbH & Co. KG, Germany 
T4 DNA-Ligase Thermo Fisher Scientific Inc., USA 
T4 Polynucleotide Kinase Thermo Fisher Scientific Inc., USA 
TEMED AppliChem, Germany 
Torin-1 Sigma Aldrich, Germany 
Triton-X-100 AppliChem, Germany 
Trypsin-EDTA (0.05%) Thermo Fisher Scientific, Germany 
Tween-20 AppliChem, Germany 
Zeocin Thermo Fisher Scientific Inc., Germany 
β-mercapthoethanol Sigma Aldrich, Germany 
2.4 Instruments 
Table 4 Instruments 
Name Supplier 
Analytical balance LP-3102 VWR International GmbH, Germany 
Analytical fine balance LA-124i VWR International GmbH, Germany 
BD AccuriTM C6 Flow cytometer BD Biosciences, Germany 
Biological safety cabinet Safe 2020 Thermo Fisher Scientific, Germany 
C1000 Touch Termal Cycler Bio-Rad Laboratories GmbH, Germany 
Centrifuge 5424 Eppendorf AG, Germany 
Centrifuge 5424 R Eppendorf AG, Germany 
Centrifuge 5810 R Eppendorf AG, Germany 
Centrifuge HeraeusMultifuge 3S-R Thermo Fisher Scientific, Germany 
Centrifuge Sorvall RC-5C plus Sorvall, Germany 
CFX Connect™ Real-Time PCR Detection System Bio-Rad Laboratories GmbH, Germany 
CO2 Cell Incubator MCO-20AIC Panasonic Healthcare Co., Ltd., Japan 
Counting chambers Brand, Germany 
ECL ChemoCam imager 3.2 INTAS Science Imaging Instruments, Germany 
Electric Power Supply EPI 500/400 Amersham Pharmacia Biotech, Germany 
ELISA plate reader Multiskan Ex Thermo Fisher Scientific, USA 
Freezer Liebherr Premium Liebherr-International Deutschland GmbH, Germany 
Fridge Med Line Liebherr-International Deutschland GmbH, Germany 
Gel-iX-imager Intas Science Imaging Instruments, Germany 
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Heidolph Duomax 1030 Heidolph Instruments GmbH & Co. KG, Germany 
HI-2211 Bench Top pH & mV Meter HANNA instruments Deutschland GmbH, Germany 
Ikamag Reo Magnetic stirrer IKA®-Werke GmbH & CO. KG, Germany 
Immunofluorescence Microscope Leica CTR MIC Leica, Germany 
Microfuge B  Beckman, Germany 
Microscope Primovert Zeiss, Germany 
MicrowaveOven CLAtronic, Germany 
Mini-PROTEAN® Tetra Handcast Systems Bio-Rad Laboratories GmbH, Germany 
Mini Trans-Blot® Cell Bio-Rad Laboratories GmbH, Germany 
Mini-PROTEAN® Tetra Vertical Electrophoresis Cell Bio-Rad Laboratories GmbH, Germany 
Mithras LB 940 Multimode Microplate Reader Berthold Technologies, Germany 
Mithras² LB 943 Multimode reader Berthold Technologies, Germany 
Multi-Axle Rotating mixer NeoLab, Germany 
Multi-channel pipette 10-100 Eppendorf, Germany 
Multi-channel pipette 10-300 Eppendorf, Germany 
NanoDrop NP-1000 Thermo Fisher Scientific, Germany 
neoLab Mini Vacuum pump and compressor NeoLab, Germany 
PerfectBlue™ Gelsystem Mini S VWR International, Germany 
Pipetboy Acu 2 Integra Biosciences GmbH, Germany 
Pipette P10 Eppendorf AG, Germany 
Pipette P1000 Eppendorf AG, Germany 
Pipette P20 Eppendorf AG, Germany 
Pipette P200 Eppendorf AG, Germany 
PowerPacTM Basic Bio-Rad Laboratories GmbH, Germany 
PowerPacTM Hc Bio-Rad Laboratories GmbH, Germany 
ThermoForma Incubator 3862 Labotect, Germany 
Thermomixer Comfort 1.5 ml Eppendorf AG, Germany 
Thermomixer F1.5 Eppendorf AG, Germany 
Trans-Blot® SD Cell Bio-Rad Laboratories GmbH, Germany 
Trans-Blot® Turbo™ System Bio-Rad Laboratories GmbH, Germany 
UV Transilluminator VilberLourmat, Germany 
Vacuubrand BVC professional Vacuubrand GmbH & Co. KG, Germany 
Vortex Genie 2 Scientific Industries Inc., USA 
Waterbath GFL 1083 GFL, Germany 
2.5 Software 
Table 5 Software 
Name Supplier Application 
(Fiji Is Just) ImageJ Wayne Rasband, NIH, USA (imagej.nih.gov/ij) [247] 
Western Blot evaluation and figure 
generation 
Bio-Rad CFX Manager Bio-Rad Laboratories, Hercules, California, USA 
qRT-PCR evaluation and 
quantification 
FlowJo V10 FlowJo LLC, Ashland, Oregon, USA Flow cytometry evaluation 
GraphPad Prism 7 GraphPad Software, San Diego, California, USA Generation of graphs and figures 
Inkscape: Open Source Scalable 
Vector Graphics Editor, 0.91 
Inkscape Community (Open 
Source, www.inkscape.org) 
Generation of figures and vector 
graphics 
INTAS Chemostar INTAS Science Imaging, Göttingen, Germany Western Blot picture acquisition 
Labimage1D INTAS Science Imaging, Göttingen, Germany Western Blot quantification 
Microsoft Office 2010 Microsoft, Redmond, USA Documentation, Calculation, Data presentation 
SnapGene GSL Biotech LLC, Chicago, Illinois, USA Plasmid design and in silico cloning 
Zotero (Mozilla Firefox 
extension) 
Roy Rosenzweig Center for History 
and New Media, George Mason 
University, Fairfax, Virginia, USA 
Citation management and 
bibliography 
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2.6 Cells 
2.6.1 Eukaryotic cells 
Table 6 Eukaryotic cells 
Name Resistance Description 
293T DKFZ - Parental cell line for 293TRIG-I and 293TMDA5 
293T MCB - Lentiviral particle production 
293TRIG-I Blasticidin - 
293TMDA5 Blasticidin - 
293TRIG-I lenticrisp empty puro Blasticidin, Puromycin 
Empty vector control for CRISPR/Cas9 
DAPK1 or DAPK3 single KO cells 
293TRIG-I lenticrisp empty puro/hygro 
Blasticidin, 
Puromycin, 
Hygromycin 
Empty vector control for CRISPR/Cas9 
DAPK1/DAPK3 double KO cells 
293TRIG-I lenticrisp empty puro/hygro/zeo 
Blasticidin, 
Puromycin, 
Hygromycin, 
Zeocin 
Empty vector control for CRISPR/Cas9 
DAPK1/DAPK3/DAPK2 triple KO cells 
293TRIG-I lenticrisp empty zeo Blasticidin, Zeocin 
Empty vector control for CRISPR/Cas9 
DAPK2 single KO cells 
293TRIG-I DAPK1_crisp [1-4] Puromycin DAPK1 KO bulk [sgRNA 1-4] 
293TRIG-I DAPK1 [clone number] Blasticidin, Puromycin DAPK1 KO single cell clone [number] 
293TRIG-I DAPK3_crisp [1-4] Puromycin DAPK3 KO bulk [sgRNA 1-4] 
293TRIG-I DAPK3 [clone number] Blasticidin, Puromycin DAPK3 KO single cell clone [number] 
293TRIG-I DAPK2_crisp[1-4] Blasticidin, Zeocin DAPK2 KO bulk [sgRNA 1-4] 
293TRIG-I DAPK1/DAPK3_crisp [1-4] 
Blasticidin, 
Puromycin, 
Hygromycin 
DAPK1/DAPK3 KO bulk [sgRNA 1-4] 
293TRIG-I DAPK1/DAPK3 [clone number] 
Blasticidin, 
Puromycin, 
Hygromycin 
DAPK1/DAPK3 KO single cell clone 
[number] 
293TRIG-I DAPK1/DAPK3/DAPK2_crisp[1-4] 
Blasticidin, 
Puromycin, 
Hygromycin, 
Zeocin 
DAPK1/DAPK3/DAPK2 triple KO bulk 
[sgRNA 1-4] 
Huh7 Lunet CD81high G418 HCV replication assays 
Huh7 Lunet CD81high MAVS-GFPNLS 
G418, 
Blasticidin 
HCV replication assays, localisation of GFP 
to nucleus after infection 
A549 - - 
A549 lenticrisp empty puro Puromycin Empty vector control for CRISPR/Cas9 DAPK1 or DAPK3 single knockout cells 
A549 lenticrisp empty puro/hygro Puromycin, Hygromycin 
Empty vector control for CRISPR/Cas9 
DAPK1/DAPK3 double knockout cells 
A549 lenticrisp empty puro/hygro/zeo 
Puromycin, 
Hygromycin, 
Zeocin 
Empty vector control for CRISPR/Cas9 
DAPK1/DAPK3/DAPK2 triple knockout cells 
A549 lenticrisp empty zeo Zeocin Empty vector control for CRISPR/Cas9 DAPK2 single knockout cells 
A549 DAPK1_crisp [1-4] Puromycin DAPK1 KO bulk [sgRNA 1-4] 
A549 DAPK1 [clone number] Puromycin DAPK1 KO single cell clone [number] 
A549 DAPK3_crisp [1-4] Puromycin DAPK3 KO bulk [sgRNA 1-4] 
A549 DAPK3 [clone number] Puromycin DAPK3 KO single cell clone [number] 
A549 DAPK2_crisp[1-4] Zeocin DAPK2 KO bulk [sgRNA 1-4] 
A549 DAPK1/DAPK3_crisp [1-4] Puromycin, Hygromycin DAPK1/DAPK3 KO bulk [sgRNA 1-4] 
A549 DAPK1/DAPK3 [clone number] Puromycin, Hygromycin 
DAPK1/DAPK3 KO single cell clone 
[number] 
A549 DAPK1/DAPK3/DAPK2_crisp[1-4] 
Puromycin, 
Hygromycin, 
Zeocin 
DAPK1/DAPK3/DAPK2 triple KO bulk 
[sgRNA 1-4] 
HeLa - Provided by Felix Hoppe-Seyler, DKFZ Heidelberg 
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2.6.2 Bacteria 
Gateway® destination and entry vectors harbouring the ccdB gene were amplified in 
One Shot® ccdB SurvivalTM 2 T1R Chemically Competent cells (Invitrogen). 
For general cloning and retransformation E. coli strain DH5a was used. 
2.7 Viruses 
Table 7 Viruses 
Name Description Origin 
SeV - Rainer Zawatzky, DKFZ Heidelberg 
Influenza A Virus WSN/1933 (H1N1) Georg Kochs, Albert-Ludwigs University Freiburg 
RVFV DNSs_Rluc, 
NSs was replaced with Renilla luciferase gene 
Friedemann Weber (Justus-
Liebig University Gießen) 
HCV JcR2A, genotype 2 harbouring a Renilla luciferase gene - 
2.8 DNA and RNA oligos 
2.8.1 Primers for cloning 
2.8.1.1 DAPK1 mutants 
Table 8 Primers for DAPK1 mutants 
Name Sequence (5’ – 3’) Description 
DAPK1 FL fw GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGACCGTGTTCAGGCAGG DAPK1
KCA 
DAPK1 Ank1 rev GGGGACCACTTTGTACAAGAAAGCTGGGTCCTACGCCTCAACGCTGGCTCCCATCAGAC DAPK1
KCA 
DAPK1 S308A fw GAAAAAATGGAAACAAGCCGTTCGCTTGATATC DAPK1KCA S308A overlap PCR 
DAPK1 S308A rev GATATCAAGCGAACGGCTTGTTTCCATTTTTT DAPK1KCA S308A overlap PCR 
DAPK1 S308D fw GAAAAAATGGAAACAAGACGTTCGCTTGATATC DAPK1KCA S308D overlap PCR 
DAPK1 S308D rev GATATCAAGCGAACGTCTTGTTTCCATTTTTTC DAPK1KCA S308D overlap PCR 
DAPK1 K42A fw GCCTCCAGTATGCCGCCGCATTCATCAAAAAAG DAPK1KCA K42A overlap PCR 
DAPK1 K42A rev CTTTTCTTGATGAATGCGGCGGCATACTGGAGGC DAPK1KCA K42A overlap PCR 
DAPK1 S289E fw CAGGCACTTAGTAGAAAAGCAGAGGCAGTAAACATGGAGAAATTC DAPK1
S289E overlap PCR 
DAPK1 S289E rev GAATTTCTCCATGTTTACTGCCTCTGCTTTTCTACTAAGTGCCTG DAPK1
S289E overlap PCR 
DAPK1 S289A fw CAGGCACTTAGTAGAAAAGCAGCCGCAGTAAACATGGAGAAATTC DAPK1
S289A overlap PCR 
DAPK1 S289A rev GAATTTCTCCATGTTTACTGCGGCTGCTTTTCTACTAAGTGCCTG DAPK1
S289A overlap PCR 
DAPK1 Y491F fw CTGTGCTGCTTGGCACGGCTTCTACTCTGTGGCCAAAGCCCTTTG DAPK1
Y491F overlap PCR 
DAPK1 Y491F rev CAAAGGGCTTTGGCCACAGAGTAGAAGCCGTGCCAAGCAGCACAG DAPK1
Y491F overlap PCR 
DAPK1 Y492F fw GTGCTGCTTGGCACGGCTATTTCTCTGTGGCCAAAGCCCTTTGTG DAPK1
Y492F overlap PCR 
DAPK1 Y492F rev CACAAAGGGCTTTGGCCACAGAGAAATAGCCGTGCCAAGCAGCAC DAPK1
Y492F overlap PCR 
DAPK1 Y491E fw GCACTGTGCTGCTTGGCACGGCGAGTACTCTGTGGCCAAAGCCCTTTG DAPK1
Y491E overlap PCR 
DAPK1 Y491E rev CAAAGGGCTTTGGCCACAGAGTACTCGCCGTGCCAAGCAGCACAGTGC DAPK1
Y491E overlap PCR 
DAPK1 Y492E fw GTGCTGCTTGGCACGGCTATGAGTCTGTGGCCAAAGCCCTTTGTG DAPK1
Y492E overlap PCR 
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2.8.1.2 DAPK2 cDNA and mutants 
DAPK2 full-length coding sequence was cloned from A549 cDNA. 
Table 9 Primers for DAPK2 mutants 
2.8.1.3 DAPK3 mutants 
The pENTR223 plasmid harbouring the DAPK3 coding sequence (open conformation) was obtained from 
the DKFZ GPCF clone repository. 
Table 10 Primers for DAPK3 mutants 
DAPK1 Y492E rev CACAAAGGGCTTTGGCCACAGACTCATAGCCGTGCCAAGCAGCAC DAPK1
Y492E overlap PCR 
DAPK1 
Y491F/Y492F fw 
CCTGCACTGTGCTGCTTGGCACGGCTTCTTCTCT
GTGGCCAAAGCCCTTTGTGAAG DAPK1
Y491/492F overlap PCR 
DAPK1 
Y491F/Y492F rev 
CTTCACAAAGGGCTTTGGCCACAGAGAAGAAGCC
GTGCCAAGCAGCACAGTGCAGG DAPK1
Y491/492F overlap PCR 
DAPK1 
Y491E/Y492E fw 
CCCTGCACTGTGCTGCTTGGCACGGCGAGGAGT
CTGTGGCCAAAGCCCTTTGTGAAGC DAPK1
Y491/492E overlap PCR 
DAPK1 
Y491E/Y492E rev 
GCTTCACAAAGGGCTTTGGCCACAGACTCCTCGC
CGTGCCAAGCAGCACAGTGCAGGG DAPK1
Y491/492E overlap PCR 
Name Sequence (5’ – 3’) Description 
DAPK2 fw  GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGTTCCAGGCCTCAATGAGG Gateway cloning of DAPK2 WT 
DAPK2 rev GGGGACCACTTTGTACAAGAAAGCTGGGTCTTAGGAGGTGCTGCTCCTCC Gateway cloning of DAPK2 WT 
DAPK2 KD fw GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGTATGACATCGGAGAGGAGCTGGGG DAPK2
Kinase 
DAPK2 KD rev GGGGACCACTTTGTACAAGAAAGCTGGGTCTCAGATCCAGGGGTGTCTGAGAGCC DAPK2
Kinase 
DAPK2 Kinase-
CaM rev 
GGGGACCACTTTGTACAAGAAAGCTGGGTCTCAC
AGGTCCTCATCCGGCCTCAGG DAPK2
Kinase-CaM 
DAPK2 K52A fw GGGGCTTGAGTATGCAGCCGCCTTCATCAAGAAGCGGCAG DAPK2
K52A overlap PCR 
DAPK2 K52A rev CTGCCGCTTCTTGATGAAGGCGGCTGCATACTCAAGCCCC DAPK2
K52A overlap PCR 
DAPK2 S318A fw GCAGGCGGTGGAAGCTTGCCTTCAGCATCGTGTCCCTGTGC DAPK2
S318A overlap PCR 
DAPK2 S318A rev GCACAGGGACACGATGCTGAAGGCAAGCTTCCACCGCCTGC DAPK2
S318A overlap PCR 
DAPK2 S318D fw GCAGGCGGTGGAAGCTTGACTTCAGCATCGTGTCCCTGTGC DAPK2
S318D overlap PCR 
DAPK2 S318D rev GCACAGGGACACGATGCTGAAGTCAAGCTTCCACCGCCTGC DAPK2
S318D overlap PCR 
Name Sequence (5’ – 3’) Description 
ZIPK fw GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGTCCACGTTCAGGCAGGAGGAC Gateway cloning of DAPK3 WT 
ZIPK rev GGGGACCACTTTGTACAAGAAAGCTGGGTCCTAGCGCAGCCCGCACTCC Gateway cloning of DAPK3 WT 
DAPK3 KD fw GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGTATGAGATGGGGGAGGAG DAPK3
Kinase 
DAPK3 KD 
rev 
GGGGACCACTTTGTACAAGAAAGCTGGGTCTCAA
ATCCAGGAATGTTCCAGGC DAPK3
Kinase 
DAPK3 delta 
KD fw 
GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATG
AAGGCGATCCGGCGGCGGAAC DAPK3
delta Kinase 
DAPK3 delta 
LZ rev 
GGGGACCACTTTGTACAAGAAAGCTGGGTCTCAT
TGCTTGGCCAGCGCCTCG DAPK3
delta Leucine zipper 
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2.8.1.4 DRAK1 from cDNA 
The pENTR221 plasmid harbouring the DRAK2/STK17B coding sequence (closed conformation) was 
obtained from the DKFZ GPCF clone repository. DRAK1 full-length coding sequence was cloned from A549 
cDNA. 
Table 11 Primers for DRAK1 cloning 
2.8.1.5 Cloning of Lenticispr v2 with different antibiotic resistance 
Different antibiotic resistance genes were cloned into Lenticrispr v2 plasmid using NEB Gibson Assembly®. 
Hygromycin resistance gene had to be codon adjusted due to BsmBI cleavage site within the resistance 
gene. 
Table 12 Lenticrispr primer 
2.8.2 CRISPR/Cas9 KO sgRNA oligos 
Table 13 sgRNA oligos 
Name Sequence (5’ – 3’) Description 
DAPK1_crisp1 fw CACCTGATTACTACGACACCGGCG Generation of DAPK1 KO 
DAPK1_crisp1 rev AAACCGCCGGTGTCGTAGTAATCA Generation of DAPK1 KO 
DAPK1_crisp2 fw CACCGTGGATGATTACTACGACAC Generation of DAPK1 KO 
DAPK1_crisp2 rev AAACGTGTCGTAGTAATCATCCAC Generation of DAPK1 KO 
DAPK1_crisp3 fw CACCTTACCTGCCAAGTTCCTCGC Generation of DAPK1 KO 
DAPK1_crisp3 rev AAACGCGAGGAACTTGGCAGGTAA Generation of DAPK1 KO 
DAPK3 K42A 
fw 
GCAAGGAGTACGCAGCCGCCTTCATCAAGAAGC
GCCGCCT DAPK3
K42A overlap PCR 
DAPK3 K42A 
rev 
AGGCGGCGCTTCTTGATGAAGGCGGCTGCGTAC
TCCTTGC DAPK3
K42A overlap PCR 
DAPK3 D161A 
fw 
CACGAATCAAGCTCATCGCCTTCGGCATCGCGCA
CAAGATC DAPK3
D161A overlap PCR 
DAPK3 D161A 
rev 
GATCTTGTGCGCGATGCCGAAGGCGATGAGCTT
GATTCGTG DAPK3
D161A overlap PCR 
Name Sequence (5’ – 3’) Description 
DRAK1 fw GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGATCCCTTTGGAGAAGCC Gateway cloning of DRAK1 
DRAK1 rev GGGGACCACTTTGTACAAGAAAGCTGGGTCtcagtagataaattctcctggaatttcttg Gateway cloning of DRAK1 
Name Sequence (5’ – 3’) Description 
Lenticrisp bb fw ACGCGTTAAGTCGACAATC Gibson assembly amplification of backbone 
Lenticrisp bb rev CGGTCCAGGATTCTCTTC Gibson assembly amplification of backbone 
Hygro fw GAGAATCCTGGACCGAAAAAGCCTGAACTCACC 
Amplification of Hygromycin resistance 
gene 
Hygro rev TGTCGACTTAACGCGTCTATTCCTTTGCCCTCGG 
Amplification of Hygromycin resistance 
gene 
Val_mut_ovlp fw CGAAAAGTTCGACAGCGTGTCCGACCTGATGCAGC Elimination of BsmBI cleavage site 
Val_mut_ovlp rev GCTGCATCAGGTCGGACACGCTGTCGAACTTTTCG Elimination of BsmBI cleavage site 
Zeo fw GAGAATCCTGGACCGGCCAAGTTGACCAGTGCC Amplification of Zeocin resistance gene 
Zeo rev TGTCGACTTAACGCGTTTACGTACGGTCCTGCTC Amplification of Zeocin resistance gene 
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DAPK1_crisp4 fw CACCCGTGTTCAGGCAGGAAAACG Generation of DAPK1 KO 
DAPK1_crisp4 rev AAACCGTTTTCCTGCCTGAACACG Generation of DAPK1 KO 
DAPK2_crisp1 fw CACCGGACTTTTATGACATCGGAG Generation of DAPK2 KO 
DAPK2_crisp1 rev AAACCTCCGATGTCATAAAAGTCC Generation of DAPK2 KO 
DAPK2_crisp2 fw CACCGTATGTTCCAGGCCTCAATG Generation of DAPK2 KO 
DAPK2_crisp2 rev AAACCATTGAGGCCTGGAACATAC Generation of DAPK2 KO 
DAPK2_crisp3 fw CACCGGAGCCATTCAAGCAGCAGA Generation of DAPK2 KO 
DAPK2_crisp3 rev AAACTCTGCTGCTTGAATGGCTCC Generation of DAPK2 KO 
DAPK2_crisp4 fw CACCGTGGAGGACTTTTATGACAT Generation of DAPK2 KO 
DAPK2_crisp4 rev AAACATGTCATAAAAGTCCTCCAC Generation of DAPK2 KO 
DAPK3_crisp1 fw CACCCCATGTCCACGTTCAGGCAG Generation of DAPK3 KO 
DAPK3_crisp1 rev AAACCTGCCTGAACGTGGACATGG Generation of DAPK3 KO 
DAPK3_crisp2 fw CACCCATGTCCACGTTCAGGCAGG Generation of DAPK3 KO 
DAPK3_crisp2 rev AAACCCTGCCTGAACGTGGACATG Generation of DAPK3 KO 
DAPK3_crisp3 fw CACCCGGCCGCCATGTCCACGTTC Generation of DAPK3 KO 
DAPK3_crisp3 rev AAACGAACGTGGACATGGCGGCCG Generation of DAPK3 KO 
DAPK3_crisp4 fw CACCCCGGCCGCCATGTCCACGTT Generation of DAPK3 KO 
DAPK3_crisp4 rev AAACAACGTGGACATGGCGGCCGG Generation of DAPK3 KO 
2.8.3 Primers for qRT-PCR 
Table 14 qRT-PCR primers 
Name Sequence (5’ – 3’) 
DAPK1 fw TGGCCATGCTGACGTGGCTC 
DAPK1 rev GGCTGTCAGGAGGGGCGTCT 
DAPK2 fw GGCTCACAATCCAAGAGGCT 
DAPK2 rev CTCACAGTTCCTCAGGTCCTC 
DAPK3 fw GTGGAGCATCGGTGTCATCA 
DAPK3 rev ATGGTCATTCTCCGCTTGGG 
IFNb fw GACGCCGCATTGACCATCTA 
IFNb rev GACATTAGCCAGGAGGTTCTC 
ISG56 (IFIT1) fw GAAGCAGGCAATCACAGAAA 
ISG56 (IFIT1) rev GAAACCGACCATAGTGGAA 
GAPDH fw GAAGGTGAAGGTCGGAGC 
GAPDH rev CAAGATGGTGATGGGATTTC 
2.9 Plasmids 
Table 15 Plasmids 
Name Tag Backbone Prokaryotic resistance 
Eukaryotic 
resistance 
DAPK1 
(WT and mutants) HA pcDNA5 AMP Hygromycin 
DAPK1_crisp1 - Lenticrispr v2 AMP Puromycin 
DAPK1_crisp2 - Lenticrispr v2 AMP Puromycin 
DAPK1_crisp3 - Lenticrispr v2 AMP Puromycin 
DAPK1_crisp4 - Lenticrispr v2 AMP Puromycin 
DAPK2 
(WT and mutants) HA pcDNA5 AMP Hygromycin 
DAPK2_crisp1 - Lenticrispr v2 AMP Zeocin 
DAPK2_crisp2 - Lenticrispr v2 AMP Zeocin 
DAPK2_crisp3 - Lenticrispr v2 AMP Zeocin 
DAPK2_crisp4 - Lenticrispr v2 AMP Zeocin 
DAPK3 
(WT and mutants) HA pcDNA5 AMP Hygromycin 
DAPK3_crisp1 - Lenticrispr v2 AMP Hygromycin 
DAPK3_crisp1 - Lenticrispr v2 AMP Puromycin 
DAPK3_crisp2 - Lenticrispr v2 AMP Hygromycin 
DAPK3_crisp2 - Lenticrispr v2 AMP Puromycin 
DAPK3_crisp3 - Lenticrispr v2 AMP Hygromycin 
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DAPK3_crisp3 - Lenticrispr v2 AMP Puromycin 
DAPK3_crisp4 - Lenticrispr v2 AMP Hygromycin 
DAPK3_crisp4 - Lenticrispr v2 AMP Puromycin 
IFIT1 Firefly  - pGL3 AMP - 
IRF3 5D  pcDNA3.1 AMP G418 
Lenticrispr empty hygro - Lenticrispr v2 AMP Hygromycin 
Lenticrispr empty puro - Lenticrispr v2 (Addgene: 52961) AMP Puromycin 
Lenticrispr empty zeo - Lenticrispr v2 AMP Zeocin 
MAVS Lumio V5 pcDNA6.2 AMP Blasticidin 
NFkB Firefly - pGL4.32 AMP - 
pcDNA3.1 (mock) - pcDNA3.1 AMP G418 
psPAX2 - - AMP - 
pDONR207 - pDONR207 Genta - 
pDONR221 STK17B closed  pDONR221 Kana - 
pDONR223 DAPK3 open - pDONR223 Spec - 
pMD2.G - - AMP - 
Renilla CMV - pcDNA3.1 AMP G418 
Renilla SV40 - pRL AMP - 
RIG-I Lumio V5 pcDNA6.2 AMP Blasticidin 
RIG-I CA Lumio V5 pcDNA6.2 AMP Blasticidin 
DRAK2 WT in Gateway  pENTR221 Kana  
DAPK3 WT in Gateway  pENTR223 Spec - 
2.9.1 siRNAs 
Table 16 siRNAs 
Name Target sequence (5’ – 3’) Supplier 
Hs_DAPK1_5 AAGCATGTAATGTTAATGTTA Qiagen, Germany 
Hs_DAPK1_6 CGGCTATTACTCTGTGGCCAA Qiagen, Germany 
DAPK1 sig1 
(SASI_Hs01_00238227) GAATTAAGCTCAAGCTGTT Sigma Aldrich, Germany 
DAPK1 sig2 
(SASI_Hs01_00238226) CAACTATGATGTTAACCAA Sigma Aldrich, Germany 
DAPK1 sig3 
(SASI_Hs01_00238225) GAGAATCGATGTCCAGGAT Sigma Aldrich, Germany 
DAPK2 sig1 
(SASI_Hs01_00206406) CTTTGGTCTGGCTCACGAA Sigma Aldrich, Germany 
DAPK2 sig2 
(SASI_Hs01_00206405) CGGAATTTGTTGCTCCAGA Sigma Aldrich, Germany 
DAPK2 sig3 
(SASI_Hs01_00206404) CAAAGCTCTTAATTCTCCA Sigma Aldrich, Germany 
Hs_DAPK3_3 CCCAGAGATTGTGAACTATGA Qiagen, Germany 
DAPK3 sig1 
(SASI_Hs01_00020911) GCTACGAGGCGCTGGCCAA Sigma Aldrich, Germany 
DAPK3 sig2 
(SASI_Hs01_00020910) CAGAGATTGTGAACTATGA Sigma Aldrich, Germany 
DAPK3 sig3 
(SASI_Hs01_00020912) CACGACATCTTCGAGAACA Sigma Aldrich, Germany 
Hs_PI4KCA_12 N/A Qiagen, Germany 
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2.10 Buffers and solutions 
Table 17 Buffers and solutions 
Name Recipe 
1% Paraformaldehyde solution 4% paraformaldehyde solution diluted in PBS 
4% Paraformaldehyde solution 4g paraformaldehyde dissolved with simultaneous stirring at 60°C in 100 ml PBS 
6x Laemmli buffer 9,75 ml Tris 0,5M (pH6.8), 15 ml Glycerol, 15 ml 10% SDS, 3,75 ml β-mercaptoethanol, 30 mg Bromophenol blue, 6.5 ml H2O 
Ampicillin stock solution (100 mg/ml) 100 mg/ml Ampicillin in ddH2O, sterile-filtered and stored at -20 °C 
Coelenterazine stock (1nM) 5 mg Coelenterazine in 11.8 ml Methanol 
Co-IP lysis buffer (HA-IP) 20 mM Tris (pH 7.6), 100 mM NaCl, 1% NP-40, 50 mM NaF, protease inhibitor tablet (Roche) 
Co-IP lysis buffer (Strep-IP) 20 mM Tris (pH 7.6), 300 mM NaCl, 1% NP-40, 50 mM NaF, protease inhibitor tablet (Roche) 
Cryo freezing medium (20% DMSO) 40 ml FCS + 10 ml DMSO 
D-Luciferine stock (1mM) 84.1mg D-luciferin in 300ml, 25mM Glycylglycine   
DMEM standard cell culture medium 
Dulbecco’s Modified Eagle Medium (High Glucose) containing 1x 
nonessential amino acids, 1% Penicillin/Streptomycin, 10% (v/v) 
Fetal Calf Serum (heat inactivated at 56 °C for 30 min)  
DMEM w/o Pen-Strep 
Dulbecco’s Modified Eagle Medium (High Glucose) containing 1x 
nonessential amino acids 10%, (v/v) Fetal Calf Serum (heat 
inactivated at 56 °C for 30 min)  
Glycylglycine (0.5M) for Luciferase buffer 33.03 g Glycylglycine (132.12 g/mol) in 500 ml H2O adjust pH to 7.8 using KOH 
In vitro kinase assay buffer (2X) 100 mM HEPES pH 7.5, 40 mM MgCl2, 1 mM CaCl2 
K2HPO4 (0.2M) for Luciferase buffer 34.83 g (174,18 g/mol) in H2O 
Kanamycin stock solution (30µg/ml) 30 mg/ml Kanamycin sulfate in H2O, sterile filtered and stored at -20°C 
KH2PO4 (0.2M) for Luciferase buffer 27.21 g KH2PO4 (136,09 g/mol) in H2O 
KPO4  (0.1M) pH7.8 17 ml KH2PO4 + 183 ml K2HPO4 in 200 ml H2O 
Luciferase Assay Buffer 
For 200 ml: 10ml Glycylglycine (0.5M pH 7.8), 30ml KPO4 (0.1M 
pH 7.8), 3 ml MgSO4 (1 M), 4 ml EGTA (0,2 M pH 7.8) 
and 153 ml H2O 
Luciferase Lysis buffer 
For 500 ml: 5 ml Triton-X100, 25 ml Glycylglycine (0.5 M pH 7.8), 
7.5 ml MgSO4 (1M), 10 ml EGTA (0,2M pH 7.8), 50 ml Glycerol, 
402.5 H2O 
Lysogeny broth (LB) Agar 30 g Bacto-Trypton, 15 g Yeast extract, 15 g NaCl, 15 g Agar in 3 l ddH2O and autoclaved 
Lysogeny broth (LB) medium 50 g Bacto-Trypton, 25 g Yeast extract, 25 g NaCl in 5 l ddH2O and autoclaved 
MgSO4 (1M) for Luciferase buffer 
15.2 g EGTA (380.35 g/mol) in 200 ml H2O, adjust pH to 7.8 using 
KOH. 
PBS  80 mM Na2HPO4, 20 mM Na2HPO4, 1.4 M NaCl, 2.7 mM KCl, 1.76 mM KH2PO4 
PBST PBS (1x), 0.1% (v/v) Tween-20 
Resolving gel buffer 1,5 M Tris Base 0,4 % SDS pH 8.8 
Ripa protein extraction buffer 10 mM Tris HCl, pH 8.0; 150 mM NaCl, 1% (v/v) NP-40, 0.5% (w/v) sodium deoxycholate, 0.1% (w/v) SDS 
Semi-dry blotting buffer 25 mM Tris Base (pH 8.3), 150 mM Glycine; 1x buffer: 100 ml 10x buffer, 800 ml H2O and 100 ml Methanol 
Spectinomycin stock solution (50 mg/ml) 50 mg/ml Spectinomycin in H2O, sterile filtered and stored at -20°C 
Stacking gel buffer 1 M Tris Base 0,8 % SDS pH 6.8 
TAE (50x) 2 M Tris, 2 M Acetic Acid, and 50 mM EDTA, pH 8.3 
TBS (10x), pH 7.5 20 mM Tris-Hcl, 150 mM NaCl, adjust pH to 7.5 with NaOH 
TBST TBS (1x), 0.1% (v/v) Tween-20 
Tris-gylcin-sulfate (TGS), 10x 25 mM Tris Base, 150 mM Glycine, pH 8.3, 
Western Blot blocking buffer 0.1% (v/v) of Tween-20, 5% milk powder in PBS 
Wet blotting buffer 25 mM Tris Base (pH 8.3), 150 mM Glycine; 1x buffer: 100 ml 10x buffer, 700 ml H2O and 200 ml Methanol 
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2.11 Primary antibodies 
Table 18 Primary antibodies 
Antibody 
(anti-) Specificity Supplier Clonality 
Dilution 
(WB/FACS) 
Calnexin rabbit Enzo Life Sciences, Inc., USA polyclonal 1:1000 (WB) 
cleaved PARP (Asp214) rabbit Cell Signaling Technology, Germany polyclonal 1:1000 (WB) 
DAPK1 mouse BD Biosciences, Germany monoclonal 1:500 (WB) 
DAPK1 rabbit Sigma Aldrich, Germany polyclonal 1:1000 (WB) 
DAPK1 p-S308 mouse Sigma Aldrich, Germany monoclonal 1:1000 (WB) 
DAPK2 rabbit Abcam, Germany monoclonal 1:500 (WB) 
DAPK3 rabbit Bethyl Laboratories, Inc., Germany polyclonal 1:1000 (WB) 
DAPK3 p-T265 rabbit tebu-bio GmbH, Germany polyclonal 1:1000 (WB) 
GAPDH mouse Santa Cruz Biotechnology, USA monoclonal 1:2500 (WB) 
HA mouse Sigma Aldrich, Germany monoclonal 1:2000 (WB) 
Influenza A NP (FITC) mouse Thermo Fisher Scientific, Germany monoclonal 1:50 (FACS) 
LC3B rabbit MBL International, Germany polyclonal 1:1000 (WB) 
MDA5 mouse Enzo Life Sciences, Inc., USA polyclonal 1:1000 (WB) 
Mx1 mouse Georg Kochs, Albert-Ludwigs University Freiburg, Germany monoclonal 1:1000 (WB) 
PI4Ka rabbit Cell Signaling Technology, Germany polyclonal 1:1000 (WB) 
p-p70S6K (Thr389) 
(108D2) rabbit 
Cell Signaling Technology, 
Germany monoclonal 1:1000 (WB) 
RIG-I (D14G6) rabbit Cell Signaling Technology, Germany monoclonal 1:1000 (WB) 
V5 rabbit Cell Signaling Technology, Germany monoclonal 1:1000 (WB) 
V5 mouse Thermo Fisher Scientific, Germany monoclonal 1:1000 (WB) 
2.12 Secondary antibodies 
Table 19 Secondary antibodies 
Antibody 
(anti-) Specificity Supplier Clonality 
Dilution 
(WB/FACS) 
mouse-HRP goat Sigma Aldrich, Germany polyclonal 1:10.000 
Rabbit-HRP goat Sigma Aldrich, Germany polyclonal 1:10.000 
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3 Methods 
3.1 Cell culture 
3.1.1 Culture and passaging of eukaryotic cells 
All cell lines were cultured in DMEM standard cell culture medium and kept at 37 °C, 
95% relative humidity and 5% CO2. For passaging, medium was removed and cells were 
washed with 1xPBS. Cells were detached by adding Trypsin-EDTA and incubating for up 
to 5 min at 37°C. Detached cells were washed off the dish using standard cell culture 
medium, diluted to desired concentration and added to a new cell culture dish. Cells 
were passaged before confluency was reached. 
Stably-transduced cell lines were grown in presence of 1 mg/ml G418, 1 µg/ml 
puromycin, 100 µg/ml zeocin and/or 5 µg/ml blasticidin, respectively. 
3.1.2 Cryopreservation and revival 
For cryopreservation a confluent 15 cm dish was detached as described above. 
Detached cells were spun down and resuspended in 9 ml fetal calf serum which was 
distributed to ten cryovials (900 µl per vial). 900 µl of 20% DMSO freezing medium were 
added to cryovials and contents were mixed by inverting cryovials several times before 
they were stored at -80°C for at least 48h. For long term storage cells were then 
transferred to liquid nitrogen. 
Cells were revived by quickly thawing contents of cryovials. Cells were added to pre-
warmed standard cell culture medium and incubated until they had attached to the plate. 
Medium was changed to remove DMSO. 
3.1.3 Cell counting 
From a cell suspension the number of cells per ml was determined by using a 
hemocytometer, i.e. Neubauer counting chamber. 10µl of single cell suspension were 
loaded to the chamber and living cells (determined by morphology) within the four large 
quadrants were counted using an inverted light microscope. The space over each large 
quarter has a defined volume of 0,1 µl. Hence, the number of counted cells multiplied by 
10.000 and divided by 4 is the number of cells per ml in the cell suspension of interest. 
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3.1.4 Transfection of expression plasmids 
3.1.4.1 Lipofectamine 2000 transfection 
Expression plasmids were transfected into 293TRIG-I using lipofectamine 2000 
transfection reagent. For a 24 well 2µl lipofectamine were incubated in 50µl OptiMEM for 
5 min and then added to 50µl OptiMEM containing 500 ng plasmid DNA. The 
DNA/lipofectamine mix was incubated for at least 20 min at RT. Medium was removed 
from target cells and replaced with 500 µl of DMEM w/o Pen-Strep. 100µl per 24 well of 
DNA/lipofectamine mix were added. 4-8h post transfection medium was changed to 
standard cell culture medium. Different amounts of DNA were transfected keeping a 
constant ratio between DNA and Lipofectamine. Within the same experiment DNA 
amounts were kept constant by adding empty vector DNA to reach the desired DNA 
amount. 
Stimulatory RNA analogues (e.g. poly(I:C)) were transfected into 293TRIG-I using 
lipofectamine 2000 transfection reagent. For a 24 well 1µl lipofectamine were incubated 
in 50µl OptiMEM for 5 min and then added to 50µl OptiMEM containing 0.4 µg/ml RNA. 
The RNA/lipofectamine mix was incubated for at least 20 min at RT. Medium was 
removed from target cells and replaced with 500 µl of DMEM w/o Pen-Strep. 100µl per 
24 well of RNA/lipofectamine mix were added. In case less RNA was transfected the 
ratio between RNA and lipofectamine were kept constant. Within the same experiment 
the amount of RNA was always kept the same within one experiment by adding non 
stimulatory polyC to reach the desired RNA amount. 
3.1.4.2 Effectene transfection 
Luciferase reporter constructs were transfected into 293TRIG-I, A549, or derived cell lines 
using Effectene transfection reagent. 150 ng firefly promoter reporter and 50 ng 
CMV/SV40 renilla plasmids were transfected following the protocol provided by the 
manufacturer. Medium was changed 4-8h post transfection. 
3.1.5 siRNA transfection 
For siRNA-based silencing 293TRIG-I, A549, or derived cell lines were seeded into 24 well 
plates with a density of ~7x104 cells per well and were immediately transfected with 
desired siRNAs. 0.3 µl 20µM siRNA were added to 100 µl of OptiMEM containing 1µl of 
RNAiMAX. The mix was incubated for 10-15 min at RT before it was added to the freshly 
seeded cells, resulting in a final siRNA concentration of 10nM. Cells were reporter 
transfected 36h and stimulated 48h post siRNA transfection. 
Page | 46  Methods 
3.1.6 Lentiviral transduction 
Stable ectopic expression of a gene or sgRNA (in case of CRISPR/Cas9) was achieved 
by lentiviral transduction of target cells. Lentiviral particles were produced by transfection 
of a lentiviral vector (.e.g pWPI) together with two packaging plasmids. Lentiviral 
particles were produced in 293T (MCB) cells, harvested, and used to infect target cells. 
To produce lentiviral particles 1.2x106 293T cells were seeded in a 6cm dish. Medium 
was changed the next day and cells were transfected with pWPI lentiviral vector, gag-pol 
(psPAX2) and VSV-G expression plasmid (pMD2.G) using CalPhos™ Mammalian 
transfection kit. 6.4 µg pWPI, 6.4 µg psPAX2 and 2.1 µg pMD2.G were diluted in a final 
volume of 438 μl sterile H2O and 62 µl 2M CaCl2 were added on top. 500 µl 2X HBS 
were added drop wise to the mix while air was blown into the liquid to provide oxygen 
aiding precipitate formation. The transfection mix was added drop-wise to 293T cells. 8h 
post transfection medium was changed. 48h after transfection supernatants were 
collected and passed through a 0.45 µm-pore filter to prevent contamination with particle 
producing 293T cells. Filtered supernatants were added onto target cells which were 
seeded the day before (4x104 cells/ 12 well). Supernatants of transfected 293T cells 
were harvested again after 8 and 24h and handled the same way as described above. 
After three rounds of target cell infection the medium was replaced with standard cell 
culture medium containing the appropriate restriction antibiotic. Antibiotics were kept 
while passaging stable cell lines to ensure constitutive expression of the gene of interest, 
but were removed when experiments were performed. 
3.2 Molecular biological methods 
3.2.1.1 Transformation of competent bacteria 
100 µl of chemically competent E.coli DH5α bacteria were thawed on ice and mixed with 
100 - 500 ng plasmid DNA for retransformations, with 5 µl of ligation reaction, or with the 
total volume of LR/BP reaction. DNA was incubated with bacteria for 20 min on ice 
followed by 70 sec of heat shock at 42°C. After a recovery period of 2 min on ice, 200 µl 
of LB medium was added and bacteria were incubated on a shaker for 1h at 37°C. 
Bacteria were plated onto LB-agar plates containing restriction antibiotics (Ampicillin (0,1 
mg/ml), Kanamycin (0,3mg/ml), Gentamicin (7µg/ml) or spectinomycin 50 (µg/mL)). 
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3.2.2 Plasmid amplification and purification 
Plasmid DNA was amplified in E.coli DH5a. Clones were picked from plates and grown 
in LB medium supplemented with plasmid-specific restriction antibiotics overnight at 
37°C while shaking. 
3.2.2.1 Small scale plasmid purification 
Transformed bacterial clones were incubated in 5 ml of LB medium containing the 
respective restriction antibiotics. Overnight cultures were spun down at 11.000 x g and 
LB medium was removed. DNA was purified from bacterial pellets using the Nucleospin® 
plasmid purification kit according to manufacturer’s instructions. DNA pellets were 
resuspended in sterile ddH2O and concentrations were determined using the Nanodrop 
photo spectrometer. 
3.2.2.2 Large scale plasmid purification 
Transformed bacterial clones were pre-cultured for 8h in 5 ml antibiotic-containing LB 
medium and then added to 250 ml of antibiotic-containing LB medium. Plasmid DNA was 
extracted from overnight cultures using the Nucleobond® PC 500 plasmid purification kit 
according to manufacturer’s instructions. DNA pellets were resuspended in sterile ddH2O 
and concentrations were determined using the Nanodrop photo spectrometer. 
3.2.3 Polymerase chain reaction 
Polymerase chain reactions (PCRs) were performed using the Q5® High-Fidelity DNA 
Polymerase and the appropriate buffer. 
PCR mixes were prepared according to the following protocol. 
Protocol 1 Q5 PCR reaction mix 
Component 50 µl reaction 
5x Q5® reaction buffer 10 µl 
10 mM dNTPs 1 µl 
10 µM Primer fw 2.5 µl 
10 µM Primer rev 2.5 µl 
Template DNA variable (~ 100 – 500 ng) 
Q5® High-Fidelity Polymerase 0.5 µl 
5x Q5® GC Enhancer 10 µl 
Nuclease-free ddH2O ad 50 µl 
PCRs using the Q5® High-Fidelity polymerase were incubated according to the following 
protocol. 
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Protocol 2 Q5 PCR programme 
Step Temperature /°C Time /sec Number of cycles 
Initial denaturing 98 30 1 
Denaturing 98 5 – 10 25 
Annealing 50 - 72 10 – 30 25 
Elongation 72 20 – 30 25 
Final elongation 72 120 1 
 
3.2.3.1 Overlap PCR 
In order to mutate a given sequence, overlap PCR was employed. Overlap primers were 
designed by choosing the desired mutation and including ~20 nucleotides up- and 
downstream of the target site so that a final overlap of ~40 nucleotides was achieved. 
This was done in fw and rev orientation. Overlap primers were combined with desired 
primers binding 5’ and 3’ of the mutation site and PCR fragments were generated. PCR 
fragments were separated on 1% agarose gels, purified and dissolved in 30 µl ddH2O. In 
a last step, both PCR fragments were used as a template in a PCR reaction containing 
the respective 5’ and 3’ primers so that the full-length mutated PCR product was 
generated. The final PCR product was either ligated into a vector or used for BP 
recombination by Gateway® cloning technology. 
3.2.4 Reverse transcription for cDNA cloning 
In order to obtain a cDNA preparation which could be used for cloning of a specific gene, 
a reverse transcription using the ExpandTM Reverse Transcriptase System and an 
anchored oligo(dT) primer and was applied. Whole cell RNA preparations were used as 
templates. Input RNA was generated from a confluent 24 well. 9 µl of RNA were mixed 
with 1 µl of anchored oligo(dT) primer. 
2X ExpandTM Reverse Transcriptase reaction mix was prepared according to the 
following protocol. 
Protocol 3 Expand RT reaction mix 
Component 10 µl reaction 
5x ExpandTM RT buffer 4 µl 
100 mM DTT 2 µl 
RNase inhibitor 0.5 µl 
10 mM dNTPs 2 µl 
ExpandTM RT 1 µl 
Nuclease-free ddH2O 0.5 µl 
ExpandTM Reverse Transcriptase reaction mix was added to RNA-primer preparation. 
Reactions were incubated at 43°C for 1h and immediately transferred to ice. 
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3.2.5 Agarose gel electrophoresis 
1% agarose gels were prepared by boiling 0.5 g agarose in 50 µl 1X TAE buffer. 2 µl of 
Midori Green gel dye was added to the slightly cooled down mixture and gels were cast 
in PerfectBlue™ Gelsystem Mini S gel slides. Appropriate combs were put into gel slide 
and gels were left until set. 6X DNA loading dye was added to DNA samples to a 1X final 
concentration and samples were loaded onto agarose gels. Gels were run until desired 
DNA separation was reached (~30 min) at 100 V. DNA was visualised using the Gel-iX-
imager (INTAS Science Imaging Instruments). 
3.2.6 PCR purification and gel extraction 
DNA fragments of the desired size were cut out from agarose gels after visualisation on 
a UV Transilluminator (VilberLourmat). UV exposition was kept as short as possible to 
avoid DNA damage. DNA extraction and purification was performed using the 
NucleoSpin® Extract II kit following the manufacturer’s instructions. 
3.2.7 DNA digestion 
PCR fragments or plasmid DNA were digested using recombinant restriction enzymes 
and the appropriate buffer system purchased from NEB. Analytic digestions were 
performed in a total volume 20 µl, preparative DNA digestions were performed in 50 µl. 
The amount of enzyme was adjusted according to amount of DNA. 
A typical DNA digestion reaction was prepared according to the following protocol. 
Protocol 4 DNA digestion mix 
Component 20 µl reaction 
10X digestion buffer 2 µl 
Input DNA 1 µl (200 – 500 ng/µl) 
Restriction enzyme 1 µl 
ddH2O ad 20 µl 
3.2.8 DNA ligation 
For ligations insert and backbone DNA were digested and the vector was additionally 
treated with calf intestine phosphatase (CIP) for 30min removing 5’ phosphates thereby 
preventing religation. Purified DNA was subsequently mixed in a molar ratio of 3 insert to 
1 backbone together with 1 µl 10X ligase buffer and 1 µl T4 ligase (Fermentas) in a total 
volume of 10µl. For control ligations ddH2O was added instead of insert DNA. Control 
ligations were performed to estimate the amount of backbone re-ligations. Ligation 
reactions were incubated at 16°C for 2h or overnight and subsequently transformed into 
competent DH5α bacteria. 
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3.2.9 Gibson Assembly® 
Gibson Assembly® uses a master mix which includes three different enzymatic activities 
that perform in a single buffer to enable quick plasmid generation from up to six DNA 
fragments. An exonuclease creates single-stranded 3’ overhangs facilitating annealing of 
fragments that share complementary regions at one end (overlap). A polymerase then 
fills the gaps within the annealed fragments. A DNA ligase seals nicks in the assembled 
DNA. 
DNA fragments were generated using overlapping primers which harboured the 
sequence of either the vector or another fragment the original fragment was to be joined 
with. By this, fragments and the vector backbone were “seamlessly” joined without 
interspacing DNA sequences. Primers were generated using the NEBuilderTM (New 
England Biolabs GmbH) online resource. Vector backbones were either linearised by 
restriction enzyme digestion or PCR amplified. After PCR amplification of fragments and 
vector backbone, all generated templates were separated on a 1% agarose gel and 
purified. Purified DNA was resuspended in 30 µl ddH2O. 
Gibson Assembly® mix was prepared according to the following protocol. 
Protocol 5 Gibson assembly reaction mix 
Component 2-3 fragment assembly 
DNA ratio Vector:insert = 1:2 
Total amount of fragments 0.03 – 0.2 pmol 
Gibson Assembly® Master Mix 10 µl 
Nuclease-free ddH2O ad 20 µl 
Gibson Assembly® mix was incubated at 50°C for 15 min and directly transformed into 
DH5a chemically competent bacteria. 
3.2.10 GatewayTM cloning 
GatewayTM cloning is based on site-specific recombination. The system is used to first 
shuttle a gene of interest into an entry vector. From this entry vector the gene of interest 
can be quickly shuttled into a variety of destination vectors harbouring different tags. The 
BP reaction mediates the recombination of PCR fragments flanked by attB sites into 
pDONR vectors harbouring attP sites. This reaction results in an entry (pENTR/pDONR) 
vector harbouring the gene of interest flanked by attL sites. As a side product a linear 
fragment is removed from the vector encoding for bacterial toxin ccdB. In case of a non-
successful recombination bacteria transformed with non-recombined pDONR plasmids 
will express the ccdB gene and die, thereby selecting for positive colonies. pDONR 
vectors can be used in an LR reaction to shuttle the gene of interest into a destination 
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vector (pDEST) that again harbours the ccdB gene flanked by attR sites. Similarly to the 
pDONR vector non-recombined pDEST will be negatively selected by the expression of 
the ccdB gene. To differentiate between pDONR and pENTR vectors different selection 
markers are used (e.g. gentamicin vs ampicillin resistance). 
3.2.10.1 Generation of entry clones (BP reaction) 
Primers were designed which harboured the attB sites necessary for recombination. A 
start codon was added to the fw and a stop codon to the rev primer. 
Table 20 BP recombination sites 
Name Sequence 5’ – 3’ 
attB fw GGGGACAAGTTTGTACAAAAAAGCAGGCTTC 
attB rev GGGGACCACTTTGTACAAGAAAGCTGGGTC 
By PCR amplification attB-flanked inserts were generated, separated on a 1% agarose 
gel and purified. DNA inserts were resuspended in 30 µl ddH2O. BP reactions were set 
up according to the following protocol. 
Protocol 6 BP reaction mix 
Component 10 µl reaction 
pDONR/pENTR 150 ng 
attB-flanked Insert 150 ng 
BP clonase 1 µl 
1x TE buffer ad 10 µl 
BP reactions were incubated for at least 2h at 25°C and subsequently transformed into 
competent DH5a bacteria. Successful BP cloning was visualised by digesting pDONR 
plasmids with BsrGI which, due to cutting both recombination sites and the vector 
backbone, generated three specific fragments. Plasmids were sequenced to ensure the 
desired sequence was amplified. 
3.2.10.2 Generation of expression clones (LR reaction) 
LR reactions were carried out by combining desired destination vectors with generated 
pDONR vectors. LR reactions were set up according to the following protocol. 
Protocol 7 LR reaction mix 
Component 10 µl reaction 
pDONR/pENTR 150 ng 
pDEST 150 ng 
LR clonase 1 µl 
1x TE buffer ad 10 µl 
LR reactions were incubated for at least 2h at 25°C and subsequently transformed into 
competent DH5a bacteria. Successful LR cloning was visualised by digesting pDEST 
plasmids with BsrGI which, due to cutting both recombination sites, generated two 
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specific fragments. Plasmids were sequenced to ensure the desired sequence was 
cloned. 
3.2.11 Sequencing of plasmid DNA 
All sequencing was performed by the GATC-Biotech service. 5 μl sequencing primer (5 
μM) was mixed with 80 – 100 ng of plasmid DNA and filled up to 10 μl with nuclease-free 
ddH2O. DNA was sent to the company and sequencing data was provided online 24 to 
48 hours later. 
3.2.12 RNA extraction and purification 
RNA isolation was performed using the Nucleospin® RNA Plus kit according to the 
manufacturer’s instructions. Cells were washed with 1X PBS prior to lysis in LBP buffer. 
Lysates were stored at -80°C until RNA extraction. Purified RNA was resuspended in 
nuclease-free ddH2O and used for ExpandTM RT or cDNA preparation for quantitative 
Real-Time PCR. 
3.2.13 cDNA preparation by reverse transcription 
Reverse transcription was performed using the High Capacity cDNA Reverse 
Transcription kit (Applied Biosystems). Reaction mixes were prepared according to the 
following protocol. 
Protocol 8 RT reaction mix 
Component 6.6 µl reaction 
10X reaction buffer 0.66 µl 
100 mM dNTPs 0.25 µl 
10X random hexamer primers 0.66 µl 
RNase inhibitor 0.33 µl 
Reverse Transcriptase 0.33 µl 
Nuclease-free H2O 1.07 µ 
RNA 3.3 µl 
Protocol 9 RT reaction programme 
 
 
For each sample, a non-amplification control was included which contained ddH2O 
instead of reverse transcriptase. 
Temperature /°C Time 
25 10 min 
37 2h 
85 5 min 
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3.2.14 Quantitative Real-Time PCR 
Quantitative Real-Time PCR (qPCR) was performed using the iTaqTM Universal SYBR® 
Green Supermix and a CFX Connect™ Real-Time PCR Detection System (Bio-Rad). 
Samples were measured in triplicates. Non-amplification and non-target controls were 
included to control for specific amplification. 
qPCR reactions were prepared according to the following protocol. 
Protocol 10 qPCR reaction mix 
Component 15 µl reaction 
2x iTaq SYBR® Green 7.5 µl 
Primer fw 1.5 µl 
Primer rev 1.5 µl 
Nuclease-free H2O 1.5 µl 
cDNA 3 µl 
 
qPCR amplification reactions were carried out with the following programme. 
Protocol 11 qPCR reaction programme 
Step Procedure Description 
1 95°C 3 min 
2 95°C 10 sec 
3 60°C 30 sec 
4 measure  
5 Go back to 2 45 cycles 
6 65°C to 95°C 0.05 sec / 0.5°C 
7 Measure every 0.5°C  
 
qPCR data was analysed using the Bio-Rad CFX Manager software. Relative mRNA 
expression was calculated using the 2-DDCt method as described in [248]. 
3.3 Biochemical methods 
3.3.1 Protein cross-linking 
In order to cross-link cellular proteins in a 24 well, cells were washed with 1X PBS and 
250 µl of 1% PFA/PBS solution was added. Cells were incubated for 10 min at RT before 
reaction was stopped adding 250 µl of ice-cold 1.25 M Glycine/PBS. Cells were washed 
once with ice-cold1.25 M Glycine/PBS. 50 µl of 1X Laemmli buffer were added and cells 
were scraped off the dish. Samples were heated to 65°C for 20 min and stored at -20°C 
until SDS PAGE. If necessary, samples were treated with Benzonase® (Merck) prior to 
gel loading. 
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3.3.2 Western Blot analysis 
3.3.2.1 Determination of protein concentration 
Protein concentrations were determined using the Pierce™ BCA Protein Assay Kit 
(Thermo Fisher Scientific) which allows protein quantification based on a colorimetric 
reaction. BCA solution was prepared according to manufacturer’s instructions. 100 µl of 
BCA solution were mixed with 5 µl of protein lysate and incubated at 60°C for 20 min. In 
parallel, a serial dilution of the provided 2 mg/ml BSA standard in protein lysis buffer was 
prepared and incubated. 95 µl of BCA-standard and BCA-sample mix were transferred 
into a clear 96 well flat bottom plate and absorption at 570 nm was determined. 
Measurements of BSA standard were displayed in a standard curve. Protein 
concentrations were calculated according to BSA standard. 
3.3.2.2 Polyacrylamide gel electrophoresis 
SDS polyacrylamide gel electrophoresis (SDS PAGE) resolving gels containing 8% or 
15% polyacrylamide (PAA) were prepared using 40% acrylamide/bisacrylamide (ratio 
29:1) stock solution diluted in resolving gel buffer (section 2.10). 1:500 TEMED 
(Applichem) and 1:500 saturated ammonium peroxydisulfate (APS) (Roth) solution were 
added to initiate polymerisation reaction. Solution was immediately cast using the Mini-
PROTEAN® Tetra Handcast System (Bio-Rad) and carefully overlaid with 100% 
isopropanol to insure plane polymerisation. 5% PAA stacking gel solution was prepared 
using 40% acrylamide/bisacrylamide (ratio 29:1) stock solution diluted in stacking gel 
buffer. TEMED and APS supplemented gel solution was cast on top of the resolving gel 
after residual isopropanol was removed. 
Cells for protein samples were lysed in 1X Laemmli buffer or Ripa buffer supplemented 
with protease inhibitors. Samples in Ripa buffer were quick frozen, thawed and debris 
was pelleted by centrifugation at full speed for 10 min. Supernatants were mixed with 6X 
Laemmli to 1X concentration. Protein samples were denatured by boiling for 5 min at 
95°C. If necessary, samples were treated with Benzonase® prior to gel loading. Equal 
amounts of samples were loaded onto gels. A lane with pre-stained protein marker was 
included to determine size of detected proteins. Gels were run in 1X TGS buffer for 30 
min at 70V and 1 – 1.5h at 130V. 
3.3.2.3 Protein blotting 
After SDS PAGE separation, proteins were blotted onto PVDF membranes using the 
Trans-Blot® SD Cell or Trans-Blot® Turbo™ System for semidry transfer or the Mini 
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Trans-Blot® Cell for wet transfer (all systems by Bio-Rad). PVDF membranes were 
activated in 100% methanol for 30 seconds before equilibration in blotting buffer (10% 
methanol for semidry transfer, 20% methanol for wet transfer) for at least 5 min. Semidry 
transfer was performed for 1.5h at 1.5 mA/cm2 of membrane. Wet transfer was 
performed for 1.5h at 350 mA/100V. 
3.3.2.4 Antibody staining of Western Blot membranes 
After blotting, membranes were incubated for at least 1h in 5% milk/PBST or TBST (for 
phospho-protein detection) to block unspecific antibody binding. Primary antibodies were 
diluted in blocking solution (section 2.10) and incubated on membranes overnight at 4°C 
or for at least 2h at RT. Primary antibodies were removed and membranes were washed 
three times 10 min in PBST/TBST before secondary antibodies diluted in blocking 
solution (section 2.10) were added. Membranes were incubated with secondary 
antibodies for at least 1h at RT. Secondary antibodies were removed and membranes 
were washed two times in PBST/TBST and a final wash was done in PBS/TBS to 
remove Tween. After addition of ClarityTM ECL Western Blotting Substrate (Bio-Rad) or 
ECL Plus Western Blot Detection System (Amersham) signals were visualised using the 
ECL ChemoCam imager 3.2 (INTAS Science Imaging Instruments). 
3.3.2.5 Western Blot quantification 
Western Blot signals were quantified using the standard protocol of the Labimage1D 
software (INTAS). Densitometric signals of bands of interest were normalised to loading 
controls. 
3.3.3 Co-immunoprecipitation 
For co-immunoprecipitation experiments, 1x107 293T cells were seeded onto a 15 cm 
dish one day prior to transfection. 62 µg of tagged constructs were transfected using 
calcium phosphate transfection, reagents were scaled up according to dish size (section 
3.1.6). Medium was changed 8h post transfection. 
3.3.3.1 HA-tag co-immunoprecipitation 
Co-immunoprecipitations of HA-tagged proteins were performed using anti-HA-coated 
agarose beads (Sigma Aldrich). 
One day after transfection a confluent 15 cm dish was lysed with 1 ml HA-Co-IP lysis 
buffer (section 2.10) for 30 min on ice. Lysates were centrifuged for 30 min at 18500 x g 
at 4°C. 50 µl supernatant were taken as an input control. The remaining supernatant was 
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added to 20 µl HA beads which had been washed 3 times with pre-chilled HA-CoIP lysis 
buffer. Lysates were incubated with the beads for 4-16 h at 4°C on an overhead rotating 
device. Samples were centrifuged at 2000 x g for 1 min to carefully pellet beads. If 
required, supernatants were used as flow through control. Subsequently, beads were 
washed two times with 1 ml of ice cold HA-CoIP lysis buffer for 15 min and two washes 
with cold PBS for 5 min. Beads were either immediately mixed with 1x sample buffer or 
an SDS based elution followed by acetone precipitation was performed. In case of an 
SDS elution 100 µl 5% SDS/PBS was added to the washed beads and shaken for 5 min 
at 1100 rpm (shaking function of thermo block) at RT. Beads were pelleted by 
centrifugation at 18500 x g for 2 min. Supernatants were collected and pellets were 
washed adding 100 µl PBS. 5 min shaking at 1100 rpm and centrifugation at 18500 x g 
was repeated. Collected supernatants (~200 µl) were mixed with ~800 µl ice-cold 
acetone and protein was precipitated overnight at -20°C. Next morning precipitates were 
spun down at full speed for 30 min at 4°C. Pellets were resuspended in 50 µl 1x sample 
buffer and boiled for 5 min at 95°C. 
3.3.3.2 Strep-tag co-immunoprecipitation 
Co-immunoprecipitations of Strep-tagged proteins were performed using MagStrep 
"type3" XT Beads (IBA Life Sciences). Separation was achieved using a magnetic rack. 
One day after transfection a confluent 15 cm dish was lysed with 1 ml Strep-Co-IP lysis 
buffer (section 2.10) for 30 min on ice. Lysates were centrifuged for 30 min at 18500 x g 
at 4°C. 50 µl supernatant were taken as an input control if needed. The remaining 
supernatant was added to 20 µl Strep beads which had been washed 3 times with pre-
chilled NP40 lysis buffer. Lysates were incubated with the beads for 2 h at 4°C on an 
overhead rotating device. Beads were washed three times with 1 ml of ice cold Strep-Co-
IP lysis buffer on the magnetic rack. Proteins were eluted from beads by addition of 75 – 
100 µl BXT biotin elution buffer and shaking for 5 min at 1100 rpm (shaking function of 
thermo block) at RT. Collected supernatants were either quick frozen in liquid nitrogen or 
stored on ice until further use. 
3.3.4 In Vitro Kinase Assay 
In vitro kinase assay buffer was prepared adding 0.1 mg/ml BSA. Reactions were 
prepared on ice according to the following protocol. 
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Protocol 12 Kinase Assay reaction mix 
Component 50 µl reaction 
2x Kinase Assay Buffer 25  µl 
1 µg/µl purified RIG-I 1 µl 
100 µM CaM 0.5 µl 
Eluted kinase 21 µl 
Phosphorylation reactions were started by adding a mix of 1 µl 2.5 mM ATP and 1.5 µl 
32P-ATP (15 µCi). Samples were incubated at 30°C for 1h. Reactions were stopped by 
boiling samples for 5 min at 95°C. Samples were separated on an 8% polyacrylamide 
gel, transferred onto PVDF membranes and incubated on storage phosphor screens to 
detect incorporated 32P-ATP. 
3.4 Viral replication assays 
3.4.1 Rift Valley Fever Virus replication assay 
For RVFV replication assays a RVFV DNSs_Rluc (originally kindly provided by 
Friedemann Weber, Gießen) stock prepared by Pascal Mutz (titer: 2.24x102 /ml TCID50 
on HeLa cells) was used. 
A549 (7x104 cells/24 well) cells were silenced for 48h with control and targeting siRNAs. 
Cells were infected with RVFV DNSs_Rluc diluted 1:100 in standard cell culture medium 
for 24h. Supernatants were removed and cells were lysed in 100 µl luciferase lysis 
buffer. Samples were stored at -80°C until measurement on the Mithras² LB 943 
Multimode reader.  
3.4.2 Influenza A Virus replication assay 
For FluAV replication assays FluAV WSN/1933 stock (titer: 3.5x106/ml TCID50 on A549 
cells) prepared by Joschka Willemsen [249] was used. 
A549 (7x104 cells/24 well) cells were silenced for 36h with control and targeting siRNAs. 
Cells were infected with an MOI of 0.01 in OptiMEM for 1h before the inoculum was 
removed and 500 µl of standard cell culture medium complete was added. 32h p.i. cells 
were analysed by flow cytometry. 
3.4.3 Hepatitis C Virus replication assay 
For HCV replication assays HCV JCR2A stock (4.85x103 /ml TCID50 on Huh7 Lunet 
cells) prepared by Christopher Dächert was used. 
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Huh7 CD81high or CD81high MAVS-GFPNLS (5x104/24 well) cells were silenced for 24h with 
control and targeting siRNAs. Cells were infected with HCV JcR2A stock diluted 1:2 in 
standard cell culture medium. Samples were harvested at 24, 48, 72, and 96h p.i. by 
removing media, washing with 1X PBS, and adding 100 µl of luciferase lysis buffer. 
Samples were stored at -80°C until measurement on the Mithras² LB 943 Multimode 
reader.  
3.5 Flow cytometry 
Intracellular antigen staining was performed using Cytofix/Cytoperm™ (BD Biosciences). 
Influenza-infected A549 cells were washed with 1X PBS, detached with 0.05% 
trypsin/0.02% EDTA and washed again with PBS. Cell pellets were carefully 
resuspended in 100µl Cytofix/Cytoperm and incubated for 20 min on ice. Cells were 
washed twice with 1ml Perm/Wash solution and then stained in 50µl 1:50-diluted Anti-
Influenza A NP FITC-coupled antibody in Perm/Wash for 30 min on ice. Cells were 
washed twice with 1ml Perm/Wash solution and transferred into PBS. Cells were filtered 
through gauze and kept on ice before analysis on an AccuriTM C6 Flow Cytometer (BD 
Biosciences). Flow cytometry analysis was performed using the FlowJo V10 software 
(FlowJo LLC). 
3.6 Luciferase reporter assay 
In the morning, cells seeded the day before were transfected with firefly and renilla 
reporter plasmids either using lipofectamine 2000 or Effectene transfection reagent. In 
the evening of the same day cells were stimulated either by poly(I:C) or plasmid 
transfection or by SeV infection (MOI 5). If not indicated otherwise, cells were stimulated 
for 16h before medium removal and lysis in 100 µl/24 well luciferase lysis buffer. Until 
measurement cells were kept at -80°C. 
Samples were measured using Mithras² LB 943 Multimode reader or Mithras LB 940 
Multimode Microplate Reader. As firefly substrate assay buffer (see section 2.10) 
supplemented with 1:20 D-luciferin stock solution (section 2.10), 1:100 100 mM ATP and 
1:1000 1 M DTT was prepared. As renilla substrate Coelenterazin was diluted 1:700 in 
assay buffer (section 2.10). Reactions were stopped using 10% SDS solution as 
samples were measured in clear 24 well plates. 
24 well plates were measured using the following protocol. 
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Protocol 13 Luciferase assay programme 
Action Procedure 
Dispense firefly substrate 4x100 µl 
Shake 2 sec 
Measure (No filter) 10 sec 
Dispense renilla substrate 4x100 µl 
Shake 2 sec 
Measure (480m20BRET filter) 10 sec 
Dispense 10% SDS 100 µl 
Shake 2 sec 
 
Luciferase samples were measured in triplicates. 
3.7 Generation of CRISPR/Cas9 knockout cell lines 
The CRISPR/Cas9 system which was introduced in 2012 [250] is now extensively used 
in genome editing. Originally, CRISPR/Cas9 is a bacterial defence mechanism against 
foreign nucleic acids. Today, it is frequently used to generate knockout cell lines, as was 
done within the course of this study. Briefly, specific guide RNAs (sgRNAs) lead the 
Cas9 to the target gene where Cas9 induces double strand breaks. This induces DNA 
repair mechanisms which, due to insertion/deletion of bases, often result in frameshift 
mutations. Occurrence of early stop codons results in nonsense-mediate decay of mRNA 
transcripts, thereby shutting down gene expression. 
Four different sgRNAs for each targeted gene were designed using the standard settings 
of the DKFZ e-crisp tool (http://www.e-crisp.org). To enable cloning into lenticrispr v2 
(Addgene: 52961), BsmBI digest-compatible overhangs were added: 
Table 21 Overhangs for crispr cloning 
Oligo Overhang 5’ – 3’ 
sense CACC 
antisense AAAC 
 
Oligos were annealed according to the following protocol. 
Protocol 14 Crispr ligation mix 
Component 10 µl reaction 
sgRNA sense 1 µl 
sgRNA antisense 1 µl 
10X T4 ligation buffer 1 µl 
T4 PNK 1 µl 
Nuclease-free H2O ad 10 µl 
 
Phosphorylation by PNK was carried out for 30 min at 37°C, followed by annealing 
starting at 95°C and ramping down to 25°C at 5°C/min. 
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3 µg of lenticrispr v2 plasmid were digested using BsmBI restriction enzyme (section 
3.2.7) and de-phosphorylated using CIP (3.2.8). Linearised plasmid was gel-purified 
(section 3.2.6). Annealed oligos were diluted 1:200 and ligated into BsmBI-digested 
plasmid (section 3.2.8). Using the human U6 primer sgRNA insertions were sequenced 
to verify correct insertion. Using the generated crispr plasmids, lentiviral particles were 
produced (section 3.1.6) and target cells were infected. Successful transduction was 
ensured by antibiotic restriction. In order to allow targeting of multiple genes, lenticrispr 
v2 plasmids harbouring a hygromycin and a zeocin resistance gene were cloned 
employing Gibson® assembly (3.2.9). Generated knockout bulks were tested for protein 
expression. Lowest expressing bulks were chosen for single cell clone generation which 
were again tested for lack of target protein expression. 
3.8 Data evaluation 
Means and error bars were calculated using the GraphPad Prism 7 software. Number of 
biological replicates is indicated in the respective figure legends. 
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4 Results 
Death associated protein kinase 1 (DAPK1) was recently identified as a negative 
regulator of RIG-I signalling using a kinome-wide siRNA screen [199]. In this screening 
approach, siRNAs were used to target over 700 cellular kinases in cells which were then 
stimulated by transfection of the dsRNA analogue poly(I:C). Effects on translocation of 
GFP-tagged IRF3 were analysed by automated fluorescence microscopy. Thereby, 
several positive and negative regulators of antiviral signalling were identified, one of 
them being DAPK1. 
The present study focused on the mechanism how DAPK1 might execute its inhibitory 
function and how this ties in with its known roles in cellular homeostasis. Furthermore, 
DAPK1 is closely-related to the other members of its protein kinase family. Based on the 
fact that DAPKs often have similar functions in signalling pathways, it was investigated if 
and how other members of the DAPK family might be involved in innate antiviral 
signalling. 
4.1 The role of DAPK1 as an inhibitor of RIG-I signalling depends on its 
kinase activity but is independent of known DAPK1 functions 
4.1.1 A minimal kinase-active DAPK1 construct inhibits RIG-I signalling 
like full-length DAPK1 
A minimal construct of DAPK1 comprising its kinase, calmodulin binding and Ankyrin 
repeats domains (termed DAPK1KCA) was identified which was able to inhibit RIG-I 
signalling activation to the same extent as full-length DAPK1 when over-expressed in 
293TRIG-I cells [199]. DAPK1 undergoes unique auto-phosphorylation at serine residue 
308 (S308) which decreases its kinase activity and it was shown that de-phosphorylation 
at S308 was necessary for full activity of DAPK1, as a phospho-mimetic mutant lost its 
apoptotic potential [251]. Extent of DAPK1 S308 phosphorylation can be observed on 
protein level using a specific antibody. In order to investigate whether DAPK1 kinase 
activity was necessary for the inhibitory effect on RIG-I signalling upon over-expression, 
several mutants of DAPK1KCA were generated, namely a supposedly kinase-inactive 
K42A mutant, a phospho-mimetic S308D and a phospho-ablatant S308A mutant, as well 
as a mutant lacking the very N-terminus of the kinase (D1-73), incapable of ATP-binding 
and transfer (Figure 9A). These mutants were over-expressed in 293T cells which stably 
over-express RIG-I (293TRIG-I cells) and may, therefore, activate IRF3 signalling when 
probed with a suitable stimulus, e.g. infection with ssRNA viruses such as Sendai virus 
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(SeV). Indeed, kinase-inactive DAPK1KCA S308D and DAPK1KCA D1-73 mutants did not inhibit 
IFIT1 promoter activity as efficiently as full-length DAPK1, DAPK1KCA or DAPK1KCA S308A 
mutant (Figure 9B). The inhibitory effect of supposedly kinase-dead DAPK1KCA K42A 
mutant was only slightly reduced compared to DAPK1KCA and did not reflect kinase-
inactive DAPK1KCA S308D mutant (Figure 9B). Moreover, DAPK1KCA K42A retained capability 
of auto-phosphorylation at S308 which was not seen for DAPK1KCA D1-73 truncation mutant 
(Figure 9C). 
 
Figure 9 Inhibition of RIG-I signalling by a minimal DAPK1 construct depends on DAPK1 kinase 
activity 
A) An overview of DAPK1 minimal construct KCA and its mutants is shown. Mutation of lysine 42 to alanine 
was shown to render DAPK1 kinase-inactive in in vitro [164], [251]. Phospho-ablatant (S308A) and phospho-
mimetic (S308D) mutants were found to exhibit increased or decreased apoptotic activity, respectively [251]. 
DAPK1KCA D1-73 mutant does not harbour the ATP binding site in the active centre of the kinase domain and is 
expected to be kinase dead. B) Comparison of DAPK1KCA mutants and full-length DAPK1 in an IFIT1 
promoter activity assay. 293TRIG-I cells were transfected with DAPK1 constructs and stimulated with 0.4 
µg/ml poly(I:C) for 16h. (modified from [199]), n = 3 C)  Western Blot of DAPK1 p-S308 levels in cells over-
expressing DAPK1 constructs left untreated or treated with phosphatase inhibitor calyculin A for 1h prior to 
lysis. Detection of HA-tagged constructs shows transfection efficiency. Arrows indicate full-length DAPK1 
and KCA mutants. A representative of three independent experiments is shown. 
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A minimal DAPK1 construct comprising its kinase domain, CaM domain and Ankyrin 
repeats inhibited RIG-I signalling activation when over-expressed in 293TRIG-I cells, given 
that it retains its kinase activity. Hence, DAPK1 kinase activity is necessary for the 
observed inhibitory effect on the RIG-I signaling pathway. 
4.1.2 Limiting the function of DAPK1 in growth factor induced signalling 
does not interfere with its role in RIG-I signalling 
The DAPK1KCA minimal variant behaved like full-length DAPK1 when over-expressed in 
293TRIG-I cells, but an even smaller construct, harbouring only the kinase domain and the 
CaM domain was not able to inhibit RIG-I signalling [199]. Hence, the Ankyrin repeats 
domain seems to be indispensable for the inhibitory effect of DAPK1 on RIG-I signalling. 
Ankyrin repeats are found in a variety of proteins and mostly mediate protein-protein 
interactions [252]. In case of DAPK1, the Ankyrin repeats are a target of several kinases 
of the growth factor signalling network, specifically ribosomal protein S6 kinase a 
(p90S6K/RSK) and proto-oncogene tyrosine-protein kinase Src, both of which act 
downstream of mitogen-activated protein kinase 1 (MAPK1), also called ERK.  
p90S6K/RSK phosphorylates DAPK1 on serine 289 (S289), resulting in decreased 
apoptotic activity and cell survival [188]. Moreover, DAPK1 activity is regulated by 
phosphorylation of tyrosine residues 491 and 492 (Y491 and Y492, respectively) by Src 
and de-phosphorylation of those residues by receptor-type tyrosine-protein phosphatase 
F (RTPRF)/LAR [185]. Y491/Y492 phosphorylation decreases DAPK1 activity. Thus, 
growth-factor signalling, resulting in Src activation and LAR suppression, will result in 
decreased apoptotic potential of DAPK1 and overall cell survival. Phospho-mutants of 
the above-mentioned residues were created in order to examine if the effect seen by 
over-expression of DAPK1KCA was mediated by a cross-talk with growth factor-induced 
signalling. In the case of S289, a phospho-mimetic S289E and -ablatant 289A mutant 
were generated, and in the case of Y491/Y492 phospho-mimetic Y491/492E and -
ablatant Y491/492F mutants were generated (Figure 10A). These mutants were over-
expressed in 293TRIG-I cells and compared to full-length DAPK1 and DAPK1KCA in terms 
of RIG-I activation upon SeV infection. All generated mutants efficiently inhibited IFIT1 
promoter activity after stimulation and behaved similar to DAPK1WT and DAPK1KCA 
(Figure 10B). 
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Figure 10 Limiting DAPK1 function in growth factor signalling does not abrogate its ability to 
inhibit RIG-I signaling 
A) Overview over DAPK1 KCA phospho-mimetic and phospho-ablatant mutants of residues important for 
growth factor related signalling B) IFIT1 promoter reporter assay in 293TRIG-I cells over-expressing DAPK1WT, 
DAPK1KCA and DAPK1KCA variants stimulated with SeV (MOI 5) for 16h, error bars correspond to two 
independent experiments C) Western Blot analysis of DAPK1 levels in A549 and 293TRIG-I cells seeded at 
different densities in 24 well plates, either unstimulated or infected with SeV (MOI 5) for 16h. 20 µg of protein 
were loaded per lane. D) Densitometric quantification of C) 
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293TRIG-I cells, in which all over-expression assays were performed, express 
endogenous DAPK1. It has not been studied how DAPK1 behaves in 293T cells in 
response to growth factor signalling and mitotic stimuli. Contact inhibition of densely 
seeded cells normally leads to stagnation of cell growth and division in culture, whereas 
cells seeded at low densities will usually grow and undergo mitosis until they reach 
confluency. As growth factor signalling is needed for induction of cell division, it will be 
influenced by the number of cells seeded onto a defined area [253]. 
In order to determine if growth factor signalling affects DAPK1 protein levels in A549 and 
293TRIG-I cells, an assay was performed in which the cells were seeded at different 
densities onto a defined area. DAPK1 levels in cells either growing fast without contact 
inhibition (low densities, strong growth factor signalling) or growing slowly with increasing 
contact inhibition (high densities, weak growth factor signalling) was examined in 
293TRIG-I and A549 cells by immune staining. 
In 293TRIG-I cells DAPK1 levels were inversely correlated with cell density, whereas in 
A549 cells, DAPK1 levels rose proportionally with increasing numbers of cells per well 
(Figure 10C and 10D), resulting in a ~2-fold difference between highest and lowest 
concentration of cells for both cell types. 
DAPK1 expression and probably its activity were influenced by cell growth in A549 and 
293TRIG-I cells, although growth-dependent regulation of endogenous DAPK1 levels 
differed between analysed cell types. Over-expression of DAPK1KCA phospho-mutants 
mimicked regulatory phosphorylation by kinases involved in growth factor signalling. 
However, all over-expressed constructs inhibited RIG-I signalling to the same extent. 
Thus, inhibition of RIG-I signalling by DAPK1 does apparently not depend on regulation 
of DAPK1 activity by Src or RSK phosphorylation, both of which are downstream targets 
of ERK, activated upon induction of growth factor signalling. 
4.2 DAPK family members are negative regulators of RIG-I signalling 
DAPK1 is the founding member of the DAPK family of protein kinases. Its closest 
relatives are DAPK2 and DAPK3 whose kinase domains display high amino acid 
sequence homology to DAPK1 (Figure 6). The minimal DAPK1KCA construct is 
significantly smaller than full-length DAPK1 and harbours only the kinase domain, CaM 
domain and Ankyrin repeats. In this, it is structurally similar to DAPK2 and DAPK3. It was 
established that DAPK1 negatively regulated RIG-I signalling in a feedback loop [199]. 
Since cells endogenously express not only DAPK1 but also other DAPK family members 
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it was investigated if and how these regulate antiviral signalling and might in turn be 
regulated in their activity. 
 
Figure 11 Gene expression profiles of human DAPK1, DAPK2, and DAPK3 
Overview of DAPK1, DAPK2, and DAPK3 gene expression in different tissues from patient samples. Gene 
expression is shown in Reads Per Kilobase of transcript per Million mapped reads (RPKM) and dashed lines 
indicate a Log10(RPKM) of zero. Highlighted tissues correspond to origins of cell lines examined in Figure 6. 
Error bars indicate different sample numbers (for more information, visit the GTEx Portal). Displayed data 
were obtained from the GTEx Portal (gtexportal.org, GTEx Analysis Release V6p, dbGaP Accession 
phs000424.v6.p1) on 05/31/17. 
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4.2.1 DAPK2, DAPK3, and DRAK1 are inhibitors of RIG-I signalling 
It is known that DAPKs can have similar functions in signalling pathways. For example, 
DAPK1 and DAPK3 both phosphorylate Beclin, but target different residues in order to 
allow tight, possibly tissue-specific regulation of the autophagic network [170], [208]. 
Hence, variable expression of DAPKs in different cell types allows flexible and tight 
regulation of not only cell death pathways, but also other signalling cascades DAPKs are 
involved in. As a matter of fact, DAPK gene expression varies considerably between 
different tissues (Figure 11). Whereas DAPK1 and DAPK3 are expressed in the liver, 
DAPK2 is not. Similarly, DAPK3 is the only of the three kinases which is expressed in 
endocervical tissue, while there is hardly any expression of DAPK1 and DAPK2. Thus, it 
is feasible that different DAPKs fulfil certain tasks in a specific cell type, based on their 
expression. 
 
Figure 12 DAPK expression in different cell lines 
A) Comparative Western Blot analysis of DAPK1, DAPK2, and DAPK3 protein expression in A549, 293TRIG-I, 
(Huh7) Lunet, and HeLa cells. Cells were either left unstimulated or infected with SeV (MOI5) for 16h. 
Arrows indicate DAPK2 monomers and dimers. 20 µg of protein were loaded. B) DAPK mRNA expression in 
different cell lines. mRNA levels of DAPK1, DAPK2, and DAPK3 were measured by qPCR in A549, 
293TRIG-I, Huh7 Lunet, and HeLa cells. Cells were either left untreated or infected with SeV (MOI 5) for 16h. 
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In order to know if and how strong the three most closely related DAPKs, DAPK1, 
DAPK2, and DAPK3 were expressed in cells of different origin, their expression levels 
were assessed in four different human cell lines. Besides the transformed human 
embryonic kidney cell line (HEK)293TRIG-I, cancer cell lines A549 (lung), Lunet (Huh7, 
hepatoma), and HeLa (endocervix) were examined. Protein levels were analysed in a 
comparative Western Blot and mRNA levels were measured via qPCR in uninfected 
versus SeV infected cells (Figure 12). 
In general, protein levels corresponded to mRNA expression levels, emphasized by 
findings for HeLa cells which expressed very low amounts of DAPK1 and DAPK2 mRNA 
and correspondingly low amounts of protein independent of virus stimulation (Figure 12). 
DAPK1 mRNA and protein expression was highest in Lunet and A549 cells and was not 
significantly changed in response to virus infection. 293TRIG-I cells expressed lower 
amounts of DAPK1 mRNA and protein than Lunet and A549 cells, while HeLa cells 
expressed virtually no DAPK1 mRNA or protein. DAPK2 mRNA and protein expression 
was highest in A549 cells, followed by Lunet and then 293TRIG-I cells. HeLa cells 
expressed very low levels of DAPK2 mRNA. Interestingly, DAPK2 protein dimerised in 
response to virus infection in A549, Lunet, and to some extent in HeLa cells, but was 
exclusively detected in its dimerised form in 293TRIG-I cells, independent of stimulation 
(Figure 12A, arrows). As a matter of fact, DAPK2 dimerisation is indicative of increased 
DAPK2 activity [160], which was examined in the course of this study (Figure 23). 
Overall DAPK3 mRNA and protein levels were similar between examined cell lines. 
While DAPK3 mRNA levels were increased in A549 and 293TRIG-I cells in response to 
virus infection, Lunet and HeLa cells expressed less DAPK3 mRNA after stimulation 
(Figure 12B). 
Taken together, DAPK1, DAPK2, and DAPK3 mRNA and protein were detectable in the 
four different cell lines, albeit expression differed considerably. While DAPK1 and 
DAPK3 were highly expressed in A549, 293T RIG-I, and Lunet cells, DAPK2 was best 
detectable in A549 cells with very low expression in the other cell lines. HeLa cells were 
found to be unsuitable for studies on endogenous DAPK functions and interactions as 
they only expressed detectable amounts of DAPK3 and hardly any DAPK1 or DAPK2. 
Interestingly, DAPK expression in the examined cell lines (Figure 12) reflected their gene 
expression profiles in human tissues (Figure 11) to a large extent. For example, HeLa 
cells, which are of endocervical origin, expressed well detectable amounts of DAPK3 
mRNA and protein, but hardly any DAPK1 or DAPK2, which are also expressed in 
limited amounts only in endocervical tissue from patient samples (Figure 11). 
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4.2.1.1 Similar to DAPK1, DAPK2 and DAPK3 dose dependently inhibit 
RIG-I signalling 
It was established DAPK1 was an inhibitor of RIG-I signalling and that this inhibitory 
effect was dose-dependent [199]. Therefore, it was analysed if the same could be 
observed for DAPK2 and DAPK3. To this end, different amounts of plasmid encoding for 
DAPK1, DAPK2, and DAPK3 were transfected into 293TRIG-I cells, cells were stimulated 
by SeV infection and the respective amount of RIG-I signalling induction was compared. 
Similar to DAPK1 (Figure 13A), DAPK2 and DAPK3 dose-dependently inhibited IFIT1 
promoter activity, i.e. RIG-I signalling (Figure 13B and 13C). Transfection efficiency was 
monitored by Western Blot and showed increasing HA signal with increasing amounts of 
transfected plasmid (Figure 13D). 
 
Figure 13 Over-expressed DAPK1, DAPK2, and DAPK3 dose-dependently inhibit RIG-I signalling 
For IFIT1 promoter reporter activation assay increasing amounts of plasmid encoding HA-tagged DAPK1 
(A), DAPK2 (B), and DAPK3 (C) were transfected into 293TRIG-I cells. Cells were infected with SeV (MOI 5) 
for 16h before IFIT1 promoter activity was measured. Transfection efficiency was assessed in Western Blot 
analysis by staining for HA (D). 
In contrast to DAPK1 and DAPK2, which reached 50% reduction of IFIT1 promoter 
activity when 200 ng of plasmid were transfected, a 50% reduction in IFIT1 induction was 
reached transfecting only 50 ng of plasmid in the case of DAPK3. Since DAPK over-
expression induced apoptosis in 293TRIG-I cells, transfection of high amounts (> 500 ng) 
of the kinases lead to a dramatic increase in cell death as seen in a large percentage of 
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floating, detached cells (data not shown). Therefore, a maximum of 500 ng of plasmid 
was used for over-expression assays in this study. 
As not only DAPK1 but also closely related DAPK2 and DAPK3 were found to be 
inhibitors of RIG-I signalling, the question remained whether this inhibitory role was a 
general trait of all members of the DAPK family. In order to investigate this, the effects of 
remaining DAPK family members DRAK1 and DRAK2 on RIG-I signalling were 
analysed. To this end, DRAK1 and DRAK2 were over-expressed in 293TRIG-I cells and 
cells were infected with SeV. 
When compared in the IFIT1 promoter activity assay, over-expressed DRAK1 inhibited 
signalling to a similar extent as DAPK1, whereas no change in IFIT1 promoter activity 
was observed upon over-expression of DRAK2 (Figure 14A). Compared to DRAK1 and 
DAPK1, expression of DRAK2 was less efficient and did not reach the same levels as 
the other DAPKs (Figure 14B). 
Over-expression of four DAPK family members strongly inhibited IFIT1 promoter activity 
in response to SeV stimulation. Only DRAK2 over-expression did not influence the RIG-I 
signalling response. 
 
Figure 14 Over-expressed DRAK1 inhibits RIG-I signalling whereas DRAK2 does not 
A) IFIT1 promoter activity assay in 293TRIG-I cells over-expressing DAPK1, DRAK1, and DRAK2. Cells were 
infected with SeV for 16h. Error bars correspond to three independent experiments. B) Western Blot 
analysis. HA-tag was stained to assess expression levels of individual kinases. 
4.2.1.2 Down-regulation of DAPK2 and DAPK3 increases RIG-I signalling 
Up to this point, all analyses regarding the role of DAPKs in RIG-I signalling were 
performed in over-expression studies in 293TRIG-I cells. Exogenous expression of 
proteins is an artificial situation and does not represent actual expression and function of 
a cellular protein. In order to assess how DAPKs might influence RIG-I signalling based 
on their natural expression levels a silencing approach was employed in which siRNAs 
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were transfected thereby depleting cells of endogenous DAPKs. Additionally, these 
silencing studies were carried out not only in 293TRIG-I cells but also the lung carcinoma 
cell line A549. Due to low expression of vital components of the antiviral signalling 
machinery, antiviral IFN signalling is greatly impaired in 293T cells, requiring over-
expression of RLRs to achieve ISG and IFN expression after RNA virus infection. A549 
cells are naturally responsive to RNA virus infection and do not require additional 
expression of RLR signalling components. Silencing studies focused on DAPK1, DAPK2, 
and DAPK3, since these are the closest related DAPK family members, their expression 
could be validated in A549 and 293TRIG-I cells (Figure 12), and they are the best studied 
DAPK family members regarding their activity and regulation.  
Kinases were silenced in A549 and 293TRIG-I cells and cells were infected with SeV. In 
the case of DAPK1, six individual siRNAs from two different suppliers were tested which 
all resulted in strong down-regulation of DAPK1 protein levels (Figure 15B). Down-
regulation of DAPK1 by three siRNAs (namely siDAPK1_5, siDAPK1 sig1 and sig2) 
resulted in an increase in IFIT1 promoter activity which confirmed an inhibitory role for 
DAPK1 in RIG-I signalling (Figure 15A and [199]). Differences in remaining DAPK1 
protein levels undetectable in Western Blot analyses and increased cytotoxicity probably 
account for a lack of effect on IFIT1 promoter activity by two siRNAs (siDAPK1_6, 
siDAPK1 sig3). SiRNA “siDAPK1 sig1” whose transfection resulted in the highest IFIT1 
promoter activity after SeV infection was chosen for knockdown of DAPK1 in subsequent 
analyses and is referred to as “siDAPK1” throughout this study. 
Subsequently, DAPK2 and DAPK3 were silenced in A549 and 293TRIG-I cells and IFIT1 
promoter activity after virus infection was analysed. DAPK2 protein levels in both cell 
lines were low, allowing detection only after exposure times of 30 to 60 minutes in 
Western Blot analysis, and were, in comparison, even lower in 293TRIG-I cells than in 
A549 (Figure 12A and Figure 15E and 15F). Therefore, it was questionable whether 
depletion of such low protein amounts would have any effect on target cells. Accordingly, 
although three tested siRNAs resulted in down-regulation of DAPK2 protein levels, there 
was little to no change in IFIT1 promoter activity in response to DAPK2 knockdown 
(Figure 15 C). One siRNA, “siDAPK2 sig1” did result in a slight increase in IFIT1 
promoter activity in 293TRIG-I cells (Figure 15C right panel), but it also down-regulated 
DAPK1 levels when transfected in A549 and 293TRIG-I cells (Figure 15 E), which probably 
resulted in the observed increase in IFIT1 promoter activity (compare Figure 15A). 
DAPK3 was generally expressed to higher levels than DAPK2 in A549 and 293TRIG-I 
cells. Three individual siRNAs targeting DAPK3 by two different suppliers resulted in up 
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to a three-fold increase in IFIT1 promoter activity after SeV infection in A549 and around 
a two-fold increase in 293TRIG-I cells (Figure 15D) and all siRNAs efficiently down-
regulated DAPK3 protein levels (Figure 15F). 
These results confirm a role of DAPK3 as an inhibitor of RIG-I signalling. Importantly, 
siRNA “siDAPK3_3” lead to a down-regulation of DAPK2 levels in both A549 and 
293TRIG-I cells (Figure 9F). “siDAPK3 sig3” transfection resulted in highest IFIT1 promoter 
activity and high knock-down efficiency. It was, therefore, chosen for subsequent 
silencing analyses and is referred to as “siDAPK3” in this study. 
Importantly, DAPK2 expression varied significantly in independent experiments 
(compare Figure 12, and Figure 15E and 15F), but was generally much lower than 
DAPK1 or DAPK3 expression (Figure 12). Additionally, DAPK2 silencing and additional 
stimulation by SeV infection often resulted in a dramatic increase in cell death, making it 
difficult to read out IFIT1 promoter activity assays in which signals were often close to 
background (data not shown). Based on these observations, subsequent analyses based 
on siRNA-mediated silencing were performed only for DAPK1 and DAPK3. 
It had been established that DAPK1 silencing not only up-regulated IFIT1 promoter 
activity, but also resulted in increased IFIT1 and IFNb mRNA levels after RIG-I 
stimulation [199]. In addition to DAPK1, DAPK3 also negatively regulated RIG-I 
signalling. This was observed in IFIT1 promoter activity assays after over-expression and 
was supported by results from siRNA-mediated silencing experiments. Since reporter-
based promoter activity assays only reflect cellular responses to a stimulus to a certain 
extent but allow no conclusion on changes in endogenous protein or mRNA levels, 
endogenous levels of IFIT1 and IFNb mRNA were analysed in response to SeV infection 
after DAPK3 depletion. These analyses were carried out in parallel to DAPK1 depletion 
to allow a comparison between both kinases. To this end, DAPK1 and DAPK3 were 
silenced in A549 and 293TRIG-I cells and RIG-I signalling was stimulated by SeV infection. 
IFIT1 and IFNb mRNA levels were determined by quantitative real-time PCR (qPCR). In 
parallel, knockdown efficiencies for DAPKs were determined measuring DAPK1, DAPK2, 
and DAPK3 mRNA levels. In analogy to results obtained in IFIT1 promoter activity 
assays, an overall increase in IFNb and IFIT1 mRNA levels was observed after silencing 
of DAPK1 and DAPK3 (Figure 16). 
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Figure 15 Silencing of DAPK family members enhances IFIT1 promoter activity (figure legend on the 
following page) 
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For IFIT1 promoter activity after silencing of DAPKs, siRNAs targeting the individual kinase were reverse 
transfected into A549 or 293TRIG-I cells. 38h after siRNA transfection, reporter plasmids were transfected, 
and 48h after siRNA transfection cells were infected with SeV (MOI 5) for 16h. A) IFIT1 promoter activity 
after silencing of DAPK1 in A549 and 293TRIG-I cells using six different siRNAs. B) Western Blots assessing 
silencing efficiency of DAPK1 corresponding to measurements in A). C) IFIT1 promoter activity assay after 
silencing of DAPK2 with E) corresponding Western Blot analysing silencing efficiency and expression of 
DAPK1, and DAPK3. D) IFIT1 promoter activity assay after silencing of DAPK3 with F) corresponding 
Western Blot analysing silencing efficiency and expression of DAPK1, and DAPK2. Mean of two (C) or three 
(D) independent experiments are shown. Western Blots show one representative result. 
While IFNb mRNA levels were increased around 6-fold in A549 and 4-fold in 293TRIG-I 
cells after silencing of DAPK1 (Figure 16A and [199]), silencing of DAPK3 resulted in an 
average increase in IFNb mRNA of 2-fold in A549 and 4-fold in 293TRIG-I cells. Silencing 
of DAPK3 also resulted in a 2-fold increase in IFIT1 mRNA levels, while the increase in 
IFIT1 mRNA levels was slightly smaller in A549 cells (Figure 16B). 
Notably, in analyses carried out in the present studies, silencing of DAPK1 had no effect 
on IFIT1 mRNA levels in either cell line, although it reproducibly up-regulated IFIT1 
mRNA in previous experiments [199]. mRNA levels of both DAPK1 and DAPK3 were 
reduced up to 90% in A549 and 293TRIG-I cells, while the knockdown of one DAPK did 
not have a strong influence on mRNA expression of the other examined kinases, with a 
mere 1.5-fold increase in DAPK2 mRNA levels after silencing of DAPK1 or DAPK3 in 
293TRIG-I cells (Figure 16C). DAPK3 mRNA levels were slightly increased in A549 cells in 
response to virus infection which is in agreement with previous findings stating that 
DAPK3 might be an ISG [205]. 
Silencing experiments lasted a total of four days. Therefore, seeding a low number of 
cells was required as cells continued to grow and divide throughout the experiment. As 
indicated above, DAPK1 protein levels were changed dramatically based on cell density 
and growth (Figure 10C and 10D) and it is not unlikely that this might be the case for 
DAPK2 and DAPK3 as well. It was observed that, probably due to varying cell growth 
and division, results of siRNA-based silencing assays, which lasted longer than over-
expression assays, were subject to larger internal variation than over-expression 
experiments. This is also a likely explanation for the here observed lack of up-regulation 
of IFIT1 mRNA upon silencing of DAPK1. 
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Figure 16 Silencing of DAPK1 and DAPK3 increases IFNβ and IFIT1 mRNA levels 
For qPCR analyses DAPK1 or DAPK3 were silenced for 48h in A549 or 293TRIG-I cells. Cells were stimulated 
with SeV (MOI 5) for 16h before mRNA levels of DAPK1, DAPK2, DAPK3, IFNb and IFIT1 were measured.  
A) IFNb and B) IFIT1 mRNA levels in A549 and 293TRIG-I cells silenced for either DAPK1 or DAPK3 are 
shown. C) mRNA levels of DAPK1, DAPK2, and DAPK3 in unstimulated and SeV infected A549 and 
293TRIG-I cells are shown. mRNA levels of target genes are normalised to GAPDH mRNA levels and shown 
as fold-induction of stimulated non-targeting siRNA control. Results are the mean of two independent 
experiments. 
No conclusions could be drawn from silencing experiments with DAPK2 due to the lack 
of an effect in IFIT1 promoter activity assays and toxicity of siRNAs in combination with 
virus infection. However, silencing of DAPK3 resulted in an increase in RIG-I signalling 
activity after SeV infection in 293TRIG-I and A549 cells as analysed by examination of 
IFIT1 promoter activity and qPCR, confirming its role as an inhibitor of the RIG-I 
signalling pathway. 
Page | 76  Results 
4.3 Induction of cell death by DAPKs is independent of RIG-I signalling 
inhibition 
4.3.1 Induction of apoptosis by DAPKs is not responsible for their 
inhibitory role in RIG-I signalling 
As indicated by their name “death-associated protein kinases”, DAPKs are known and 
well-described inducers of cell death pathways such as apoptosis and autophagy [161], 
[164], [200], [207], [219], [228]. Hence, in order to assure cell survival, their activity is 
tightly regulated. 
DAPK1, DAPK2, and DAPK3 induced cell death in 293TRIG-I cells when over-expressed 
which could be observed by an increased amount of detached and floating cells 
compared to mock transfection (data not shown). Since cell death induction is one of the 
main cellular functions of DAPKs, it could not be ruled out that their effects on RIG-I 
signalling were mediated by an increase in apoptosis, especially after over-expression in 
293TRIG-I cells. In order to determine whether increased induction of apoptosis upon 
DAPK over-expression was responsible for reduced RIG-I signalling activity, cells were 
treated with small molecule inhibitors which potently inhibit apoptosis induction and 
effects on RIG-I signalling activation in response to SeV stimulation were observed. 
First, in order to assess their inhibitory potential and find working concentrations, small 
molecule pan-caspase inhibitors Q-VD-OPh [254] and zVAD [255] were tested in 
293TRIG-I and A549 cells. To this end, cells were treated with apoptosis-inducing drugs 
staurosporine, which besides broadly inhibiting cellular kinases such as PKC [256] also 
directly enhances caspase-3 activity [257], and actinomycin D, an inhibitor of DNA 
transcription [258], [259]. After drug treatment, extent of Poly ADP ribose polymerase 
(PARP) cleavage was analysed by Western Blot quantification. PARP is an enzyme 
involved in DNA repair and a direct target of activated caspase-3 [240], [241]. Induction 
of apoptosis, i.e. caspase 3 activation, results in the proteolytic cleavage of full-length 
PARP in its 24 kDa DNA-binding and 89 kDa catalytic domain (cleaved PARP, c-PARP). 
The extent of caspase-3 activity and PARP cleavage is directly proportional, allowing a 
relative quantification of cell death induction by quantification of PARP cleavage. 
Page | 77 
 
 
Results 
 
Figure 17 Q-VD-OPh is a non-toxic apoptosis inhibitor 
Analysis of PARP cleavage after treatment of 293TRIG-I or A549 cells with apoptosis inducers staurosporine 
and actinomycin D. Cells were treated with drugs for 4h (A549) or 8h (293TRIG-I) either in the absence or 
presence of different concentrations of Q-VD-OPh or zVAD and PARP cleavage was observed. Western 
Blots (A) were quantified by densitometry (B). 
Whereas treatment with staurosporine induced strong (over 3 fold) PARP cleavage in 
A549 cells and weak (0.5 fold) PARP cleavage in 293TRIG-I cells, treatment with 
actinomycin D did not lead to an increase in PARP cleavage (Figure 17B lower panels). 
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Generally, 293TRIG-I cells displayed higher endogenous levels of cleaved PARP 
compared to A549 cells (Figure 17A). Although PARP cleavage, i.e. apoptosis induction, 
in 293TRIG-I cells in response to staurosporine treatment was low (Figure 3B upper left 
panel), it was efficiently and dose-dependently inhibited by treatment with Q-VD-OPh, 
which also potently inhibited PARP cleavage in A549 cells. zVAD did not inhibit 
apoptosis induction in A549 cells (Figure 17B upper right panel) as efficiently as Q-VD-
OPh, and, at least in tested concentrations, was toxic in 293TRIG-I cells, in which PARP 
cleavage was increased after zVAD treatment. 
Based on the above results Q-VD-OPh in a concentration of 20 µM was chosen as an 
inhibitor of apoptosis induction for subsequent assays. 
To address whether inhibitory effects on RIG-I signalling by DAPKs were mediated by 
their cell death-inducing properties, 293TRIG-I cell were transfected with DAPK family 
members all of which have been described to induce apoptosis [161], [200], [217]. 
Importantly, DRAK2 was excluded since it did not inhibit RIG-I signalling when over-
expressed in 293TRIG-I cells (Figure 14). Pre- and co-treatment with Q-VD-OPh was 
compared to vehicle control. Effects on RIG-I signalling were analysed assessing IFIT1 
promoter activity, while apoptosis induction was monitored by Western Blot analysis for 
PARP cleavage. 
Over-expression of all DAPK family members induced apoptosis in 293TRIG-I cells as 
observed by an up to 2.5 fold increase in PARP cleavage (Figure 18A and 18B). Out of 
all DAPKs, DAPK3 showed highest levels of cleaved PARP both in unstimulated and 
infected cells. PARP cleavage induced by DAPK1 and DAPK2 was slightly increased in 
infected cells compared to the unstimulated control. PARP cleavage, i.e. apoptosis 
induction, was inhibited in cells expressing DAPK1, DAPK2 and DAPK3 which were pre- 
and co-treated with Q-VD-OPh. Notably, DRAK1 over-expression resulted in only a mild 
increase in PARP cleavage which could not be inhibited by Q-VD-OPh treatment (Figure 
18B). Over-expression of all examined DAPK family members strongly inhibited IFIT1 
promoter activity. However, neither in untreated nor in infected cells did inhibition of 
apoptosis induction by Q-VD-OPh treatment change RIG-I signalling induction or the 
inhibition of the former by DAPKs (Figure 18C). Based on these results it is unlikely that 
DAPKs mediate an inhibition of RIG-I signalling by induction of the apoptotic machinery. 
Instead, regulation of RIG-I signalling by DAPK family members seems to happen 
independently of their apoptosis-promoting function. 
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Figure 18 Inhibition of RIG-I signalling by DAPKs is not due to cell death induction 
A) Western Blot for PARP cleavage in 293TRIG-I cells expressing HA-tagged DAPK family members. Cells 
were infected with SeV (MOI 5) for 16h and either pre- and co-treated with 20 µM Q-VD-OPh or treated with 
vehicle control. Transfection efficiency was monitored by detection of the HA-tag. B) Quantification of c-
PARP signal from A) in untreated compared to infected cells. C) IFIT1 promoter reporter assay of untreated 
and infected cells pre- and co-treated either with vehicle control or 20 µM Q-VD-OPh. Data is the mean of 
four independent experiments for DAPK1, DAPK2 and DAPK3 and one experiment for DRAK1. 
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4.3.2 Autophagy may influence RIG-I signalling, but is not induced by 
DAPK over-expression in 293TRIG-I cells 
DAPK1, DAPK2, and DAPK3 are not only involved in the induction of type I (apoptotic) 
cell death pathways, but also promote type II (autophagic) cell death by several 
mechanisms such as direct phosphorylation of beclin-1 [170], [171], [208], [228] and 
interaction with cytoskeletal components, promoting autophagic vesicle formation [260]. 
Autophagy was found to influence cellular antiviral responses. On the one hand, 
induction of autophagy helps degrading viral components which have entered the 
cytoplasm, as was shown in PKR-mediated clearance of herpes simplex virus type 1 
[261]. On the other hand, proteins of the ATG family, whose activation is crucial for the 
autophagic machinery, may inhibit the RIG-I signalling pathway by direct interaction with 
either RIG-I or MAVS [262], [263]. Thus, it appears feasible that an induction of 
autophagy by over-expression of DAPK1, DAPK2, and DAPK3 will have an impact on 
antiviral signalling and could explain the observed inhibition of the RIG-I signalling 
pathway. 
Autophagy induction relies on the formation of isolation membranes by the Beclin-
VPS34-ATG14L complex inducing production of PI3P which is incorporated in the 
growing membranes. Another essential protein which is necessary for autophagosomal 
membrane expansion is lipidated LC3B. In its non-lipidated form LC3B is referred to as 
LC3B-I. In response to autophagy induction, LC3B is cleaved and lipidated and the 
generated product is referred to as LC3B-II. LC3B-II is characterised by distinct running 
behaviour in polyacrylamide gels and its relative amount is often used to quantify the 
amount of autophagy induction, e.g. after drug treatment of cells [245]. Hence, inhibition 
of autophagy by Spautin-1 which interferes with local PI3P production [244] can be 
observed as an increase in LC3B-I compared to LC3B-II levels. In contrast, induction of 
autophagy by mTOR inhibitor Torin-1 [243], [264] results in a decrease in LC3B-I levels 
as most LC3B will be lipidated. 
In order to examine if the effect on RIG-I signalling mediated by DAPK1, DAPK2, and 
DAPK3 was due to an induction of autophagy, the three kinases were over-expressed in 
293TRIG-I cells. In parallel, cells were treated with Spautin-1 or with Torin-1. IFIT1 
promoter activity was measured after stimulation. To assess changes in autophagy 
induction in transfected cells, immune staining for LC3B-I and LC3B-II was employed. 
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Figure 19 Autophagy may influence RIG-I signalling but is not induced by over-expression of DAPK 
family members 
A) 293TRIG-I cells over-expressing DAPKs were either left unstimulated or infected with SeV (MOI 5) for 16h. 
Additionally, cells were treated with 20 µM Spautin-1 or 250 nM Torin-1 for 16h, either without stimulation or 
in combination with SeV (MOI 5) infection. Data is the mean of three (DAPK2, DAPK3, Torin-1) or four 
(mock, DAPK2, Spautin-1) experiments. B) Western Blot analysis of LC3B levels under DAPK over-
expression or drug treatment. P-S6K levels indicated state of mTOR inhibition. Expression of DAPK 
constructs was monitored by staining HA-tag. A representative of three independent experiments is shown. 
While inhibition of autophagy by Spautin-1 treatment did result in a slight but 
reproducible decrease of IFIT1 promoter activity, induction of autophagy by Torin-1 
treatment did not change IFIT1 promoter activity as compared to mock transfected, 
vehicle treated cells (Figure 19A). Efficiency of autophagy inhibition by Spautin-1 or 
induction by Torin-1 was assessed by observation of LC3B-I and –II levels on Western 
Blot. As expected, Spautin-1 treatment resulted in increased LC3B-I (Figure 19A, upper 
LC3B signal) levels, whereas Torin-1 treatment resulted in a strong decrease in LC3B-I 
levels (Figure 19B). This is in line with findings that the autophagic flux in mTOR inhibitor 
treated cells is strongly increased and most LC3B will be found as membrane-associated 
LC3B-II (Figure 19A, lower LC3B signal). Efficiency of mTOR inhibition by Torin-1 was 
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assessed by analysis of p70-S6 kinase (p-S6K) phosphorylation status, which was not 
found in its phosphorylated form after Torin-1 treatment (Figure 19B). 
 Over-expression of DAPK1, DAPK2, and DAPK3, significantly decreased IFIT1 
promoter activity (Figure 19A) as observed previously (Figure 13A, 13B, 13C). Neither 
DAPK1, nor DAPK2 or DAPK3 over-expression resulted in a change in LC3B levels 
compared to mock transfected cells, indicating that, contrary to previous reports, DAPK 
over-expression does not induce autophagy in the 293TRIG-I cells used in our study. 
Although autophagy inhibition did result in a slight decrease in IFIT1 promoter activity, 
the observed effect was not as strong as the inhibition observed upon DAPK over-
expression. Furthermore, autophagy was not detectably induced (nor inhibited) after 
DAPK over-expression, arguing that the observed inhibitory effect of DAPKs on RIG-I 
signalling is not linked to known DAPK functions in type II cell death, i.e. autophagic 
pathways. 
4.4 The role of DAPK2 and DAPK3 in the RIG-I signalling pathway 
4.4.1 Inhibition of RIG-I signalling by DAPK2 and DAPK3 is kinase-
dependent 
Similar to DAPK1, DAPK2 and DAPK3 were found to be negative regulators of RIG-I 
signalling. It was established that RIG-I signalling inhibition by DAPK1 was dependent on 
kinase activity as shown above (Figure 1) and in [199]. Hence, it was likely that DAPK2 
and DAPK3 acted similarly and that their function as negative regulators of RIG-I 
signalling was also based on their kinase activity. Five different mutants of DAPK2 and 
DAPK3, respectively, were cloned which either included or lacked different known 
domains of the kinases (Figure 20). Apart from reportedly kinase-dead DAPK2K52A and 
DAPK3K42A, additional mutants which were reported to have lost kinase activity were 
generated, namely DAPK3D161A which was reported to harbour a destabilised active 
centre of the kinase domain [160] and DAPK3K42A D161A double mutant. In analogy to 
S308 mutants generated for DAPK1 (Figure 1), DAPK2S318D (phospho-mimetic) and 
DAPK2S318A (phospho-ablatant) mutants were generated which have been studied and 
found to display either increased (DAPK2S318A) or decreased (DAPK2S318D) kinase activity 
[265]. Additionally, DAPK2Kinase and DAPK3Kinase, kinase-only mutants, and DAPK2Kinase-
CaM, a mutant comprising kinase and CaM domain, and a mutant lacking the kinase 
domain of DAPK3 (DAPK3deltaKinase) were generated. 
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Figure 20 DAPK2 and DAPK3 mutants 
A) Overview of DAPK2 mutants B) Overview of DAPK3 mutants 
Unlike DAPK3, DAPK2 is a CaM-dependent kinase. Its C-terminal domain displays no homology to any 
other known protein domain. In addition to its nuclear localisation signals (NLS), the C-terminus of DAPK3 
contains a Leucin zipper domain which mediates protein-protein interaction. A DAPK3 mutant lacking the 
Leucin zipper domain was generated. It generally behaved like full-length DAPK3 (compare appendix, figure 
40) and is, therefore, omitted here. 
DAPK2 and DAPK3 mutants were compared to full-length DAPK2 and DAPK3 by 
assessing changes in IFIT1 promoter activity. 
DAPK2K52A and DAPK2Kinase-CaM inhibited IFIT1 promoter activity to the same extent as 
full-length (WT) DAPK2, whereas DAPK2Kinase lost part of its ability to inhibit RIG-I 
signalling (Figure 21A). Remarkably, there was a clear difference between constitutively 
kinase-active DAPK2S318A and kinase-inactive DAPK2S318D regarding their ability to inhibit 
IFIT1 promoter activity, with DAPK2S318A behaving similar to DAPK2WT. DAPK2 
constructs were expressed to similar levels as shown in Western Blot staining for HA-tag 
(Figure 21C). DAPK3K42A, DAPK3D161A, DAPK3K42A D161A, and DAPK3Kinase inhibited RIG-I 
signalling to the same extent as full-length (WT) DAPK3 when over-expressed in 
293TRIG-I cells (Figure 21B). DAPK3deltaKinase, however, did not reduce but rather 
enhanced IFIT1 promoter activity compared to mock transfection. DAPK3 constructs 
were expressed to similar levels when over-expressed in 293TRIG-I cells (Figure 21D). For 
DAPK3K42A, DAPK3Kinase and DAPK3deltaKinase similar results were obtained in a NFkB 
promoter activity assay, in which DAPK3K42A and DAPK3Kinase inhibited RIG-I signalling to 
the same extent as DAPK3WT. DAPK3deltaKinase mutant did not show any inhibitory effect 
(appendix, figure 40). 
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Figure 21 Inhibition of RIG-I signalling by DAPK2 and DAPK3 is kinase-dependent 
IFIT1 reporter assay of 293TRIG-I cells over-expressing DAPK2 (A) or DAPK3 (B) mutants. Cells were 
transfected with kinase mutants and stimulated by SeV (MOI 5) infection for 16h. Results show mean of four 
(DAPK2 WT, S318A, and S318D) or three (rest) independent experiments. Western Blot stains for HA-tag 
were performed to assess expression efficiency (C, D) and a representative result is shown. 
Supposedly kinase-inactive DAPK2K52A and DAPK3K42A/D161A inhibited IFIT1 promoter 
activity to the same extent as the full-length constructs. It is possible that these mutants 
retain kinase activity in over-expression experiments, similar to DAPK1KCA K42A for which 
auto-phosphorylation at S308 was observed when it was over-expressed in 293TRIG-I 
cells (Figure 1C). 
Nevertheless, the above results suggest that inhibition of RIG-I signalling by DAPK2 is 
kinase activity-dependent as a constitutively kinase-active mutant of DAPK2, 
DAPK2S318A, conferred full inhibition of IFIT1 promoter activity, whereas a constitutively 
inactive mutant, DAPK2S318D, lost this inhibitory function. Similarly, in case of DAPK3, its 
kinase domain alone acted like full-length DAPK3, but over-expression of a mutant 
lacking the kinase domain did not lead to RIG-I signalling inhibition. It has to be noted 
that the DAPK3delta Kinase construct is extremely small in comparison to full-length DAPK3. 
Hence, it remains to be examined whether inhibition of RIG-I signalling by DAPK3 really 
depends on DAPK3 kinase activity. 
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4.4.2 Activity of DAPK2 and DAPK3 is regulated upon initiation of 
antiviral signalling 
As shown above in Figure 1, DAPK1 is subject to auto-phosphorylation at S308 which 
impacts its activity [251]. In fact, DAPK1 needs to be de-phosphorylated at S308 for full 
kinase activity and its activation status can be monitored by immune staining for p-
DAPK1 S308 in Western Blotting. Not only did DAPK1 negatively regulate RIG-I upon 
over-expression, but it was also increasingly activated upon initiation of antiviral 
signalling ([199] and Figure 22). Therefore, it was proposed that DAPK1 is part of a 
negative feedback loop in which it is increasingly activated after initiation of antiviral 
signalling. DAPK1, being an inhibitor of RIG-I signalling, phosphorylates and deactivates 
RIG-I, providing a means of control of the antiviral response and preventing an 
overshooting immune response which could be detrimental for the host. 
 
Figure 22 DAPK1 activation after dsRNA stimulation 
A549 cells were stimulated with 5’ppp-dsRNA over a time course of 24h. Increasing RIG-I signalling activity 
is indicated by rising relative levels of p-TBK1. At the same time, relative p-DAPK1 S308 levels decrease 
steadily until hardly any p-DAPK1 is detected 24h after stimulation. Adapted from [199]. 
Experiments performed in this study identified DAPK2 and DAPK3 as negative 
regulators of RIG-I signalling. Moreover, their inhibitory function seemed to be kinase 
activity-dependent. These findings were similar to those previously obtained for DAPK1. 
Therefore, it was not unlikely that DAPK2 and DAPK3 activity might be regulated upon 
initiation of antiviral signalling. It was examined if activity of endogenous DAPK2 and 
DAPK3 changed upon initiation and progression of RIG-I-mediated antiviral signalling. 
4.4.2.1 DAPK2 dimerises increasingly after SeV infection and initiation of 
RIG-I signalling 
Analogous to DAPK1, DAPK2 is auto-phosphorylated at S318 which decreases kinase 
activity. Although there is an antibody available which supposedly detects p-DAPK2 
S318 in ELISA analyses, it was not possible to obtain a specific signal for p-DAPK2 on 
Western Blot level using this antibody (data not shown). However, it is known that 
endogenous DAPK2 homodimerises and this dimerisation process was shown to be 
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especially efficient for constitutively kinase-active DAPK2 S318A [160], suggesting that 
DAPK2 dimerisation indicates increased DAPK2 activity. Furthermore, DAPK2 dimers 
were found to be extremely stable, allowing their detection even after denaturing SDS-
PAGE [160]. 
DAPK2 over-expression did frequently result in a signal of higher apparent molecular 
weight whose size matched that of putative DAPK2 homodimers (Figure 26A). 
Remarkably, potential dimerisation was also observed for endogenous DAPK2, 
seemingly induced after virus infection (Figure 12A). To facilitate detection of DAPK2 
dimers, chemical cross-linking of whole cell lysates from DAPK2 over-expressing 
293TRIG-I cells was employed. Indeed, in addition to DAPK2 monomers, dimers, trimers 
and higher molecular weight oligomers were observed after cross-linking (Figure 23A), 
which was especially efficient using a concentration of 1% paraformaldehyde. 
 
Figure 23 DAPK2 dimerisation 
A) Western Blot analysis of dimer- and oligomerisation of over-expressed DAPK2 in 293TRIG-I cells treated 
with increasing concentrations of paraformaldehyde (PFA). Arrows indicate DAPK2 monomers and 
oligomers. B) Western Blot analysis of DAPK2 dimerisation in A549 and 293TRIG-I cells in a time course 
experiment. Cells were infected with SeV (MOI 5) and proteins were cross-linked at different time points after 
infection. A representative of three independent experiments is shown. Arrows indicate DAPK2 monomers 
and dimers. 
This cross-linking approach was then used to detect dimerisation of endogenous 
DAPK2, and, in fact, an increasing amount of endogenous homodimerised DAPK2 was 
detected in A549 and 293TRIG-I cells after SeV infection compared to unstimulated 
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controls in a time course experiment (Figure 23B). This suggests virus- or antiviral-
signalling-dependent dimerisation of DAPK2 in A549 and 293TRIG-I cells. 
4.4.2.2 DAPK3 activating phosphorylation decreases in response to virus 
infection 
Although DAPK3 has not been studied as extensively as DAPK1 and DAPK2 in regard to 
regulation of its kinase activity, it was reported that several residues of DAPK3 must be 
phosphorylated for full activity, one of them being threonine 265 (T265) [203] which sits 
in the kinase domain of DAPK3 (Figure 24A). In order to examine whether antiviral 
signalling caused changes in DAPK3 activity, DAPK3 activating phosphorylation at T265 
in response to SeV infection was analysed in A549 cells using an antibody which 
specifically detects p-DAPK3 T265. In contrast to uninfected controls, in which p-DAPK3 
T265 levels remained stable, prolonged infection with SeV lead to a decrease in p-
DAPK3 T265 levels, whereas total DAPK3 levels were not changed (Figure 24B). 
However, close examination and densitometric quantification of p-DAPK3 T265 levels in 
independent experiments revealed that DAPK3 phosphorylation was not always 
decreased to the same extent (Figure 24C, 1 and 2) and in some instances even 
increased over time (Figure 24C, 3). Nevertheless, virus infection ultimately resulted in 
significantly lower p-DAPK3 T265 levels compared to unstimulated controls at late time 
points in all experiments. 
Taken together, activities of endogenous DAPK2 and DAPK3 were regulated upon 
initiation of antiviral signalling. DAPK2 dimerised increasingly after onset of RIG-I 
signalling, indicating increased activity. DAPK3, however, lost its activating 
phosphorylation at T265 over time after virus infection, suggesting decreased activity in 
response to RIG-I signalling initiation. 
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Figure 24 DAPK3 activity is decreased in response to virus infection 
A) Overview of DAPK3. T265 is subject to phosphorylation which is necessary for full kinase activity. B) 
Western Blot analysis of p-DAPK3 T265 levels in a time course experiment in A549 cells. Cells were infected 
with SeV (MOI 5) and protein levels of p-DAPK3 T265, Mx1, total DAPK3 and loading controls were 
analysed after at different times after infection. A representative of three independent experiments is shown. 
C) Overview over DAPK3 phosphorylation at T265 and total DAPK3 protein levels after SeV infection in 
three independent experiments. Relative protein levels were measured by densitometry. 
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4.4.3 DAPK1 and DAPK2 interact with RIG-I and all DAPK family members 
phosphorylate RIG-I in vitro 
It was shown that DAPK1 interacted with RIG-I when over-expressed in 293TRIG-I cells 
and that DAPK1 phosphorylated RIG-I in vitro. Furthermore, phospho-mimetic mutations 
of DAPK1-targeted residues on RIG-I rendered RIG-I incapable of an initiation of antiviral 
signalling [199]. As the above results suggest an additional, possibly kinase-dependent 
inhibition of RIG-I signalling by DAPK family members DAPK2 and DAPK3, it was 
examined whether these interacted with RIG-I. DAPK family member DRAK1 was 
included in this analysis since it was just as capable of mediating RIG-I signalling 
inhibition as DAPK1, DAPK2, and DAPK3. 
 
Figure 25 RIG-I CoIP 
A) Experimental setup. 293TRIG-I cells were co-transfected with HA-tagged DAPKs and V5-tagged RIG-I. 
Equal amounts of plasmid DNA were transfected. HA-tagged proteins were pulled down using anti-HA 
agarose beads. After overnight acetone precipitation, samples were analysed by SDS-PAGE. B) Western 
Blot analysis. V5 signal shows co-purified RIG-I. HA signal shows pulled down kinases. A representative 
result of five independent experiments is shown. 
Interaction of DAPKs with RIG-I was examined in a co-immunoprecipitation assay in 
which DAPKs were co-transfected with RIG-I in 293TRIG-I cells. DAPKs were purified from 
cell lysates and (co-)purified protein samples were analysed by Western Blot (Figure 
25A).  
DAPK1, DAPK2, DAPK3 and DRAK1 were efficiently pulled down by anti-HA 
immunoprecipitation, but RIG-I only co-purified with DAPK1 and DAPK2, and was not 
found in eluate from DAPK3 or DRAK1 pull-downs (Figure 25B). Thus, RIG-I strongly 
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interacts with DAPK1 and DAPK2, but might not or only transiently interact with DAPK3 
or DRAK1. 
 
Figure 26 In vitro phosphorylation of RIG-I by DAPKs 
For in vitro phosphorylation assays, Strep-tag-fused DAPKs or kinase-inactive mutants were over-expressed 
in 293TRIG-I cells and purified using strep-tactin coated magnetic beads (compare Figure 25). Eluted kinases 
were incubated with 1µg of purified, recombinant RIG-I and 32P-ATP and samples were analysed SDS-
PAGE and Western Blot. Incorporation of 32P-ATP was visualised by exposure of membranes on storage 
phosphor screens. A) Radioactive signal from phosphorylation reactions with or without RIG-I. B) Western 
Blot of membranes shown in A) stained for HA-tag and RIG-I. A representative of six independent 
experiments is shown. Arrows indicate auto-phosphorylated DAPKs. 
Since DAPK1 was found to phosphorylate RIG-I in vitro, it was examined whether the 
same could be observed for the other DAPK family members. DRAK2 was analysed in 
addition to DAPK2, DAPK3, and DRAK1, because it behaved differently to DRAK1 when 
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over-expressed in 293TRIG-I cells and did not confer inhibition of RIG-I signalling (Figure 
14A). 
RIG-I was phosphorylated in vitro by DAPK1, DAPK2, DAPK3, and DRAK1 (Figure 26A). 
In addition to RIG-I phosphorylation, auto-phosphorylation of WT DAPKs was detected 
as well. Kinase-inactive DAPK2K52A and DAPK3K42A did not show signal for auto-
phosphorylation, nor did they phosphorylate RIG-I. Auto-phosphorylation signals of 
DAPK2 dimers (compare Figure 23A) were close to signals for phosphorylated RIG-I, 
which was, therefore, difficult to examine in some assays but clear in others, depending 
on the extent of DAPK2 dimerisation. Amounts of purified kinases and recombinant RIG-I 
were visualised by Western Blotting (Figure 26B). DRAK2 was neither auto-
phosphorylated, nor did it phosphorylate RIG-I. As it was expressed in similar amounts to 
the other kinases, but no phosphorylation signals were observed in the respective 
samples, DRAK2 was apparently kinase-inactive when over-expressed in 293TRIG-I cells, 
although the cloned coding sequence showed no non-silent deviation to that of a 
published reference [163]. 
The above findings show that although strong interaction of RIG-I was only observed for 
DAPK1 and DAPK2, all kinase-active DAPK family members phosphorylated RIG-I in 
vitro. The fact that DRAK2 was kinase-inactive when over-expressed might be the 
reason for its inability to inhibit IFIT1 promoter activity in previous analyses (Figure 14A). 
4.4.4 DAPK family members interact 
Although we detected no or only transient interaction of DAPK3 and DRAK1 with RIG-I, 
both kinases inhibited RIG-I signalling. As it was published that DAPKs interact [201], 
[216], it was conceivable that some DAPKs might not directly bind to RIG-I, but instead 
recruit other DAPK family members. By this indirect interaction with RIG-I, DAPK3 and 
DRAK1 might confer RIG-I signalling inhibition. 
In order to find out if and how DAPKs interacted, in vitro kinase reactions containing 
pulled down DAPK2, DAPK3, and DRAK1 were subjected to mass spectrometry 
analyses. Earlier experiments analysing DAPK1 co-immunoprecipitations already 
showed that DAPK3, indeed, co-purified with DAPK1 and was, in fact, the second most 
abundant hit (Table 22). 
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Table 22 Most abundant hits (5) of DAPK1 interactome obtained by mass spectrometry. 
Hit No. Protein name Gene name Score 
1 Death-associated protein kinase 1 DAPK1 32,68 
2 Death-associated protein kinase 3 DAPK3 29,35 
3 Hsp90 co-chaperone Cdc37 CDC37 27,43 
4 Hypoxia-inducible factor 1-alpha inhibitor HIF1AN 27,27 
5 
MAPK-interacting and 
spindle-stabilizing 
protein-like 
MAPK1IP1L 26,56 
HA-tagged DAPK1 was over-expressed in 293TRIG-I cells and pulled down using anti-HA-tag beads. 
Immunoprecipitates were analysed by mass spectrometry (LC-MS/MS). Only the 5 most abundant detected 
proteins are displayed. A representative of three independent experiments is shown. The pulled down 
protein is indicated in bold, other DAPK family members are highlighted in red. 
Importantly, interactome data for DAPK1 was obtained by using a different mass 
spectrometer and different means of data evaluation than for analyses concerning the 
other DAPK family members. This is the reason why obtained (arbitrary) scores from 
DAPK1 and DAPK2/DAPK3/DRAK1 analyses differ in magnitude. For DAPK2, DAPK3 
and DRAK1 samples were taken from in vitro kinase assays. Thus, added recombinant 
RIG-I and CaM were among the most abundant hits obtained from those samples (table 
23, table 24). 
DAPK2 was found as a DAPK3-interacting protein among the most abundant hits in the 
DAPK3 interactome (table 23). Furthermore, DAPK2 and DAPK3 were found as DRAK1-
interacting proteins among the most abundant hits in the DRAK1 interactome (table 24). 
No DAPK family member was found among the most abundant hits in the DAPK2 
interactome. However, in agreement with a recent publication [226], DAPK2 interacted 
strongly with different proteins of the 14-3-3 family which represented 6 of the 14 most 
abundant DAPK2 interacting proteins (appendix, table 25). Conceivably, other DAPK 
family members are found in the DAPK2 interactome, especially since DAPK2 appeared 
in the DAPK3 interactome. However, in present experiments co-purification was 
apparently not as efficient as that for other interactors and did, consequently, not allow 
representation among the 14 most abundant hits. 
Interestingly, the most abundant hit in the DAPK2 interactome (after recombinant RIG-I 
and CaM) was DDX3X, a RNA helicase which has been shown to be involved in RIG-I 
signalling. DDX3X was described to stimulate IRF3 activation by interaction with TBK1 
[266], and to bind viral RNAs, associate with MAVS and enhance downstream signalling 
[267]. 
Page | 93 
 
 
Results 
Table 23 Overview of proteins identified in the DAPK2 and DAPK3 interactomes 
Hit 
No. Protein name 
Gene 
name Score 
Hit 
No. Protein name 
Gene 
name Score 
1 
Probable ATP-dependent 
RNA helicase DDX58 
(RIG-I) 
DDX58 5001 1 
Probable ATP-
dependent RNA 
helicase DDX58 (RIG-I) 
DDX58 5514 
2 Death-associated protein kinase 2 DAPK2 2627 2 
Death-associated 
protein kinase 3 DAPK3 2214 
3 ATP-dependent RNA helicase DDX3X DDX3X 2131 5 Calmodulin CALM 899 
4 Calmodulin CALM 788 13 Death-associated protein kinase 2 DAPK2 170 
Samples from in vitro kinase assays (Figure 26) were analysed by mass spectrometry (LC-MS/MS). Only the 
14 most abundant detected proteins are displayed. A representative of two independent experiments is 
shown. The pulled down protein is indicated in bold, other DAPK family members are highlighted in red. For 
an overview of the 14 most abundant hits, refer to appendix, table 25. 
Table 24 Overview of proteins identified in the DRAK1 interactome 
Hit 
No. Protein name 
Gene 
name Score 
Hit 
No. Protein name 
Gene 
name Score 
1 
Probable ATP-dependent 
RNA helicase DDX58 
(RIG-I) 
DDX58 5604 4 Serine/threonine-protein kinase 17A ST17A 619 
2 Keratin, type II cytoskeletal 1 K2C1 933 12 
Death-associated protein 
kinase 3 DAPK3 69 
3 Calmodulin CALM 910 14 Death-associated protein kinase 2 DAPK2 49 
Samples from in vitro kinase assays (Figure 26) were analysed by mass spectrometry (LC-MS/MS). Only the 
14 most abundant detected proteins are displayed. A representative of two independent experiments is 
shown. The pulled down protein is indicated in bold, other DAPK family members are highlighted in red. For 
an overview of the 14 most abundant hits, refer to appendix, table 26. 
Mass spectrometry analysis showed that DAPK family members did interact. Moreover, 
DAPK2 was found to interact with DDX3X. As DDX3X was shown to enhance the IFN 
response, regulation of DDX3X by DAPK2 could be another means by which DAPK2 
controls the RIG-I signalling response. 
4.5 DAPK1, DAPK2, and DAPK3 may interact but inhibit RIG-I signalling 
independently of each other 
The above findings showed that, although an interaction with RIG-I could only be shown 
for DAPK1 and DAPK2, all DAPK family members phosphorylated RIG-I on specific 
residues. Additionally, the interactome obtained by mass spectrometry indicated that 
DAPKs interacted with each other, as most of the other kinase family members were 
found in the interacting protein fractions of a respective analysed kinase (table 21 - 24). 
In fact, interaction and cross-talk between DAPKs had been described before [201], 
[216]. 
Based on this knowledge, it was investigated whether DAPK1, DAPK2, and DAPK3, 
were dependent on each other with regard to their roles as inhibitors of RIG-I signalling. 
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4.5.1 Combined down-regulation of DAPK1 and DAPK3 results in an 
intermediate phenotype compared to effects on RIG-I signalling 
seen by single knockdown 
Since DAPK2 protein levels were low in the examined cell types (Figure 12) and 
knockdown of DAPK2 had no effect on IFIT1 promoter activity (Figure 15C), a first 
approach examined possible interdependence between DAPK1 and DAPK3. 
Furthermore, as DAPK3 potently inhibited RIG-I signalling but showed no direct 
interaction with RIG-I in our biochemical assays, it was deemed feasible that DAPK3 
might require DAPK1 to be directed towards RIG-I. In order to investigate a possible 
interdependence between both kinases, DAPK1 and DAPK3 were silenced in A549 and 
293TRIG-I cells either alone or in combination. Effects on RIG-I signalling were assessed 
by IFIT1 promoter reporter assay and quantification of IFNb and IFIT1 mRNA levels. 
In both A549 and 293TRIG-I cells combined knockdown of DAPK1 and DAPK3 mostly 
resulted in an intermediate phenotype compared to single knockdown of each kinase as 
seen in IFIT1 promoter activity assays and qPCR analysis for IFNb and IFIT1 mRNA 
(Figure 27A and C, compare to Figure 15A and D, and Figure 16A and B). Silencing 
efficiencies for both kinases were not as high when siRNAs were co-transfected, 
resulting in higher residual protein levels, especially in the case of DAPK1, in double 
knockdown samples compared to single knockdown (Figure 27B). This was also 
reflected on mRNA levels for DAPK1 and DAPK3 (Figure 27D). Similar to what was 
observed before (Figure 16C), DAPK2 mRNA levels were slightly increased in response 
to double knockdown of DAPK1 and DAPK3 in 293TRIG-I cells. 
Knockdown of genes using siRNAs is never 100% efficient. Furthermore, combined 
knockdown of DAPK1 and DAPK3 was even less efficient than single knockdown of 
each kinase and resulted in an intermediate phenotype which did not allow any 
conclusion as to whether DAPKs interdepend in their function as inhibitors of RIG-I 
signalling. 
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Figure 27 Intermediate effect of combined DAPK1 and DAPK3 silencing 
For IFIT1 promoter reporter assays after silencing of DAPKs, siRNAs targeting the individual kinase were 
reverse transfected into A549 or 293TRIG-I cells. 38h after siRNA transfection, reporter plasmids were 
transfected, and 48h after siRNA transfection cells were infected with SeV (MOI 5) for 16h. A) IFIT1 
promoter activity after silencing of DAPK1 in A549 and 293TRIG-I cells with corresponding Western Blots 
assessing silencing efficiency in B). For qPCR analyses DAPK1 or DAPK3 were silenced for 48h in A549 or 
293TRIG-I cells. Cells were stimulated with SeV (MOI 5) for 16h before mRNA levels of DAPK1, DAPK2, 
DAPK3, IFNb and IFIT1 were measured. C) IFNb and IFIT1 mRNA levels after combined down-regulation of 
DAPK1 and DAPK3 in A549 and 293TRIG-I cells. D) DAPK1, DAPK2, and DAPK3 mRNA in unstimulated and 
SeV infected A549 and 293TRIG-I cells are shown. mRNA levels of target genes are normalised to GAPDH 
mRNA levels and shown as fold-induction of siRNA control. Results are the mean of two independent 
experiments. 
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4.5.2 Generation of stable DAPK knockout cell lines 
In order to allow exact studies on the effects of individual DAPKs on RIG-I signalling and 
to find out how they might interact or depend on each other, a knockout approach was 
chosen. The CRISPR/Cas9 system was employed to deplete cells of endogenous DAPK 
expression. Loss of protein expression was indicative of successful knockout. 
4.5.2.1 Stable knockout of DAPK1 does not facilitate RIG-I signalling in 
A549 or 293TRIG-I cells 
A549 cells will naturally engage in antiviral RIG-I-mediated signalling when infected with 
RNA viruses. On top of that, they express high endogenous levels of DAPK1 (Figure 12). 
Hence, as a first line of investigating whether knockout of DAPK1 would reproduce the 
increase in RIG-I signalling observed upon siRNA-mediated DAPK1 knockdown, DAPK1 
was targeted using the CRISPR/Cas9 system. Four different small guide RNAs 
(sgRNAs) were tested and stably expressed in A549 cells by lentiviral transduction. Of 
those four sgRNAs, sgRNA 3 (crisp3) and 4 (crisp4) were most efficient in knocking 
down DAPK1 expression when assessed by Western Blotting in A549 bulks (Figure 
28A). Since some cells of the transfected bulks retained DAPK1 expression which was 
unfavourable for further studies on DAPK interdependence, single cell DAPK1 knockout 
(KO) clones were generated and examined for DAPK1 expression. 
Although DAPK1 was undetectable on protein level in all A549 single KO clones (Figure 
28B) only one clone, 3.4, displayed a marked increase in IFIT1 promoter activity upon 
SeV stimulation (Figure 28C). Additionally, IFIT1 promoter activity was up to 3-fold 
different in unstimulated samples from different clones, suggesting that inter-clonal 
variation would result in significant changes in antiviral signalling in a single cell 
compared to bulk measurements. 
In parallel to A549 cells, DAPK1 was knocked out in 293TRIG-I cells since these are easily 
transfectable with expression plasmids, allowing not only re-constitution of DAPK1, but 
also expression of other DAPKs. Similar to what was observed in A549 cells, there was 
some leftover DAPK1 protein expression in 293TRIG-I KO bulks after lentiviral 
transduction (Figure 29A). Thus, single cell KO clones were generated from sgRNA bulk 
3 (crisp3) and 4 (crisp4), which were, again, displaying highest KO efficiency. 
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Figure 28 A549 DAPK1 crispr knockout cell lines 
A) Western Blot for DAPK1 expression in A549 cells stably transfected with plasmids encoding Cas9 and 
DAPK1-targeting sgRNAs (crisp1-4). B) Western Blot for DAPK1 in A549 DAPK1 single cell knockout clones 
originating from sgRNA bulk 3 and 4. C) IFIT1 promoter reporter assay of A549 DAPK1 knockout clones 
stimulated with SeV (MOI 5) for 16h before lysis. 
Although most 293TRIG-I single cell DAPK1 KO clones showed no DAPK1 protein 
expression (Figure 29B and data not shown), the overall induction of IFIT1 promoter 
activity after SeV stimulation was similar to that seen for empty vector controls and WT 
293TRIG-I cells (Figure 29C). However, IFIT1 promoter activity in unstimulated samples 
differed significantly, demonstrating again that clonal expansion might change signalling 
capacity of individual clones dramatically. 
Stable KO of DAPK1 in A549 and 293TRIG-I cells did not reflect what had been observed 
for transient knockdown as there was no general increase in IFIT1 promoter activity in 
DAPK1-depleted cells. 
Page | 98  Results 
 
Figure 29 293TRIG-I DAPK1 crispr knockout cell lines 
A) Western Blot for DAPK1 expression in 293TRIG-I cells stably transfected with plasmids encoding Cas9 and 
DAPK3-targeting sgRNAs (crisp1-4). B) Western Blot for DAPK1 in 293TRIG-I DAPK3 single cell knockout 
clones originating from sgRNA bulk 3 and 4. C) IFIT1 promoter reporter assay of 293TRIG-I DAPK1 knockout 
clones stimulated with SeV (MOI 5) for 16h before lysis. Error bars correspond to measurement of one 
biological replicate measured in triplicates. 
4.5.2.2 Stable knockout of DAPK3 does not facilitate RIG-I signalling in 
A549 or 293TRIG-I cells 
DAPK3 protein was abundant in A549 and 293TRIG-I cells and mRNA levels were even 
higher than those observed for DAPK1 (Figure 12). Knockdown of DAPK3 was 
accompanied by a marked increase in IFIT1 promoter activity. Therefore, it was 
investigated if DAPK3 KO would reproduce the stimulatory effect on RIG-I signalling 
observed upon siRNA-mediated knockdown in A549 and 293TRIG-I cells. 
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Figure 30 DAPK3 crispr knockout cell lines 
Western Blot for DAPK3 expression in (A) A549 and (B) 293TRIG-I single cell DAPK3 knockout clones. C) 
IFIT1 promoter reporter assay of A549 and 293TRIG-I DAPK3 knockout clones stimulated with SeV (MOI 5) 
for 16h before lysis. Error bars correspond to measurement of one biological replicate measured in 
triplicates. 
CRISPR/Cas9-mediated KO of DAPK3 in A549 cells using 4 different sgRNAs resulted 
in a strong decrease of DAPK3 protein levels with protein levels being lowest in sgRNA 2 
(crisp2) and 3 (crisp3) samples (data not shown). Almost all generated A549 and 
293TRIG-I single cell DAPK3 KO clones did not express DAPK3 protein (Figure 30A and 
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32B), but, reminiscent of what had been observed for DAPK1 (Figure 28C and 31C), 
there was no marked increase in IFIT1 promoter activity in DAPK3 KO clones compared 
to empty plasmid transduced or WT control cells after SeV infection (Figure 30C). While 
a few A549 DAPK3 KO clones showed a minor increase in IFIT1 promoter activity, some 
293TRIG-I DAPK3 KO clones even displayed a reduced signalling response after 
stimulation. 
Similar to what was observed for DAPK1, stable KO of DAPK3 in A549 and 293TRIG-I 
cells did not yield comparable results to transient knockdown, as there were, if at all, only 
minor changes in RIG-I signalling activity in response to viral infection. Importantly, 
variability in IFIT1 reporter activity between individual single cell clones was substantial. 
Hence, inter-clonal variability could mask changes in RIG-I signalling caused by DAPK 
knockout.  
4.5.2.3 Combined stable knockout of DAPK1 and DAPK3 has no effect on 
RIG-I signalling 
Neither stable KO of DAPK1 nor DAPK3 alone had any effect on RIG-I signalling. 
Comparatively long time spans lay between lentiviral CRISPR/Cas9-transduction and 
functional assays since single cell clones were selected by antibiotic resistance and went 
through clonal expansion. Based on protein expression DAPK1 and DAPK3 were the two 
highest expressed members of DAPKs in A549 and 293TRIG-I cells and it was known that 
they had similar functions in basic cellular processes such as cell death induction. 
Therefore, it was possible that stable KO of one DAPK was compensated for by up-
regulation of another DAPK, an effect which would not be seen in the relatively short 
time span of a siRNA-silencing based reporter assay or qPCR experiment. 
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Figure 31 DAPK1/DAPK3 crispr double knockout bulks 
Western Blots for DAPK3 expression in A) A549 and B) 293TRIG-I DAPK1 knockout (KO) cell clones stably 
transfected with plasmids encoding Cas9 and DAPK3-targeting sgRNAs (crisp1-4). C) IFIT1 promoter 
reporter assay in A549 DAPK1/DAPK3 double knockout bulks in response to 16h of SeV (MOI 5) 
stimulation. D) IFIT1 promoter reporter assay in 293TRIG-I DAPK1/DAPK3 double knockout bulks in response 
to 16h of SeV (MOI 5) stimulation. Error bars correspond to measurement of one biological replicate 
measured in triplicates. 
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Figure 32 DAPK1/DAPK3 crispr double knockout clones 
Western Blots for DAPK3 expression in A) A549 and C) 293TRIG-I DAPK1/DAPK3 single cell knockout 
clones. IFIT1 promoter reporter assays in B) A549 and D) 293TRIG-I DAPK1/DAPK3 double knockout clones 
(DKO) in response to SeV (MOI 5) infection for 16h. E) Western Blot for DAPK2 expression in A549 
DAPK1/DAPK3 double knockout cell lines. Signals for DAPK3 in DAPK3 knockout clones are due to high 
background of the DAPK3 antibody as DAPK3 knockout had been previously established (compare Figure 
30). 
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In order to avoid up-regulation of DAPK3 in DAPK1 stable KO lines and vice versa, 
DAPK1/DAPK3 double knockout (DKO) cell lines were created by stable expression of 
DAPK3 sgRNAs in existing DAPK1 KO clones. For this, two A549 and two 293TRIG-I 
DAPK1 KO clones were chosen. DAPK3 protein levels were already strongly reduced in 
all A549 and 293TRIG-I DAPK1-3 double knockout bulks expressing DAPK3 sgRNA 2 
(crisp2) and in A549 double knockout bulks expressing DAPK3 sgRNA 3 (crisp3) (Figure 
31A and 31B). When these DAPK1/DAPK3 DKO bulks were tested in IFIT1 promoter 
activity assays, however, no significant increase in reporter activity in response to SeV 
infection was observed (Figure 31C and 33D). Surprisingly, this did not change when 
DAPK1/DAPK3 DKO single cell clones were generated. When IFIT1 reporter activity in 
response to SeV infection was examined in those clones which did not express DAPK3 
(Figure 32A and 32C), no marked increase in reporter activity was observed (Figure 32B 
and 32D). Interestingly, in comparison to WT and empty vector transduced cells, DAPK2 
protein levels were increased in most A549 DAPK1/DAPK3 double knockout cell clones 
(Figure 32E). 
Combined KO of DAPK1 and DAPK3 in A549 and 293TRIG-I cells did not result in 
enhanced RIG-I signalling activity, other than indicated by previous transient knockdown 
experiments. In response to stable DAPK1 and DAPK3 KO, DAPK2 protein levels were 
elevated, indicative of compensatory effects initiated by combined loss of DAPK1 and 
DAPK3 expression. 
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4.5.2.4 Stable single knockout of DAPK2 or combined triple knockout of 
DAPK1, DAPK2, or DAPK3 has no effect on RIG-I signalling 
Elevated DAPK2 levels in DAPK1/DAPK3 double knockout cell lines compared to WT 
cells suggested a compensatory mechanism of up-regulation in case cells were depleted 
of the other DAPK family members which might be the reason why there was no obvious 
effect on RIG-I signalling upon loss of DAPK1, DAPK3, or both. 
Since DAPK2-targeting siRNAs were found to be toxic in combination with virus infection 
(data not shown), the CRISPR/Cas9 system was employed to generate stable DAPK2 
KO cell lines. In parallel to WT A549 and 293TRIG-I cells, DAPK2 was knocked out in 
previously established DAPK1/DAPK3 DKO clones. KO of DAPK2 in bulks generated by 
transduction with sgRNA 1 (crisp1) and 4 (crisp4) was highly efficient showing no 
residual DAPK2 protein (Figure 33A). IFIT1 promoter activity after SeV infection, 
however, remained unchanged in response to loss of DAPK2 in A549 (Figure 33C) and 
293TRIG-I (Figure 33D) WT and DAPK1/DAPK3/DAPK2 triple KO bulks.  
In summary, the CRISPR/Cas9 system was successfully employed for the generation of 
DAPK knockout cell lines. However, neither single nor combined knockout of DAPK1, 
DAPK2, and DAPK3 had any impact on the induction of RIG-I signalling after virus 
infection. 
4.5.3 DAPKs inhibit RIG-I signalling independently of each other 
It was observed that only DAPK1 and DAPK2 interacted with RIG-I (Figure 25), although 
all DAPKs (except DRAK2) phosphorylated RIG-I in vitro and inhibited RIG-I signalling 
when they were over-expressed (Figure 13, Figure 14). Similar to what was previously 
observed [201], [216], an interaction between DAPKs was observed in the present study 
(interactome data, tables 1-3). Thus, it was possible that DAPK3 which did not interact 
with RIG-I, depended on DAPK1 expression in order to regulate RIG-I signalling. 
Similarly, RIG-I signalling inhibition of DAPK2 or DRAK1 could be mediated by 
interaction with other DAPK family members. In order to examine if and how DAPKs 
might interact to fulfil their role as negative regulators of RIG-I signalling, it was tested if 
DAPK1, DAPK2, and DAPK3 were capable of RIG-I signalling inhibition when cells were 
depleted of the other respective DAPK family members. 
First, since DAPK1 and DAPK3 were the highest expressed DAPK family members in 
A549 and 293TRIG-I cells (Figure 12), it was investigated whether DAPK1 depended on 
DAPK3 to confer inhibition of RIG-I signalling. To this end, DAPK3 was down-regulated 
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by siRNA-transfection in 293TRIG-I cells and DAPK1 was over-expressed before SeV 
infection. 
 
Figure 33 DAPK2 crispr single knockout and DAPK1-2-3 triple knockout bulks 
Western Blots for DAPK2 expression in A) A549 and B) 293TRIG-I WT and DAPK1/DAPK3 knockout cell 
clones stably transduced with plasmids encoding Cas9 and DAPK2-targeting sgRNAs (crisp1-4). C) IFIT1 
promoter reporter assay in A549 WT and DAPK1/DAPK3 double knockout bulks in response to 16h of SeV 
(MOI 5) stimulation. D) IFIT1 promoter reporter assay in 293TRIG-I WT and DAPK1/DAPK3 double knockout 
bulks in response to 16h of SeV (MOI 5) stimulation. Error bars represent the standard deviation of technical 
triplicates in one experiment. 
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Similarly to what was observed previously (Figure 15D), DAPK3 knockdown alone 
resulted in a ~3 fold increase in IFIT1 promoter activity (Figure 34A). DAPK1 over-
expression reduced IFIT1 promoter activity in DAPK3 knockdown cells to the same 
extent (~65%) as in control siRNA-transfected cells, indicating that DAPK1 did not 
depend on high levels of DAPK3 to act as an inhibitor of RIG-I signalling. 
As siRNA knockdown would always result in some residual protein being present after 
transfection, further DAPK over-expression experiments were performed in previously 
generated 293TRIG-I DAPK1 and DAPK3 knockout cell clones. Interestingly, re-
introduction of DAPK1 in DAPK1 knockout cell clones had the same inhibitory effect on 
IFIT1 promoter activity as in 293TRIG-I empty vector control cells in about half of the 
clones, but resulted in no strong down-regulation of IFIT1 promoter activity in the rest of 
the clones (Figure 34B). This was probably due to remaining Cas9 activity in some 
clones, as DAPK1 was not detectable or only detected in small amounts on protein level 
in those clones (Figure 34C). Over-expression of DAPK3, however, was successful in all 
clones (Figure 34C) and resulted in a reduction of IFIT1 promoter activity similar to that 
observed in empty vector control cells (Figure 34B). Thus, DAPK3 apparently inhibited 
RIG-I signalling independently of DAPK1. 
Along the same lines, DAPK1 and DAPK2 over-expression in 293TRIG-I DAPK3 knockout 
clones resulted in a reduction of IFIT1 promoter activity similar to that observed for 
empty vector control cells (Figure 34D), indicating that DAPK1 and DAPK2 did not 
require DAPK3 expression to mediate inhibition of RIG-I signalling. 
Importantly, over-expression of DAPK3Kinase and DAPK3K42A was not successful in most 
clones (Figure 34E) which was probably due to remaining Cas9 activity. Because of this, 
no conclusion as to whether these DAPK3 constructs depend on the expression of other 
DAPKs in order to fulfil their inhibitory role in RIG-I signalling could be drawn. Of note, 
strength of IFIT1 promoter activity, i.e. signalling induction, varied between DAPK3 
knockout clones, emphasizing once again that high clonal variability might mask some of 
the effects caused by DAPK knockout. 
Taken together, results from DAPK over-expression assays in DAPK knockout cell lines 
suggest that DAPK1, DAPK2, and DAPK3 do not interdepend in their function as 
negative regulators of RIG-I signalling. Additionally, re-constitution of kinase constructs 
harbouring the sgRNA-targeted sequence was impossible in most clones due to retained 
Cas9 activity after stable transduction and genomic integration. 
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Figure 34 DAPKs act independently of each other (figure legend on the following page) 
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A) IFIT1 promoter reporter assay in 293TRIG-I cells over-expressing DAPK1. Cells were either silenced with 
control or DAPK3-targeting siRNA for 48h before DAPK1 was over-expressed, and stimulated by SeV (MOI 
5) infection for 16h before lysis. B) IFIT1 promoter reporter assay in 293TRIG-I DAPK1 knockout clones over-
expressing either DAPK1 or DAPK3 and stimulated with SeV (MOI 5) for 16h. C) Western Blot analysis for 
HA-tag expression corresponding to results shown in B). D) IFIT1 promoter reporter assay in 293TRIG-I 
DAPK3 knockout clones over-expressing DAPK3 mutants, DAPK1, or DAPK2. Cells were infected with SeV 
(MOI 5) for 16h. Error bars correspond to one biological replicate measured in triplicates. E) Western Blot 
analysis for HA-tag expression corresponding to results shown in D). 
4.6 DAPK1 and DAPK3 regulate the antiviral response to infection with 
different RNA viruses 
Up to this point, experiments performed within the context of this study investigating the 
role of DAPKs in RIG-I signalling focused on assays which assessed the antiviral 
response based on promoter activity assays and qPCR analyses. It was unclear how 
endogenous DAPKs might control RIG-I signalling and regulate antiviral responses in 
actual virus infections. Therefore, we next examined how the replication cycles of 
different RNA viruses were influenced by expression of DAPKs. To this end, DAPK1 and 
DAPK3 were down-regulated by siRNA transfection and cells were infected with RNA 
viruses. Virus replication was assessed either through a luciferase reporter gene within 
the viral genome, or by flow cytometry analysis after staining for viral components. As 
DAPK2 protein levels were low and knockdown showed no effect or was even toxic in 
previous experiments, this kinase was not analysed in viral replication assays. 
4.6.1 Down-regulation of DAPK1 or DAPK3 limits Rift Valley Fever Virus 
replication 
In a first approach, in order to analyse how DAPK1 and DAPK3 might influence RNA 
virus replication in cell culture, both kinases were down-regulated by siRNA transfection 
in A549 cells. Cells were then infected with Rift Valley Fever Virus (RVFV) DNSs_Rluc 
and luciferase activity was measured (Figure 35A).  
Down-regulation of DAPK1 resulted in 85% reduction in RVFV replication (in line with 
findings from [199]), DAPK3 down-regulation reduced RVFV to approximately 50% and 
combination of both siRNAs resulted in an intermediate phenotype (Figure 35B). 
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While single knockdown of DAPK1 was very efficient with no detectable protein on 
Western Blot level, some residual protein was detectable after single knockdown of 
DAPK3, and combination of both siRNAs was not as efficient as single knockdown, since 
more residual protein was detectable (Figure 35C). Interestingly, some counter-
regulation of the kinases (which might occur in case of down-regulation of one DAPK 
family member) was observed as DAPK1 protein levels were increased in DAPK3-
silenced cells and DAPK1 knockdown negatively influenced DAPK3 expression. 
The observed inhibition of RIG-I signalling by DAPK1 and DAPK3 (section 4.2), 
therefore, was confirmed. Moreover, increased antiviral signalling upon silencing of 
DAPK1 and DAPK3 was directly reflected by significantly impaired replication of RVFV, 
with DAPK1 seemingly being a stronger effector in this setup. 
 
Figure 35 Rift Valley Fever Virus replication in A549 cells silenced for DAPK1 and DAPK3 
A) Experimental setup. Virus particle adapted from CVR University of Glasgow. B) Luciferase assay of 
RVFV DNSs_Rluc replication. Relative renilla luciferase counts are shown. Results are mean of three 
independent experiments, each measured in triplicates. C) Western Blot assessing knockdown efficiency of 
DAPK1 and DAPK3 in the experiment shown in B). A representative of three independent experiments is 
shown. 
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4.6.2 Down-regulation of DAPK3 impairs influenza A virus replication 
To complement data from RVFV infection with a different virus, DAPK1 and DAPK3-
silenced in A549 cells were infected with influenza A (WSN/33) virus (FluA). In order to 
quantify viral replication FluA nucleoprotein (NP) was stained and cells were analysed by 
flow cytometry (Figure 36A). Interestingly, although knockdown efficiency for DAPK1 was 
high (Figure 36C), DAPK1 down-regulation had no effect on Influenza A virus replication 
in this experiment, whereas DAPK3 knockdown lead to about 75% reduction in the 
percentage of FluA infected cells (Figure 36B). In a repetition of the assay in which a 
higher overall infection rate was achieved, DAPK1 knock-down also impacted FluA 
replication (data not shown), similar to what we have published previously [199]. 
Targeting both DAPK1 and DAPK3 simultaneously resulted in an intermediate 
phenotype with around 50% reduction of FluA infected cells. In double knockdown 
settings, however, DAPK3 down-regulation was not as efficient as when it was targeted 
alone (Figure 36C).  
It was shown that DAPK1 inhibited antiviral signalling and controlled virus replication in 
the context of FluA infection [199], even though this effect was not reproduced in the 
experiments shown here. Moreover, DAPK3 was found to be a novel potent inhibitor of 
antiviral signalling in the context of FluA infection and, accordingly, its knockdown 
profoundly decreased viral replication. 
4.6.3 Down-regulation of DAPK1 and DAPK3 favours hepatitis C virus 
replication 
Finally, it was examined how DAPK1 and DAPK3 silencing might influence hepatitis C 
virus (HCV) replication. We recently described DAPK1 as a negative regulator of RIG-I 
and could show that silencing of DAPK1 resulted in enhanced FluA replication [199]. 
Additionally, the present study showed that RVFV replication was increased in cells 
silenced for DAPK1 and DAPK3. We decided to assess if and how DAPK silencing 
would influence HCV replication since a recent study found an inhibitory role for DAPK1 
in HCV replication. In the respective study, DAPK1 expression was up-regulated after 
IFNa treatment and promoted antiviral signalling by the mTOR pathway. Consequently, 
DAPK1 silencing enhanced HCV replication [268]. 
In order to examine if and how DAPK1 and DAPK3 silencing might influence HCV 
replication, both kinases were silenced in Huh7 Lunet cells which stably over-expressed 
HCV entry factor CD81 (Huh7 Lunet CD81high) and were, therefore, susceptible to HCV 
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infection. Renilla luciferase-tagged HCV genotype 2a strain JCR2A was used for 
infection of cells and luciferase activity was measured at different time points post 
infection (Figure 37A). In a first approach, low luciferase counts indicated that HCV 
JCR2A replicated inefficiently in Huh7 Lunet CD81high cells (Figure 37B). Furthermore, 
DAPK3 was not down-regulated by siRNA “siDAPK3_3” (Figure 28C). Nevertheless, 
silencing of DAPK1 even if it was not as efficient as in A549-based experiments (Figure 
35 and Figure 36) resulted in increased HCV replication at 72h and 96h post infection. 
For a second approach, a different cell line was used, namely Huh7 Lunet CD81high 
MAVS-GFPNLS, which did not differ from the original Huh7 Lunet CD81high functionally, 
but was found to support HCV JCR2A replication better than the previous cell line (data 
not shown). Luciferase counts were about 2-fold higher than in the initial assay, and, 
again, silencing of DAPK1 resulted in enhanced HCV replication starting at 48h after 
infection and continuing until the end of the time course, reaching an ~3-fold increase. 
Interestingly, although there was an effect on HCV replication, DAPK1 down-regulation 
was not very efficient at early time points and virtually non-existent at late time points 
(Figure 37E) after infection. Silencing of DAPK3 resulted in an ~1.8-fold increase in HCV 
replication at 96h post infection, although overall silencing efficiency was equally low as 
observed for DAPK1. As a control, silencing of HCV host factor PI4Ka was included, 
whose down-regulation allowed no HCV replication (Figure 37D). Due to its size and 
tendency to form stable complexes, it was not possible to assess PI4Ka knockdown 
efficiency on Western Blot level. 
In contrast to results from RVFV and FluA replication assays in which DAPK1 
knockdown impaired viral replication, down-regulation of DAPK1 and DAPK3 favoured 
HCV JCR2A replication. This is in line with results presented by Liu et al. reporting an 
inhibitory role for DAPK1 in HCV replication [268]. Interestingly, Liu et al. used HCV 
genotype 1b for their experiments whereas we used a genotype 2a virus. Thus, DAPK1 
seems to restrict replication of different genotypes of HCV. As the present study found 
an inhibitory role for DAPK1 and a potentially inhibitory role for DAPK3, experiments with 
a combined and more efficient knockdown might yield even more significant results. 
Furthermore, it is possible that DAPKs also regulate RIG-I signalling in liver cells. This 
function might simply be outweighed by the dependency of mTOR signalling in 
combating HCV replication. 
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Figure 36 Influenza A virus replication in A549 cells silenced for DAPK1 or DAPK3 
A) Experimental setup. Virus particle design by Vincent Racaniello (Columbia University) B) Flow cytometry 
analysis. DAPKs were silenced for 36h in A549 cells. Cells were infected with FluA (MOI 0.01) for 32h before 
analyses were performed. C) Western Blot analysis showing knockdown efficiencies for DAPK1 and DAPK3 
in the experiment shown in B). Flow cytometry and Western Blot were performed in two independent 
replicates, one representative result is shown. 
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Figure 37 Hepatitis C virus replication in Huh7 Lunet cells silenced for DAPK1 and DAPK3 
A) Experimental setup. HCV particle adapted from [269]. B) HCV replication measured by luciferase activity 
in Huh7 Lunet cells infected with HCV JCR2A (MOI 0.03) and lysed at indicated time points. C) Western Blot 
analysis for DAPK1 and DAPK3 silencing efficiency for data shown in B). D) HCV replication measured by 
luciferase activity in Huh7 Lunet cells infected with HCV JCR2A (MOI 0.03) and lysed at indicated time 
points. E) Western Blot analysis for DAPK1 and DAPK3 silencing efficiency for data shown in D). Luciferase 
activity for each condition and time points was measured in triplicates. 
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4.7 DAPK1, DAPK2, and DAPK3 inhibit MDA5-dependent antiviral 
signalling 
Up to this point all analyses on the role of DAPKs in antiviral signalling were limited to 
RIG-I-dependent signalling, as over-expression experiments were performed in 293T 
cells over-expressing RIG-I, and SeV, whose replication intermediates are specifically 
recognised by RIG-I [270], was used to stimulate A549 cells. The question remained 
whether control of antiviral signalling by DAPKs was exclusively limited to an inhibition of 
RIG-I or if DAPKs would generally inhibit RLR signalling, including signalling initiated by 
MDA5. Besides RIG-I, MDA5 is the other main cytoplasmic receptor for dsRNA, i.e. viral 
replication intermediates. It was shown that in contrast to RIG-I, which mainly recognises 
short, 5’-triphosphorylated dsRNA, MDA5 favours the recognition of longer dsRNA, e.g. 
in the replication cycle of paramyxoviruses [38], [39]. 
In order to find out whether the three most closely related DAPKs, DAPK1, DAPK2, and 
DAPK3, inhibited MDA5-mediated signalling a cell line was established in which the RLR 
response to dsRNA was exclusively mediated by MDA5. To this end, the same 293T 
cells which had been used for the generation of the 293TRIG-I cells employed in this study 
were stably transfected with MDA5 by lentiviral transduction. MDA5-over-expressing 
293T cells expressed high amounts of MDA5, but no RIG-I (Figure 38A). This new cell 
line was termed 293TMDA5. Responsiveness of 293TMDA5 cells to dsRNA ligands was 
tested in the IFIT1 promoter activity assay. In contrast to 293TRIG-I cells which dose-
dependently induced IFIT1 promoter activity up to 23-fold when transfected with different 
concentrations of low molecular weight (LMW) poly(I:C), 293TMDA5 cells did not respond 
to this type of stimulation (Figure 38B). 
Only when high molecular weight (HMW) poly(I:C) was transfected 293TMDA5 cells 
responded with a dose dependently increased activation of the IFIT1 promoter (Figure 
38C), which is in line with previous findings regarding substrate specificity of RIG-I and 
MDA5 [271]. The average length of both poly(I:C) preparations was examined on a non-
denaturing agarose gel. LMW poly(I:C) corresponded to a length of approximately 200 
bp, whereas HMW poly(I:C) corresponded to a length of around 3-5 kb (Figure 38D). It 
has to be noted that 293TRIG-I cells responded similarly to low and high molecular weight 
poly(I:C). Hence, HMW poly(I:C) was used to stimulated both 293TRIG-I and 293TMDA5 
cells over-expressing DAPK1, DAPK2, and DAPK3 in a direct comparison of both cell 
lines. DAPK1, DAPK2, and DAPK3, which had been found to be inhibitors of RIG-I-
mediated signalling reduced IFIT1 promoter activity in 293TMDA5 cells to a similar extent 
(Figure 38E). 
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Figure 38 DAPKs inhibit MDA5-dependent antiviral signalling 
A) Western Blot analysis of RIG-I and MDA5 expression in both 293TRIG-I and 293TMDA5 cells. B) IFIT1 
promoter reporter assay in 293T cells stably over-expressing RLRs in response to transfection of increasing 
amounts of low molecular weight (LMW) poly(I:C). C) IFIT1 promoter reporter assay in 293T cells stably 
over-expressing RLRs in response to transfection of increasing amounts of low molecular weight (HMW) 
poly(I:C). Mean of three independent experiments is shown. D) Agarose gel showing the average length of 
LMW and HMW poly(I:C). Two different DNA ladders are used to mark bp sizes. E) IFIT1 promoter reporter 
assay in 293T cells stably expressing RLRs and transiently over-expressing DAPKs. Cells were stimulated 
by transfection of the indicated amount of HMW poly(I:C). For 293TMDA5 cells the mean of two independent 
experiments is shown. For IFIT1 promoter reporter assays cells were stimulated for 16h before lysis. 
As the original 293T cell line was not able to induce IFN signalling in response to 
poly(I:C) (data not shown and [249]), antiviral signalling initiated in 293TMDA5 cells was 
exclusively dependent on MDA5 activity. DAPK1, DAPK2, and DAPK3 inhibited IFIT1 
promoter activity in 293TMDA5 cells to a similar extent as in 293TRIG-I cells. This shows that 
DAPKs are capable of inhibiting not only RIG-I- but also MDA5-mediated antiviral 
signalling. 
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4.8 Inhibition of antiviral signalling by DAPKs is not limited to control of 
RLR activity 
The three closest related members of the DAPK family, DAPK1, DAPK2, and DAPK3, 
are inhibitors of RIG-I signalling and we could show that in the case of DAPK1 this was 
achieved by direct, inhibitory phosphorylation of RIG-I. In order to examine whether the 
effect of DAPKs was solely carried out on the level of RIG-I activation, other means of 
stimulation which did not depend on active RIG-I were tested in 293TRIG-I cells. 
Interestingly, DAPKs were also capable to inhibit the signalling pathway when it was 
stimulated downstream of the effector molecule RIG-I. When 293TRIG-I cells were 
stimulated by over-expression of the RIG-I CARD domains (RIG-I CA) or MAVS, which 
both strongly induce the signalling cascade but omit the activation step of RIG-I, 
signalling was strongly inhibited in DAPK1 over-expressing cells (Figure 39A). The same 
effect of DAPK1 expression was observed in cells stimulated by over-expression of a 
constitutively active form of IRF3 (IRF3 5D). Similarly, DAPK2 and DAPK3 over-
expression inhibited IFIT1 promoter activity in cells stimulated either by over-expression 
of MAVS or IRF3 5D (Figure 39B). Furthermore, it was observed that the C-terminus of 
DAPK1 was able to inhibit RIG-I signalling in a kinase-independent fashion. Previous 
results obtained in our lab showed that a DAPK1 construct merely missing the kinase 
domain and the CaM domain, but containing the full C-terminus of the protein 
(DAPK1DKC), was able to inhibit IFIT1 promoter activity to a similar extent as full-length 
DAPK1 [249]. As this mutant was not able to phosphorylate RIG-I, another means of 
inhibition must take place when it was over-expressed. As mentioned above, Ankyrin 
repeats, which this mutant contained, can mediate protein-protein interaction. 
As 293TRIG-I cells expressed endogenous DAPK1, it was possible that via its Ankyrin 
repeats DAPK1DKC recruited WT DAPK1 and thereby mediated RIG-I signalling inhibition. 
If this were true, dimerisation with WT DAPK1 could happen with any DAPK1 mutant 
containing the Ankyrin repeats domain. The newly established 293TRIG-I DAPK1 knockout 
cell lines were employed to investigate if DAPK1DKC would rely on endogenous DAPK1 to 
inhibit RIG-I signalling. When over-expressed in DAPK1 KO cells, DAPK1DKC inhibited 
IFIT1 promoter activity to the same extent as in WT 293TRIG-I, indicating that it acted 
independently of endogenous DAPK1 (Figure 39C). It remains to be investigated if 
DAPK1DKC requires other DAPK family members to confer its inhibitory function in RIG-I 
signalling. Interestingly, over-expression of full-length DAPK1 was not possible on some 
KO clones, probably because they expressed active Cas9 and N-terminal targeting 
sgRNA (Figure 39D). 
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Figure 39 Inhibition of antiviral signalling by DAPKs is not limited to the level of RIG-I 
phosphorylation 
A) IFIT1 promoter activity in 293TRIG-I cells transfected with DAPK1 and stimulated by over-expression of 
constitutively active RIG-I (RIG-I CA) or MAVS for 16h. B) IFIT1 promoter activity in 293TRIG-I cells 
transfected with DAPK1, DAPK2, or DAPK3 and stimulated by over-expression of MAVS or constitutively 
active IRF3 (IRF3 5D) for 16h. C) 293TRIG-I with (WT) or without (DAPK1 KO) endogenous expression of 
DAPK1 were transfected with DAPK1WT, DAPK1KCA K42A or DAPK1DKC mutants. Cells were infected with SeV 
(MOI 5) for 16h before lysis. D) Western Blot of over-expression assay in C). Expression efficiency of 
transfected constructs was assessed by staining for HA-tag. Expression of DAPK1KCA K42A construct was 
included but not evaluated in IFIT1 promoter activity assay. 
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All three DAP kinases, DAPK1, DAPK2 and DAPK3, are capable to inhibit RLR 
signalling, not only by direct inhibition of RIG-I by inhibitory phosphorylation, but also 
downstream of the level of RLR receptors. In fact, DAPK1, DAPK2, and DAPK3 can 
seemingly modulate gene expression at the level or downstream of the transcription 
factor IRF3, as shown by their inhibitory effect when a constitutively active form of IRF3 
was expressed. In case of DAPK1, this inhibition might be independent of its kinase 
activity, since a mutant lacking the kinase and CaM domain inhibited RIG-I signalling as 
efficiently as full-length DAPK1 and this was not due to dimerisation with endogenous 
DAPK1. 
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5 Discussion 
Due to their role in death and survival signalling pathways, DAPKs have been of special 
interest ever since their discovery. Sure enough, the view on their function in the cell has 
since then expanded. Initially, the main function of all DAPK family members was 
thought to be that of mere inducers of apoptotic and autophagic cell death [161], [163], 
[164], [200], [207], [219], [228]. Since then, intensive research established that DAPKs 
are, actually, involved in the control of cell death and survival on different levels. They 
might, on the one hand, directly interact with p53 to induce apoptosis [226], [272], but 
can also facilitate cell survival, e.g. by promoting mTOR signalling [187], [227]. 
Furthermore, DAPKs control induction of inflammatory responses [197], [216] and are 
thought to be tumour suppressors [173]–[175], [220], [273].  
RIG-I-like receptor-mediated antiviral signalling is crucial for an adequate induction of 
type I and type III interferons in response to recognition of cytosolic viral replication 
intermediates. Several post-translational modifications control RIG-I activity. Some of 
them are activating like TRIM25 and Riplet-mediated ubiquitinylation [122], [123], others 
are inhibiting like CARD phosphorylation by PKCa/b which also negatively regulates 
MDA5 activity [274]. 
The present study identified the DAPK family of serine/threonine kinases as negative 
regulators of RLR signalling. It had been established that DAPK1 regulates RIG-I activity 
in a negative feedback loop [199], a mechanism dependent on DAPK1 kinase activity, 
which our present results confirm and corroborate. Furthermore, this study describes the 
other members of the DAPK family as novel negative regulators of antiviral signalling 
with special emphasis on DAPK2 and DAPK3 regulation. Importantly, it was shown that 
control of RIG-I signalling by DAPKs happens independently of apoptosis and autophagy 
induction. 
5.1 DAPK1 kinase-dependently inhibits RIG-I signalling 
Using an siRNA-based screening approach, we identified DAPK1 as an inhibitor of RIG-I 
signalling [199]. A minimal construct comprising the DAPK1 kinase domain, CaM domain 
and Ankyrin repeats (DAPK1KCA) was found to exert the same effect as full-length 
DAPK1, but lost its inhibitory potential when a small, N-terminal part of the kinase 
domain was deleted (DAPK1D1-73, figure 9). As a critical lysine (K42) in the ATP acceptor 
site was deleted in DAPK1D1-73 and this residue mediates phosphate transfer in 
phosphorylation reactions, failure of this mutant to inhibit RIG-I signalling indicated a 
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dependency on DAPK1 kinase activity (compare section 5.2.3) . Along those lines, 
constitutively active DAPK1KCA S308A, a construct which mimics the active, de-
phosphorylated state of DAPK1 [159], acted like DAPK1KCA. 
We previously established that Ankyrin repeats were necessary for the inhibitory function 
of DAPK1 in RIG-I signalling, as a construct comprising only the kinase and CaM domain 
(DAPK1KC) was not able to confer RIG-I signalling inhibition [199]. Besides mediating 
protein-protein interactions, e.g. with MIB1 [194], DAPK1 Ankyrin repeats are targeted by 
kinases involved in growth factor signalling. These phosphorylation events inhibit DAPK1 
kinase activity. Interestingly, we found that neither phospho-mimetic nor phospho-
ablatant mutations of either S289 or Y491/Y492, targets of RSK and Src, respectively 
[188], [185], changed the ability of DAPK1KCA to inhibit RIG-I signalling (figure 10). It is, 
therefore, unlikely that control of RIG-I by DAPK1 is linked to its role in growth factor 
signalling. However, DAPK1KCA does not contain the C-terminal domain of DAPK1 which 
is targeted by growth factor-induced ERK. Phosphorylation of S735 increases DAPK1 
activity which has been shown to negatively regulate ERK activity, promoting its retention 
in the nucleus [186]. Thus, activity of endogenous full-length DAPK1 might be regulated 
in response to growth factor signalling and thereby also influence RIG-I signalling. 
Supporting an influence of cell growth and mitogenic signalling, we observed a strong 
influence of cell growth and division on DAPK1 expression levels, as we measured up to 
two-fold differences in protein expression in cells seeded at different densities (figure 
10). Interestingly, DAPK1 expression was reversely regulated in the two examined 
epithelial cell types, 293TRIG-I and A549 and it is not clear how control of DAPK1 
expression differs between these two cell types. DAPK1 expression might in fact be 
influenced by ERK. It was shown that cell density dramatically influenced oscillations of 
ERK shuttling between nucleus and cytoplasm [275]. Moreover, DAPK1 mediates growth 
arrest in response to chemotherapeutic drugs [276], [277] and it is established that cell 
cycle progression depends on growth factor signalling. Not much is known about how 
DAPK1 expression is regulated in response to cues like epidermal growth factor (EGF) 
stimulation, but it is possible that there are feedback mechanisms which link DAPK1 
expression to ERK activity, especially since DAPK1 activity is tightly controlled by growth 
factor signalling-related kinases. Our results emphasize that the outcome of assays 
analysing endogenous DAPK1 function might be strongly dependent on the number of 
cells seeded in an individual well, as well as variability in growth rates. Small differences 
in the number of seeded cells might, therefore, account for high variations of results from 
different biological replicates. This is in fact reflected in the comparatively high variation 
among silencing experiments performed throughout our study. 
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5.2 Extending the view to the DAPK family 
Besides DAPK1, the DAPK family of protein kinases comprises four other members. 
DAPK2 and DAPK3 are closely related to DAPK1 and share high amino acid sequence 
homology in their respective kinase domain (figure 6 and appendix, figure 41). 
STK17A/DRAK1 and STK17B/DRAK2 are not as closely related to DAPK1 but amino 
acid sequences of their respective kinase domains are highly homologous (appendix, 
figure 41). 
As the kinase domains of DAPKs are structurally similar, it is not surprising that DAPKs 
have common target proteins. DAPKs are phylogenetically related to MLCKs [278]. 
Therefore, all DAPKs may phosphorylate MLC [207], [279], [280] which induces 
cytoskeletal rearrangement, often accompanied by membrane blebbing. Interestingly, a 
common PEF/Y (PEF in DAPK1, DAPK2, DAPK3; PEY in DRAK1 and DRAK2) motif 
was identified which is critical for substrate recognition and interaction. It was shown that 
for DAPK1 this motif also mediates interaction with an autoinhibitory loop and is, 
therefore, crucial in regulating kinase activity [281]. Although DAPK N-terminal kinase 
domains are structurally similar, their C-terminal domains are very different (figure 6). 
This might provide means of differential regulation of DAPKs and explain reported 
substrate specificity. For example, only DAPK3 was shown to interact with and to 
phosphorylate STAT3 [282], and interaction with 14-3-3 proteins was only shown for 
DAPK2 [226]. Importantly, DAPKs have overlapping sets of target proteins, but can 
phosphorylate a common target at different residues, thereby influencing the targeted 
signalling pathway in different ways. This was shown, for example, in case of autophagy 
induction. Beclin1 is targeted by both DAPK1 and DAPK3 but is phosphorylated at 
different residues. In the case of DAPK1 this was shown to result in dissociation of Bcl2 
family members from Beclin1 [170], while it is not fully understood how DAPK3-mediated 
phosphorylation of Beclin1 enhances autophagy induction [208]. Importantly, targeting of 
Beclin1 by DAPK3 seemed to be tissue-specific as this phosphorylation was shown to 
take place in skeletal muscle, but not in liver cells. Targeting different residues of the 
same protein by several kinases allows fine-tuning and exact regulation of a signalling 
pathway. Which DAPK targets a widely expressed effector protein in a certain context 
might depend on the tissue-specific expression of the kinase. 
The present study examined roles and expression of DAPK family members in the 
context of viral infection. We previously described DAPK1 as a negative regulator of 
RIG-I [199]. As DAPKs often have similar targets, it was investigated whether the other 
members of the DAPK family influenced antiviral signalling as well. It was first addressed 
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how expression of the three most closely related DAPKs, DAPK1, DAPK2, and DAPK3, 
might differ in certain cell lines and tissues and if expression changed upon viral 
infection. 
5.2.1 DAPK expression varies in different tissues and derived cell lines 
DAPK gene expression data derived from the GTEx portal shows tissue-specific 
expression of DAPK1, DAPK2, and DAPK3 (figure 11), which is to a large extent 
reflected in cancer cell lines derived from these tissues (figure 12). Interestingly, while 
DAPK1 and DAPK2 expression varied substantially, DAPK3 mRNA and protein levels 
were similar in the analysed cell lines. This reflected DAPK3 gene expression data from 
patient samples in which, other than DAPK1 and DAPK2, DAPK3 was expressed in all 
analysed tissues (log10(RPKM) ~ 1). Importantly, expression of DAPK1, DAPK2, and 
DAPK3 seems to be especially high in tissues which frequently encounter viral infections 
and, therefore, rely on a well-regulated IFN response, such as the lung and the 
gastrointestinal tract. Thus, it is plausible that DAPKs might be involved in the control of 
antiviral signalling in these tissues and might indeed control RIG-I activity. 
While virus infection resulted in slight changes in DAPK mRNA levels in the analysed cell 
types, protein levels remained largely unchanged. DAPK3 mRNA levels were increased 
in A549 and 293TRIG-I cells in response to virus infection, which was frequently observed 
and is discussed in section 5.3. In Huh7 Lunet and HeLa cells, however, DAPK3 mRNA 
levels were slightly decreased after SeV infection. Interestingly, DAPK2 protein stains 
revealed a shift in signal size upon viral infection which corresponded to dimerised 
DAPK2 (implications of DAPK2 dimerisation are discussed in section 5.3). While this 
shift was clearly visible in A549 and Lunet cells, DAPK2 seemed to constitutively 
dimerise in 293TRIG-I cells. As it was suggested that dimerisation of DAPK2 indicates 
increased activity [160], it remains to be determined how protein targets might be 
regulated by this seemingly highly active DAPK2 in 293TRIG-I cells. 
Interestingly, we found that expression of one DAPK might be influenced by expression 
of another DAPK family member as we observed that transfection of some siRNAs 
which, based on their seed sequence, were predicted to target only one DAPK family 
member, also diminished protein levels of another DAPK (figure 15). Therefore, it may 
be necessary to assess the expression of the most closely-related DAPK family 
members in addition that targeted by a siRNA before interpreting respective results. 
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5.2.2 DAPK2 and DAPK3 are negative regulators of RIG-I signalling 
As we had established that, in addition to DAPK1, A549 and 293TRIG-I cells also 
expressed DAPK2 and DAPK3 (figure 12), we now sought to determine whether these 
DAPK family members would also influence RIG-I signalling. 
Moreover, the minimal construct DAPK1KCA is similar to DAPK3 which harbours the N-
terminal Kinase domain and a C-terminal Leucine zipper domain which, like the 
DAPK1KCA Ankyrin repeats, mediates protein-protein interaction [218]. In that it contains 
the DAPK1 CaM domain, DAPK1KCA is structurally related to DAPK2, which is, like 
DAPK1, a CaM-dependent kinase.  
When over-expressed in 293TRIG-I cells, both DAPK2 and DAPK3 dose-dependently 
inhibited antiviral signalling similarly to DAPK1 (figure 13). DAPK3 seemed to inhibit RIG-
I signalling more efficiently than DAPK2 since four times more plasmid encoding DAPK2 
was necessary to reach 50% reduction in IFIT1 promoter activity (50 ng DAPK3 vs 200 
ng DAPK2). Due to the difference in size of encoding plasmid DNA and expressed 
protein, DAPK1 could not be directly compared to DAPK2 and DAPK3. For a direct 
comparison of efficiency, DAPK1, DAPK2, and DAPK3 expression would have to be 
monitored by gradient PAGE and Western Blot analysis. Furthermore, assessing IFIT1 
promoter activity at different time points post infection could provide information as to 
how kinetics of RIG-I signalling inhibition might differ between DAPKs. 
In addition to over-expression assays, we also chose to silence the DAPKs using specific 
siRNAs. Assessing changes in the antiviral response upon DAPK silencing, we further 
validated their roles as inhibitors of RIG-I signalling. Sure enough, silencing of DAPK3 
increased IFIT1 promoter activity in response to RNA virus infection (figure 15). 
Additionally, IFNb and IFIT1 mRNA levels were increased when DAPK3 was silenced 
prior to RNA virus infection (figure 16). As DAPK2 was expressed at much lower levels 
than DAPK1 and DAPK3 (figure 12), it was not surprising that knockdown of DAPK2 had 
no effect on the antiviral signalling response. However, it was observed that survival of 
cells silenced for DAPK2 and infected with SeV was significantly reduced with most cells 
detached and floating after 16h of infection. Knockdown of DAPK2 was shown to 
facilitate TRAIL-mediated apoptotic pathways by NFkB activation [227]. DAPK2 might 
inhibit apoptosis-promoting NFkB activation in response to SeV infection which would 
explain increased cell death in DAPK2-deficient SeV-infected cells. 
Inhibition of antiviral signalling seems to be a conserved function amongst all DAPKs 
since DRAK1 inhibited RIG-I signalling to a similar extent as DAPK1 when over-
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expressed in 293TRIG-I cells (figure 14). Unexpectedly, despite harbouring the correct 
sequence compared to a reference sequence [163], DRAK2 was kinase inactive when 
over-expressed in 293TRIG-I cells (figure 14) and also in vitro (figure 26) and did, 
consequently, not influence RIG-I signalling. Due to the limited expression of DRAKs in 
most tissues (appendix, figure 42), though, it remains debatable whether an inhibition of 
RIG-I signalling by DRAKs is physiologically relevant. 
5.2.3 DAPKs kinase-dependently target RIG-I 
It was established that truncation constructs of DAPK2 and DAPK3, mainly comprising 
the kinase domains, carried out inhibition of RIG-I signalling to the same extent as the 
respective full-length kinases (figure 21). Dependency on DAPK2 kinase activity was 
observed as DAPK2S318A conferred signalling inhibition, DAPK2S318D did not, which was in 
line with findings for DAPK1KCA S308 mutants (figure 1). Also, DAPK2Kinase did not inhibit 
IFIT1 promoter activity as efficiently as DAPK2Kinase-CaM, likely reflecting decreased kinase 
activity upon loss of the CaM domain. Contrarily, earlier studies found increased kinase 
activity of a DAPK2 construct lacking the CaM domain [161], [283]. However, these 
earlier publications examined DAPK2 kinase activity in in vitro kinase and membrane 
blebbing assays only. Furthermore, DAPK2 constructs examined in these early studies 
lacked only the CaM domain while the complete C-terminal part of DAPK2 was deleted 
in the present study. Hence, it is possible that DAPK2 activity is regulated differently in a 
construct which only comprises the kinase domain in contrast to a construct containing 
kinase and CaM domain. As there are no reports about constitutively active or inactive 
mutants of DAPK3, it could not be validated that inhibition of RIG-I signalling by DAPK3 
really depended on its kinase activity. As DAPK3 activity is differently regulated than 
activity of DAPK1 and DAPK2 (section 5.3), it is possible that kinase activity of DAPK3 is 
not as crucial for the control of RIG-I signalling as that of DAPK1 and DAPK2. 
Substitution of K42/K52 with alanine creates DAPK mutants which are reportedly kinase 
dead [161], [164], [200]. This was reproducible in our in vitro phosphorylation assays 
(figure 26 and data not shown). However, supposedly kinase-inactive DAPK2K52A and 
DAPK3K42A (and DAPK3D161A or DAPK3K42A/D161A, respectively) constructs behaved like 
WT kinases when over-expressed and analysed in IFIT1 promoter reporter assays, 
although they were kinase-dead in in vitro phosphorylation assays (figure 26). Similarly, 
DAPK1KCA K42A did not rescue IFIT1 promoter reporter activity to the same extent as 
constitutively inactive DAPK1KCA S308D (figure 9). 
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Notably, it was reported for DAPK3 that K42A mutation only abrogated kinase activity 
when ATP concentrations were low (10-50 µM, typically used in in vitro assays), but 
retained kinase function under physiological ATP concentrations (5-10 mM) [284]. 
Additionally, Lee et al. reported that K42A mutation did not abrogate DAPK1-mediated 
Pin1 phosphorylation in cells [285], suggesting that the same might hold true for DAPK1. 
In line with this, we found the DAPK1KCA K42A construct to retain kinase activity in cells, as 
this construct auto-phosphorylated as efficiently as DAPK1KCA (figure 9). Thus, residual 
kinase activity of DAPK1KCA K42A might explain why this construct did not rescue RIG-I 
signalling inhibition similarly to the phospho-mimetic, constitutively inhibited DAPK1KCA 
S308D (figure 9). Analogously, it is likely that DAPK2K52A and DAPK3K42A (and D161 point 
mutations) are not kinase-dead under physiological ATP concentrations and retain 
kinase activity to some extent which allows them to influence RIG-I signalling when over-
expressed in 293TRIG-I cells. 
In line with our cell-based assays, all DAPK family members were capable of RIG-I 
phosphorylation in vitro. Auto-phosphorylation signals were indicative of kinase activity 
and served as an internal control (figure 26). However, in binding assays, strong and 
reproducible interaction with RIG-I was only observed for DAPK1 and DAPK2 (figure 25). 
This does not necessarily indicate that RIG-I would not be a natural substrate of DAPK3 
and DRAK1. In fact, due to the transient nature of kinase-substrate interactions co-
immunoprecipitation experiments might not be an ideal approach to verify if a kinase 
interacts with a target protein. Instead, proximity ligation and FRET-based reporter 
systems have proved more successful in the identification of kinase targets [286], [287] 
and could be employed in order to examine whether DAPK3 and DRAK1 interact with 
RIG-I. Furthermore, also for DAPK1 and DAPK2, it remains to be determined if they 
require accessory proteins for an interaction with RIG-I or if they directly bind their target. 
Ultimately, as we identified T667 as a central residue phosphorylated by DAPK1 [199], it 
will be exciting to investigate if DAPK2 and DAPK3 phosphorylate the same or different 
residues on RIG-I. 
5.3 Antiviral signalling influences DAPK2 and DAPK3 activity 
We described DAPK1 to be part of a negative feedback loop. Upon activation of antiviral 
signalling, DAPK1 activity is increased and mediates a subsequent down-regulation of 
RIG-I signalling [199]. As an overshooting, prolonged immune response can be 
detrimental for the host, DAPK1 thereby ensures that an initial, strong IFN response 
finds a timely end. 
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Since DAPK2 and DAPK3 are closely related to DAPK1, we wondered whether activity 
of them, too, might be influenced by antiviral signalling. 
Similar to activating dephosphorylation of S308 of DAPK1, dephosphorylation of S318 
indicates increased DAPK2 activity [160]. As a DAPK2 p-S318-specific antibody did not 
give reliable signal in our hands, we decided to examine dimerisation of endogenous 
DAPK2 instead. Sure enough, we observed a shift of DAPK2 signal to a higher 
molecular weight (corresponding to the size of DAPK2 dimers) in Western Blot analyses 
of SeV-infected A549 and Huh7 Lunet cells (figure 12). 
It has to be noted that it is still not entirely clear whether formation of DAPK2 dimers 
indicates increased or decreased kinase activity. Crystal structure analyses found murine 
DAPK2 dimers to be oriented in a way which does not allow substrate interaction [288]. 
Other than in the case of DAPK3, amino acid sequences of murine and human DAPK2 
are highly homologous. However, since constitutively active DAPK2S318A was shown to 
preferentially dimerise while non-active DAPK2S318D does not, another group proposed 
that DAPK2 dimerisation is indicative of and necessary for DAPK2 activity [160]. 
Importantly, this group worked with human DAPK2 and included a variety of functional 
assays to show increased activity of DAPK2S318A. We observed enhanced DAPK2 
dimerisation over time in virus-infected cells as compared to non-infected controls, 
indicating that DAPK2 was increasingly activated in response to viral infection. Thus, 
DAPK2 might be involved in a similar negative feedback regulation as DAPK1. This 
might be especially relevant in tissues with high DAPK2 and low DAPK1 expression, 
such as the heart (figure 11). 
In contrast to DAPK2 whose activity was likely up-regulated in response to viral infection, 
activity of DAPK3 seemed to decrease over time upon SeV infection (figure 24). While 
total DAPK3 protein levels remained stable over time, p-DAPK3 T265 levels decreased. 
It has to be stated that although phosphorylation of multiple residues of DAPK3 
determines DAPK3 kinase activity and subcellular localisation [203], there are only two 
reports which state that especially T265 phosphorylation is needed for full DAPK3 
activity [203], [204]. So far, DAPK3 T265 was found to be auto-phosphorylated as well as 
targeted by ROCK1 which caused stress fibre formation [284]. Importantly, the same 
publication also identified other residues, namely T180 and T225, whose 
phosphorylation was, in their hands, crucial for full DAPK3 activity. Unfortunately, no 
other antibody which might help identify activating phosphorylation of DAPK3 than the 
one detecting p-DAPK3 T265 is currently available. If T265 dephosphorylation truly 
indicates decreased DAPK3 activity, present findings indicate that DAPK3 activity is 
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reduced in response to viral infection, indicating that DAPK3 might be reversely 
controlled to DAPK2, given that dimerised DAPK2 is active. This seems counter-intuitive 
taking into account that DAPK3 mRNA levels were repeatedly up-regulated in virus-
infected cells (figure 12 and 16). Also, DAPK3 was reported as an ISG in an earlier 
publication [205]. It is possible that dephosphorylation of DAPK3 T265 does not influence 
kinase activity. In this case, one would have to find other means of determining if and 
how active DAPK3 is in response to viral infection. As a matter of fact, the initial study 
which first described the kinase and its structure proposed that DAPK3 oligomerises and 
is trans-phosphorylated to attain full kinase activity [200]. A later study described that 
active DAPK3 forms trimers [201]. If active DAPK3 oligomerises in a similar way as 
DAPK2, a cross-linking approach or native PAGE could be employed to visualise DAPK3 
oligomers, allowing observation of formation or dissociation of oligomers over time after 
viral infection. 
If DAPK2 dimerisation indeed indicates enhanced activity, it seems, at this point, that 
DAPK2 is increasingly activated in response to viral infection, similar to what was 
observed for DAPK1. As DAPK2, like DAPK1, is an inhibitor of RIG-I signalling, this 
would imply DAPK2 is included in a similar negative feedback mechanism down-
regulating an initial strong IFN response. Unlike for DAPK1 where dephosphorylation of 
S308 indicates activity, there is no definitive marker for the identification of active 
DAPK3. Until then, the results in this work indicate that DAPK3 activity might decrease 
when antiviral signalling is initiated, the implications of which are so far not clear. 
5.4 It’s not a question of life and death 
The role of DAPKs in cell death induction has been studied extensively. The founding 
DAPK family member DAPK1 was first described as the main effector of IFNg-induced 
cell death in HeLa cells [164]. Sure enough, DAPKs induce apoptosis by interaction with 
members of the p53 pathway [180], [205], [272]. Additionally, they promote autophagy 
induction by phosphorylation of Beclin1 [171], [208] or mTOR [228]. As we did not know 
how exactly DAPKs conferred inhibition of antiviral signalling, we decided to investigate if 
their inhibitory role in the RIG-I signalling pathway was dependent on their cell death-
inducing properties. To this end, we inhibited apoptosis on the one hand, and either 
inhibited or triggered autophagy on the other hand, and examined how this would 
change RIG-I signalling.  
We did observe that DAPK over-expression consistently resulted in a certain degree of 
cell death indicated by membrane blebbing and cell detachment. Consequently, PARP 
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cleavage was increased in cells over-expressing DAPKs (figure 18), indicating that, 
indeed, DAPKs promoted apoptosis in target cells. Pre- and co-treatment of cells with 
small molecule pan-caspase inhibitor Q-VD-OPh significantly reduced PARP cleavage, 
i.e. apoptosis induction, in response to DAPK expression. Importantly, there was no 
change their potency to inhibit RIG-I signalling when apoptosis was inhibited (figure 18). 
This indicated that negative regulation of RIG-I signalling conferred by DAPKs is not 
linked to their apoptosis-promoting function. 
Interestingly, over-expression of DRAK1 hardly induced PARP cleavage. Even more 
strikingly, PARP cleavage induced by DRAK1 was not reduced by caspase inhibitor 
treatment. Although results based on DRAK1 over-expression are preliminary and 
require repetition, they suggest that the apoptosis-promoting function of DRAK1, at least 
in 293TRIG-I cells, is limited. In fact, as DRAK1-induced PARP cleavage was low and not 
influenced by caspase inhibition, it is possible that instead of promoting apoptosis, 
DRAK1 actually induces autophagy. In fact, in the first publication describing DRAK1, 
conclusions regarding the cell death-promoting function of the kinase were based solely 
on phenotypic observations but included no mechanistic investigation as to how DRAK1 
might induce apoptosis [163]. It is possible that DRAK1 over-expression rather promotes 
autophagy induction which either precedes or entails apoptotic cell death. Autophagy 
might also contribute to caspase-independent cell death, a mechanism which was first 
described in macrophages which died in response to lipopolysaccharide treatment in the 
presence of caspase inhibitors [289]. Moreover, DRAK1 is more closely related to 
DAPK2 than to DAPK1 or DAPK3 (appendix, figure 41). While the role of DAPK2 in 
apoptotic cell death is still debated [222], it has been repeatedly shown to influence the 
autophagic network [219], [221], [228]. Thus, if DRAK1 behaved similar to DAPK2, it 
would rather influence autophagic than apoptotic cell death. Up to this day neither 
DRAK1 nor DRAK2 have been examined in the context of autophagy induction. 
In contrast, all three “classical” DAPKs, DAPK1, DAPK2, and DAPK3, have been 
described to induce autophagy, be it by phosphorylation of autophagy-promoting Beclin1 
or by interfering with survival-promoting mTOR. By direct interaction of ATG12 and 
ATG5 with the CARD domains of RIG-I and MAVS, induction of autophagy inhibits RIG-I 
signalling in response to viral infections [290]. This mechanism probably prevents an 
overproduction of IFNs in response to viral infections, as ATG5-/- mouse embryonic 
fibroblasts produced extensive amounts of IFN and were resistant to vesicular stomatitis 
virus infection. If autophagy was induced upon DAPK expression, this could, therefore, 
result in an inhibition of RIG-I signalling. 
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Strikingly, none of the above-mentioned DAPKs induced autophagy when they were 
over-expressed in 293TRIG-I cells as evidenced by LC3-I and –II levels remaining 
unchanged in comparison to mock transfected cells (figure 19). Pharmacological 
inhibition and induction of autophagy, however, was successful indicated by increased or 
decreased levels of LC3B-II, respectively. Torin-1 efficiently inhibited mTOR as assessed 
by p-S6K staining. Interestingly, DAPK1 and DAPK2 over-expression caused an 
increase in p-S6K levels compared to mock transfected cells. This indicated an increase 
in mTOR activity upon DAPK1 and DAPK2 over-expression, suggesting that the mTOR-
stimulating functions of DAPK1 (and possibly DAPK2) predominated in 293TRIG-I cells. If 
DAPK expression rather stimulated mTOR activity in 293TRIG-I cells, this would explain 
the absence of autophagy in response to DAPK over-expression as mTOR activity 
usually restricts autophagy induction. 
It was described before that the autophagic machinery was activated upon initiation of 
antiviral signalling and restricted IFN production. The present results indicate that this 
regulation does not take place in 293TRIG-I cells as pharmacological autophagy induction 
did not inhibit the RIG-I signalling response. On the contrary, Spautin-1-mediated 
autophagy inhibition slightly reduced the antiviral signalling response. It is possible that 
excessive amounts of RIG-I, which is stably over-expressed in 293TRIG-I cells, 
overwhelms the autophagic machinery rendering this way of regulation inefficient. 
All in all, examinations of the cell death-promoting functions of DAPKs in the context of 
viral infection showed that although DAPKs induce apoptosis in transfected cells this 
does not account for their inhibitory effect on RIG-I signalling. Additionally, inhibition of 
RIG-I signalling by DAPKs was conferred independently of autophagy induction as 
DAPKs did not trigger type II cell death in the analysed cells, but strongly inhibited RIG-I 
signalling. 
5.5 The role of DAPKs in RNA virus infection 
The role of DAPKs as negative regulators of RIG-I signalling was confirmed in viral 
replication assays which highlighted the physiological relevance of our biological assays. 
In the present study only DAPK1 and DAPK3 were analysed and compared in viral 
replication assays as knockdown of DAPK2, probably due to low expression in examined 
cell lines, did not impact on IFIT1 promoter reporter activity. 
Knockdown of DAPK1 and DAPK3 inhibited RVFV and FluAV replication (figure 37 and 
figure 38). Both viruses have been shown to specifically activate RIG-I which recognises 
the panhandle structure formed by complementary regions in their genomes [103], [104], 
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[111]. Combined knockdown of both kinases did not result in stronger suppression of 
viral replication, but rather resulted in an intermediate phenotype which ranged in 
between levels of single knockdown of either kinase. This was probably due to lower 
knockdown efficiency when both kinases were targeted, as indicated by remaining 
protein signal on Western Blot level. Interestingly, down-regulation of DAPK1 impacted 
RVFV replication to a much larger extent than knockdown of DAPK3. DAPK3, however, 
seemed to be more important than DAPK1 in controlling RIG-I signalling during FluAV 
replication, as only few virus-infected cells were detectable when it was silenced. 
Strikingly, in one experiment in our present study, knockdown of DAPK1 did not 
influence FluAV replication at all, whereas in earlier experiments knockdown of DAPK1 
resulted in strong and reproducible inhibition of FluAV replication ([249] and [199]). The 
main differences between those previous and present results are that infection rates 
were much higher in earlier experiments (~80% infected cells in contrast to ~16%) and 
that a different siRNA targeting DAPK1 was used. It is possible that effects on FluAV 
replication mediated by DAPK1 are smaller than those mediated by DAPK3 and that the 
measurement window in the present experiments was too limited to show DAPK1-
mediated effects. As DAPK3 was described to shuttle between cytoplasm and nucleus 
[202], [203] and FluAV replication happens in the nuclear compartment [291], it is 
possible that DAPK3 restricts the recognition of FluAV replication intermediates in the 
nucleus. This idea is especially intriguing since recent observations indicate that RIG-I 
might be present in the nuclear compartment and even recognise FluAV replication 
intermediates there (conference talk, unpublished research by the group of Friedemann 
Weber, Gießen University). Higher cytosolic concentrations of DAPK1, however, might 
restrict RIG-I after initial recognition of RVFV genomes. Also, it was previously shown 
that DAPK activity was changed upon viral infection. It is possible that DAPK1, DAPK2, 
and DAPK3 activity is regulated differently in response to certain RNA viruses. While 
infection with one virus might result in an increase in DAPK1 kinase activity, which 
benefits viral replication since it restricts RIG-I, another virus might cause up-regulation 
of DAPK3 and, therefore, react more sensitive when this kinase is down-regulated. 
Ultimately, it is not known if DAPKs influence other antiviral proteins and thereby 
specifically inhibit signalling in response to a certain virus. 
In contrast to findings for RVFV and FluAV replication, silencing of DAPK1 and, to some 
extent, DAPK3, resulted in enhanced HCV JCR2A replication (figure 39). Generally, as 
HCV JCR2A replicated inefficiently in the examined Lunet CD81high and Lunet CD81high 
MAVS-GFPNLS (~10 fold increase in signal between the 24h and the 96h time point), the 
measurement window was quite small. However, HCV replication was clearly increased 
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when DAPK1 was knocked down, although DAPK1 protein levels recovered 72h after 
HCV infection. For down-regulation of DAPK3 only a slight increase in HCV replication 
was observed at 96h post infection. In light of our previous results it seems 
counterintuitive that DAPK knockdown should favour HCV replication. However, it should 
be noted that HCV permissive Huh7-derived cells are virtually deficient of interferon 
induction, meaning that the negative impact of DAPKs on the antiviral response might 
not play any role. Moreover, it was shown that pegylated IFNa suppresses HCV 
replication by an activation of DAPK1 which in turn activates mTOR [268]. Importantly, 
Liu et al. did not determine DAPK1 activity by staining for p-DAPK1 S308 but rather by 
examining phosphorylation of S735 which is targeted by ERK [186]. Also, their study 
provides no functional link between DAPK1 kinase activity and an increase in mTOR 
signalling, but merely shows an up-regulation of mTORc1 upon DAPK1 over-expression. 
Still, phenotypically, our results presented here support the notion of Liu et al. that 
DAPK1 might actually inhibit HCV replication. Of note, Liu et al. examined replication of 
HCV genotype 1b, whereas our JCR2A virus corresponds to genotype 2a. Therefore, 
DAPK1 apparently influences replication of HCV belonging to different genotypes. 
Interestingly, hyper-methylation of the DAPK1 promoter was found to negatively 
influence therapy responses in chronic HCV genotype 4 infection and was prominent in 
hepatocellular carcinomas (HCC) caused by chronic HCV infection [292], [293], 
indicating that high DAPK1 expression might be favourable in the context of HCV 
infection. Still, it needs to be remembered that DAPK1 might actually promote tumour 
growth in cancers harbouring p53 mutations [189]. Hence, although high DAPK1 
expression might first restrict HCV replication, it might be detrimental when p53 
mutations occur in the course of HCC progression. 
So far, it has not been investigated if DAPK2 or DAPK3 facilitate or restrict HCV 
replication. Present data indicate that DAPK3 might, similarly to DAPK1, negatively 
influence HCV (JCR2A) replication (figure 39). Assessing viral replication in cells where 
both kinases are down-regulated could contribute to better understanding of the role of 
DAPKs in HCV replication, since DAPK3 was up-regulated in cells silenced for DAPK1 
(figure 39). This also suggests a counter-regulatory mechanism of DAPK expression 
which will be discussed in the following section. 
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5.6 DAPKs do not interdepend in their role as negative regulators of 
RIG-I signalling 
5.6.1 Never alone? – Interaction of DAP kinases 
We identified DAPKs as negative regulators of RIG-I signalling and found that all DAPK 
family members were capable of RIG-I phosphorylation. However, we only observed 
interaction with RIG-I for DAPK1 and DAPK2, but not for DAPK3 and DRAK1. It had 
been reported that DAPK1 and DAPK3 interacted [201] and that this interaction 
depended on a motif in their kinase domains termed the “basic loop”. As the basic loop 
found in DAPK1 and DAPK3, which comprises four arginine residues and is mostly 
conserved in DAPK2, except for a substitution of one arginine for glutamine (appendix 
figure 41). Thus, it is feasible that interaction of DAPK2 with both of the other kinases is 
mediated in a similar fashion. 
We hypothesised that DAPK3/DRAK1 interacted with the other RIG-I-binding DAPKs 
and thereby mediated inhibition of RIG-I signalling. Hence, we decided to examine 
whether we could observe interaction between DAPK family members. 
In line with the previous report on DAPK1-mediated regulation of DAPK3 [201], we did, in 
fact, find DAPK3 in the fraction of DAPK1 interacting proteins (table 21). When we 
analysed which proteins were pulled down with the other DAPK family members, we 
observed interaction between DAPK3 and DAPK2, and also between DRAK1 and 
DAPK2, as well as DAPK3 (table 23, table 24). We did not find DAPK1 in the interacting 
protein fractions of the other kinases, maybe because DAPK1 is a large protein and 
might be difficult to pull down alongside another, smaller protein. Furthermore, we only 
examined the 14 most enriched proteins and DAPK1 could be present among the less 
abundant proteins in DAPK2/DAPK3/DRAK1-interacting protein fractions. 
Interestingly, we found a member of the antiviral signalling network, DDX3X, among the 
most abundant hits in the fraction of DAPK2-interacting proteins (table 23). This 
association of DDX3X with DAPK2 was also found by a different group which sought to 
determine DAPK2 interaction partners by coupling a proteomics approach with 
bimolecular fluorescence complementation [294]. DDX3X has been shown to bind viral 
RNAs and associate with MAVS, enhancing down-stream IFN production [267]. 
Furthermore, DDX3X interacts with TBK1, thereby increasing IRF3 activity [266]. It is 
tempting to speculate that, in addition to regulating RIG-I, DAPK2 might decrease 
DDX3X activity, which could result in an inhibition of antiviral signalling. 
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More advanced and more detailed proteomic analyses might shed further light on 
possible interactions between DAPKs and members of the antiviral RIG-I signalling 
pathways. Furthermore, it remains to be investigated if and how DAPK2 might influence 
the function of DDX3X in the RIG-I signalling pathway. 
5.6.2 Stable knockout of DAPKs does not influence RIG-I signalling 
We observed that DAPKs interacted and were frequently found to associate to another 
DAPK family member. It could, therefore, not be ruled out that effects on RIG-I signalling 
observed for DAPK2 and DAPK3 were actually mediated via an interaction with DAPK1 
or vice versa. 
In order to examine if inhibition of RIG-I signalling by DAPK1 depended on DAPK3, we 
employed a combined knockdown approach in which both, DAPK1 and DAPK3, were 
targeted simultaneously (figure 29). We excluded DAPK2, since it was expressed at very 
low levels in the examined cell lines. Therefore, it seemed unlikely effects on antiviral 
signalling observed for DAPK1 and DAPK3 were mediated by DAPK2. Interestingly, 
combined down-regulation of DAPK1 and DAPK3 resulted in an intermediate phenotype 
in terms of IFIT1 promoter activation and IFNb/IFIT1 mRNA expression compared to 
what was observed when either kinase was targeted alone (figure 15 and figure 16). This 
was probably due to inefficient knockdown when both kinases were targeted 
simultaneously as especially DAPK1 protein levels were higher in the combined 
compared to the single knockdown samples. Thus, combined siRNA-mediated down-
regulation of DAPK1 and DAPK3 did not yield conclusive results as to whether the 
observed inhibitory effect on RIG-I signalling was dependent on an interaction of both 
kinases. 
In order to further investigate possible functional interactions between different DAPKs 
and their relevance in the regulation of RIG-I signalling a CRISPR/Cas9-mediated 
approach was chosen to stably deplete cells of DAPK expression. 
DAPK1, DAPK3, and, eventually, DAPK2 were successfully knocked out in A549 and 
293TRIG-I cells (figure 31 to figure 34) as determined by undetectable levels of the 
respective DAPK protein in Western Blots. Knockout was not verified on DNA level 
except for a few DAPK1 knockout clones (data not shown), but even if some residual 
DAPK expression remained, it was less than achieved by siRNA-mediated knockdown. 
Surprisingly, IFIT1 promoter reporter assays of cells lacking either DAPK1, DAPK2, or 
DAPK3 did not resemble results obtained from transient siRNA-mediated silencing, as 
the antiviral response was virtually unaltered in cells lacking DAPK expression. We 
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observed that transfection of several siRNAs targeting different regions of the DAPK1 
mRNA resulted in an increase in antiviral signalling. Therefore, we think it unlikely that 
the effect on RIG-I signalling seen upon DAPK1 silencing is due to off-target effects of 
the transfected siRNAs. 
Knockout of DAPKs was achieved by lentiviral transduction of plasmids encoding Cas9 
and sgRNAs and subsequent selection for antibiotic resistance. Furthermore, single cell 
knockouts were created by limiting dilution of knockout bulks. Growth of single cell 
colonies lasted several weeks until they could be tested for DAPK protein expression 
and IFIT1 promoter activation. Since DAPKs were shown to function in similar signalling 
pathways and often affect the same target proteins, it was initially assumed that down-
regulation of one DAPK might trigger compensatory up-regulation of another kinase 
family member; especially since single cell clones were grown for several weeks and had 
plenty of time to adapt to DAPK loss. Indeed, compensatory up-regulation of DAPK2 was 
observed in most DAPK1/DAPK3 DKO single cell clones (figure 34). However, even 
when these cells were depleted of DAPK2, creating a DAPK1/DAPK2/DAPK3 triple 
knockout, no change in IFIT1 promoter activation was observed (figure 35). 
Nevertheless, it was shown that triple knockout of DAPK1, DAPK2, and DAPK3 is 
possible and that cells lacking all three kinases are viable. 
It remains to be determined why stable DAPK knockout, in contrast to transient siRNA-
mediated knockdown, has no effect on antiviral signalling induction. 
 As mentioned above, DAPKs are very important in the control of cell death and survival. 
DAPK1 was shown to be an important mediator of apoptosis. However, DAPK1 knockout 
mice have no defect in developmental apoptosis and grow normally [295] which either 
means that DAPK1 is dispensable for this type of apoptosis or that loss of DAPK1 is 
compensated for by another kinase. So far, DAPK2 and DAPK3 expression has not been 
analysed in DAPK1 knockout mice. Usually, the two remaining DAPK family members, 
DRAK1 and DRAK2, are expressed at low levels in tissues which do not belong to the 
blood-forming system. It is possible that combined loss of DAPK1, DAPK2, and DAPK3 
results in an up-regulation of either DRAK1 or DRAK2, especially since these kinases 
have also been linked to apoptosis induction. Moreover, loss of one DAPK might not only 
result in compensatory up-regulation of another DAPK family member but might instead 
trigger up-regulation of a kinase which has hereto not been described to be able to take 
over DAPK functions. 
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5.6.3 Over-expression of DAPKs in knockout cell lines 
Although single and combined knockout of DAPKs had no effect on antiviral signalling, 
generated KO cell lines were employed to determine effects of possible interaction 
between DAPKs upon over-expression. First results based on transient DAPK3 
knockdown already suggested that DAPK1, when over-expressed in cells silenced for 
DAPK3, did not depend on DAPK3 to mediate inhibition of RIG-I signalling (figure 36). 
And indeed, when DAPK1 was expressed in DAPK3 KO clones, it efficiently inhibited 
IFIT1 promoter activation in response to SeV infection. Similarly, RIG-I signalling 
inhibition by DAPK2 did not depend on endogenous DAPK3 expression and DAPK3 
inhibited RIG-I signalling when it was over-expressed in DAPK1 KO cells. Thus, the 
negative regulation of RIG-I signalling by DAPK1 did not depend on DAPK3 expression. 
Furthermore, DAPK2 inhibited RIG-I signalling independently of DAPK3 and the negative 
influence of DAPK3 on RIG-I signalling was not dependent on DAPK1. It remains to be 
examined if DAPK2 knockout influences the inhibitory function of DAPK1 and DAPK3 in 
RIG-I signalling, which is not likely as endogenous DAPK2 levels were very low in the 
examined cell types. 
We previously observed that a DAPK1 construct lacking the kinase and CaM domain, 
DAPKDKC inhibited RIG-I signalling in a similar way as full-length DAPK1 [249]. DAPKDKC 
contains the DAPK1 Ankyrin repeats which were shown to mediate protein-protein 
interaction. Therefore, we hypothesised that DAPKDKC conferred inhibition of RIG-I 
signalling by dimerisation with endogenous full-length DAPK1. However, over-expression 
of DAPK1DKC in DAPK1 KO clones showed that this was not the case, since DAPK1DKC 
inhibited RIG-I signalling to the same extent as in control cells (figure 39). 
Unfortunately, reconstitution of full-length DAPKs was not possible in most of the single 
cell KO clones generated for the respective kinase if the transfected construct contained 
the sequence targeted by the stably expressed sgRNA (such as in the case of DAPK3 
K42A, figure 34). This was probably due to remaining Cas9 activity which was integrated 
into target cell genomes alongside the sgRNA sequence during lentiviral transduction. 
Interestingly, Cas9 remained expressed even when selection antibiotics were withdrawn. 
Many DAPK KO clones were positive for FLAG-tag expression which the Cas9 was 
labelled with (data not shown). 
In order to analyse how reconstituted DAPKs and mutants containing the sgRNA-
targeted sequence behave in DAPK KO cells, one would have to introduce mutations 
into the sgRNA-targeted region in the expression construct. Alternatively, the Cas9 itself 
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could be targeted using a specific sgRNA and clones depleted of Cas9 expression could 
be selected. 
In summary, results from over-expression assays in DAPK KO cells suggested that 
DAPK1, DAPK2, and DAPK3 do not interdepend in their function as negative regulators 
of RIG-I signalling. Moreover, DAPK1DKC did not depend on endogenous DAPK1 for 
inhibition of RIG-I signalling. Implications of RIG-I signalling inhibition by DAPK1DKC are 
discussed in the following section. 
5.7 Control of antiviral signalling by DAPKs is not limited to negative 
regulation of RIG-I 
The present study describes a kinase-dependent inhibitory role of not only the previously 
examined DAPK1 [199], but also DAPK2, DAPK3, and DRAK1 on RIG-I-mediated 
antiviral signalling. Remaining DAPK family member DRAK2 could not be analysed as it 
was kinase-inactive when over-expressed, although the cloned construct did not differ 
from a published sequence which was shown to be kinase active, albeit with reduced 
activity compared to DRAK1 [163]. 
We initially chose to over-express DAPKs in easy-to-transfect 293T cells. As the original 
293T cell line expressed hardly any RIG-I, it did not induce signalling when it was 
stimulated with poly(I:C). Therefore, it was stably transduced with RIG-I (293TRIG-I) and 
thereby made responsive to dsRNA stimulation [249]. Consequently, dsRNA was 
exclusively sensed by RIG-I in this cell line. 
We stably introduced MDA5 into the original 293T cell line (293TMDA5) in order to study 
whether DAPKs inhibited MDA5-mediated antiviral signalling. 
5.7.1 DAPKs inhibit MDA5-mediated antiviral signalling 
In line with previous reports stating that MDA5 predominantly recognises long dsRNA 
[271], only high molecular weight  poly(I:C) (HMW poly(I:C), ~3-6 kb) activated antiviral 
signalling in 293TMDA5 cells while low molecular weight  poly(I:C) (LMW poly(I:C), ~200 
bp) did not. Thus, we used HMW poly(I:C) to stimulate DAPK over-expressing 293TMDA5 
cells in order to find out if DAPK over-expression had an effect on MDA5-mediated 
signalling. 
In a direct comparison with 293TRIG-I cells, DAPKs inhibited MDA5-mediated antiviral 
signalling with similar efficiency (figure 30). As transfected poly(I:C) was exclusively 
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sensed by MDA5 in 293TMDA5 cells, we concluded that inhibition of antiviral signalling 
conferred by DAPKs is not limited to an inhibition of RIG-I. 
PKCa/b inhibits RIG-I activity by negative phosphorylation of the RIG-I CARD domains 
[274], but has so far not been described to phosphorylate MDA5. Dephosphorylation by 
PP1a/b, however, has been shown to activate both RIG-I and MDA5 since it targets their 
highly homologous CARD domains [144]. Alignment of RIG-I and MDA5 shows that 
T667 in the Hel2 domain of RIG-I, which is phosphorylated by DAPK1, corresponds to 
S760 of MDA5. Being serine/threonine kinases, it can be speculated that DAPKs could 
also target S760. It remains to be determined whether a phosphorylation which might 
interfere with RNA-binding to RIG-I [199] will have the same effect when transferred onto 
the corresponding residue in MDA5. 
Although DAPKs clearly inhibited MDA5-mediated antiviral signalling, it remains to be 
examined whether this is due to interaction with and direct phosphorylation of MDA5. As 
a matter of fact, results presented within this study indicate that DAPKs might also 
regulate antiviral signalling downstream of RNA-recognition by RLRs. 
5.7.2 Inhibition of antiviral signalling by DAPKs downstream of RLRs 
The RIG-I signalling cascade is not only activated upon dsRNA recognition, but also by 
over-expression of the RIG-I CARD (CA) domains [15], MAVS [296] or a constitutively 
active mutant of IRF3 called IRF3 5D [297]. Thus, it is possible to determine at which 
level a regulatory factor influences the signalling cascade. If a factor interferes with 
signalling at or above the level of IRF3 activation, no other stimulus than IRF3 5D over-
expression should result in IFN induction. 
Our group discovered that DAPK1 negatively regulates RIG-I activity, likely by direct 
inhibitory phosphorylation [199]. When we examined whether DAPK1 would also 
influence RIG-I signalling downstream of the step of dsRNA recognition, we saw that 
RIG-I signalling was still efficiently inhibited by DAPK1 if the pathway was stimulated by 
either RIG-I CA, MAVS or IRF3 5D over-expression (figure 41). Having observed striking 
similarities between the DAPK family members, we decided to further examine 
downstream pathway inhibition by DAPK2 and DAPK3. Similar to what we observed for 
DAPK1, MAVS- and IRF3 5D-mediated signalling induction was strongly inhibited by 
DAPK2 and DAPK3. 
Moreover, we observed that DAPK1DKC (which lacked kinase and CaM domain and was 
therefore incapable of RIG-I phosphorylation) inhibited antiviral signalling when it was 
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over-expressed in DAPK1 KO clones. As discussed above, DAPK1DKC is unable to 
recruit endogenous DAPK1 (e.g. via its Ankyrin repeats) in these cells. Since DAPKs 
seem to interact via the basic loop in their kinase domains it is also unlikely that 
DAPK1DKC recruits other DAPK family members. Still, it cannot be excluded that DAPKs 
interact with and recruit other kinases which may instead phosphorylate their targets. 
After all, antiviral signalling was unaffected by DAPK loss in triple KO bulks. It remains to 
be determined how DAPKs might inhibit RIG-I signalling downstream of IRF3 activation. 
DAPK1 was described to regulate Pin1 stability by interaction with its ROC-COR domain 
[285] which is present in DAPK1DKC. Once activated Pin1 marks IRF3 for degradation 
[136]. However, DAPK1-mediated Pin1 regulation was shown to be kinase-dependent 
and can, therefore, not be mediated by DAPK1DKC. 
In summary, DAPKs seem to confer inhibition of RLR-mediated antiviral signalling not 
only on the level of RIG-I which, as it seems, is phosphorylated and inhibited by all 
DAPKs, but also downstream of RIG-I activation, maybe even on the level of IRF3 and 
IRF7 activation. One report describes DAPK1 as an IRF3/IRF7-interacting protein. 
However, contrary to what our group described, that report found DAPK1 to positively 
influence RIG-I signalling which is surprising given the fact that experiments were mainly 
performed in 293T cells [198], the same cell line our group used for DAPK1 over-
expression assays. Moreover, Zhang et al. found DAPK1 functions in antiviral signalling 
to be kinase-independent. It is possible that DAPK1 kinase-independently modulates 
antiviral signalling downstream of RIG-I. Still, this does not explain the discrepancy 
between DAPK1 being solely inhibitory in assays performed in our group and results 
obtained by Zhang et al. As the present study showed that not only DAPK1, but also 
DAPK2 and DAPK3 controlled antiviral signalling, changes in DAPK1 functions might 
depend on DAPK2 and DAPK3 expression in the respective examined cell type. 
Furthermore, we showed that DAPK1 expression was influenced by cell growth. Thus, 
seeding cells at different densities might already heavily influence DAPK1 expression 
and function. 
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In summary, DAPK1 seems to possess kinase-independent properties which regulate 
antiviral signalling at the level of or downstream of the transcription factor IRF3. In 
addition to DAPK1, most other DAPK family members were found to inhibit RIG-I 
signalling in our present study. DAPK2, which dimerises and is potentially activated in 
response to viral infection, might be involved in a similar negative feedback loop as 
DAPK1. How DAPK3 regulates RIG-I signalling remains to be investigated. Similarly, it 
remains questionable if regulation of antiviral signalling by DRAKs is physiologically 
relevant since their expression is limited in most tissues. Importantly, DAPKs were found 
not only to regulate signalling on the level of RLR activation, but also as far downstream 
as on the level of IRF3-mediated gene transcription. Generated DAPK single and 
combined KO cell lines will help determine the exact mechanism of DAPK-mediated 
antiviral signalling regulation. Moreover, they might prove helpful in determining other 
functions of DAPKs and how their activity is controlled in cellular survival and death. 
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Figure 40 A minimal DAPK3 construct, DAPK3Kinase, inhibits NFkB activation 
A) IFIT1 reporter assay. DAPK3 constructs were over-expressed in 293TRIG-I cells and cells were stimulated 
by SeV (MOI 5) infection. Error bars correspond to three independent biological replicates. B) Western Blot 
analysis for assay performed in A). A representative of three independent biological replicates is shown. 
Table 25 Most abundant hits (14) of DAPK2 and DAPK3 interactomes obtained by mass 
spectrometry. 
Hit 
No. Protein name 
Gene 
name Score 
Hit 
No. Protein name 
Gene 
name Score 
1 Probable ATP-dependent RNA helicase DDX58 (RIG-I) DDX58 5001 1 
Probable ATP-dependent 
RNA helicase DDX58 
(RIG-I) 
DDX58 5514 
2 Death-associated protein kinase 2 DAPK2 2627 2 
Death-associated protein 
kinase 3 DAPK3 2214 
3 ATP-dependent RNA helicase DDX3X DDX3X 2131 3 
Keratin, type II cytoskeletal 
1 K2C1 1317 
4 Calmodulin CALM 788 4 Keratin, type I cytoskeletal 9 K1C9 1153 
5 Heat shock 70 kDa protein 1A HS71A 639 5 Calmodulin CALM 899 
6 14-3-3 protein epsilon 1433E 569 6 Heat shock protein HSP 90-beta HS90B 566 
7 Serum albumin ALBU 445 7 Heat shock protein HSP 90-alpha HS90A 475 
8 14-3-3 protein theta 1433T 254 8 Serum albumin ALBU 440 
9 14-3-3 protein zeta/delta 1433Z 246 9 Keratin, type II cytoskeletal 2 epidermal K22E 408 
10 14-3-3 protein eta 1433F 230 10 Keratin, type I cytoskeletal 10 K1C10 376 
11 14-3-3 protein gamma 1433G 205 11 Pyruvate carboxylase, mitochondrial PYC 290 
12 14-3-3 protein beta/alpha 1433B 149 12 Heat shock 70 kDa protein 1A HS71A 276 
13 
NADH dehydrogenase 
[ubiquinone] 1 alpha 
subcomplex subunit 8 
NDUA8 94 13 Death-associated protein kinase 2 DAPK2 170 
14 Apolipoprotein A-I APOA1 90 14 Apolipoprotein A-I APOA1 83 
Samples from in vitro kinase assays (figure 26) were analysed by mass spectrometry (LC-MS/MS). Only the 
14 most abundant detected proteins are displayed. A representative of two independent experiments is 
shown. The pulled down protein is indicated in bold, other DAPK family members are highlighted in red. 
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Table 26 Most abundant hits (14) of DRAK1 interactome obtained by mass spectrometry. 
Hit 
No. Protein name 
Gene 
name Score 
Hit 
No. Protein name 
Gene 
name Score 
1 Probable ATP-dependent RNA helicase DDX58 (RIG-I) DDX58 5604 8 
Heat shock 70 kDa protein 
1A HS71A 466 
2 Keratin, type II cytoskeletal 1 K2C1 933 9 Keratin, type II cytoskeletal 2 epidermal K22E 411 
3 Calmodulin CALM 910 10 Pyruvate carboxylase, mitochondrial PYC 322 
4 Serine/threonine-protein kinase 17A ST17A 619 11 
Pyrroline-5-carboxylate 
reductase 2 P5CR2 110 
5 Keratin, type I cytoskeletal 10 K1C10 589 12 
Death-associated protein 
kinase 3 DAPK3 69 
6 Keratin, type I cytoskeletal 9 K1C9 529 13 Apolipoprotein A-I APOA1 67 
7 Serum albumin ALBU 467 14 Death-associated protein kinase 2 DAPK2 49 
Samples from in vitro kinase assays (figure 26) were analysed by mass spectrometry (LC-MS/MS). Only the 
14 most abundant detected proteins are displayed. A representative of two independent experiments is 
shown. The pulled down protein is indicated in bold, other DAPK family members are highlighted in red. 
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Figure 41 Similarities and differences of DAPKs 
A) and B) were generated using the KinBase online tools (http://www.kinase.com/kinbase) 
A) Kinase domain alignment of DAPK family members. Amino acids are colour-coded. Kinase domains of 
DAPK1, DAPK2, and DAPK3 are highly homologous, while DRAK1 and DRAK2 are more distantly related to 
them, but highly homologous to each other. B) Phylogenetic tree corresponding to alignment in A. 
Page | 156  Appendix 
 
Figure 42 Tissue-specific expression of DRAK1 and DRAK2 
Overview of DRAK1 and DRAK2 expression in different tissues from patient samples. Gene expression is 
shown in Reads Per Kilobase of transcript per Million mapped reads (RPKM) and dashed lines indicate a 
Log10(RPKM) of zero. Displayed data were obtained from the GTEx Portal (gtexportal.org, GTEx Analysis 
Release V6p, dbGaP Accession phs000424.v6.p1) on 06/13/17. 
 
